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SECTION I
SOME ASPECTS ON THE TURNOVER OF CATECHOLAMINES
IN COBALT-INDUCED EPILEPSY IN THE RAT.
INTRODUCTION
The individual experimental models of epilepsy have their
separate advantages and disadvantages. In many of these models
the epileptic behaviour lasts for a short time as in the case of
epilepsy induced by the administration of systemic convulsants
and epilepsies induced by the topical application of convulsant
agents such as oestrogen or penicillin to brain tissue. The long
term models are more relevant to clinical situations and include
chronic epileptiform foci induced by freezing, the audiosensitive
and photosensitive reflex epilepsies and the models induced by
the topical application of heavy metals, particularly cobalt. The
cobalt model is relatively cheap and simple to reproduce. Besides,
various aspects of its biochemistry, histochemistry and pharmacology
have been studied in the MRC Brain Metabolism Unit, Department of
Pharmacology, Edinburgh University.
A. THE COBALT MODEL OF EPILEPSY
1. Review of literature
Kopeloff et al (1942) first reported that the application
of powdered metal cobalt to the frontal cortex of monkeys
produced epileptiform discharge in the electroencephalogram.
o
Since that original observation, the application of cobalt as
a powder or as a gelatin stick to the frontal cortex has been
used to create reproducible epileptic foci in a variety of
animals including the rat (Dow et al, 1962., Dawson § Holmes,
2 o
1966, Fischer et al, 1967). Dawson 5 Holmes (1966) observed
that no motor seizures were seen if cobalt was implanted in
cortical sites far from the frontal motor area of the rat brain.
Cobalt powder has also been used to induce subcortical epileptic
foci (Mancia § Lucioni, 1966).
Following the unilateral application of cobalt to the
right frontal cortex, a primary epileptogenic focus develops
in the tissue surrounding the implant. A distinct secondary
focus is also formed in the contralateral cortex (Dow et al,
1962, 1972). Epileptiform spikes were maximal at 8 to 12
days and were less marked at 4 weeks after cobalt implantation.
The behavioural response took the form of contralateral fore-
limb clonic movements and bilateral whisker twitches occurring
at 4 to 10 days following implantation (Dow et al, 1962).
Furthermore, the animals developed a lowered threshold to
systemic anti-convulsants within one week of the application
of cobalt (Hartman, Colosanti $ Craig, 1964). Ashcroft et al,
(1974) suggested that the secondary focus arises as a response
to the spread of epileptic activity from the primary focus across
the corpus collosum, and possibly other pathways.
Histologically, the focal application of cobalt produced
intense cellular damage with necrosis, together with focal
meningeal inflammation (Payan, 1971, Fischer et al, 1968,
Emson 8 Joseph, 1975). Degenerative changes were also seen in
the secondary focus, as well as striatum and the thalamus on both
3,
sides (Ashcroft et al, 1974)„ Cobalt ion was also detected in
the secondary focus as well as the striatum and occipital
cortex on both sides of the brain, as early as 6 days and also
at 3 weeks following cobalt application to the right frontal
cortex (Clayton § Emson, 1976) indicating axonal transport
of cobalt ion (Pitman et al, 1972).
Dow et al (1962) suggested that the focal hypersynchronous
epileptic activity characteristic of this model closely
approximated epileptic EEG pattern of some human epilepsies.
This was supported by Dawson § Holmes (1966). Ashcroft et
al (1974) have found that ethosuximide, an anti-convulsant
effective in petit mal, reduced epileptic activity in cobalt
implanted rats while phenobarbitone and diphenylhydantoin
were without effect. The pattern of response to anti¬
convulsants and the fact that cobalt rats showed focal motor
epileptic signs but only rarely developed generalised convulsions
suggest the cobalt model is more suitable for focal or
myoclonic seizure or petit mal. From the biochemical aspect,
this may be advantageous since biochemical analysis will not
be overshadowed by the effects of generalised convulsions.
2. Biochemical alterations in cobalt-induced epilepsy
Emson § Joseph (1975) showed that the levels of glutamic
acid decarboxylase and choline acetylase, enzymes that are
respectively associated with gabbaminergic and cholinergic
4.
systems, were reduced in the primary cortical focus induced
by cobalt implant to the right frontal cortex. This
reduction was maximal when epileptic spiking was at its peak,
and the enzyme levels recovered rapidly as spiking declined.
The concentration of several transmitter amino acids including
gamma-aminobutyric acid and aspartate were also diminished in
the primary focus as the spike frequency increased and they
recovered as the spike activity decreased.
These changes in the primary focus were not consistently
paralleled in the secondary focus. The levels of choline
acetylase and glutamic acid decarboxylase were only slightly
reduced while the concentrations of gamma-aminobutrytic acid
was slightly elevated in comparison to control value. This
might mean that the changes in the primary focus are more due
to the trauma of the implantation procedure itself than to a
concomitant epileptic response. It might also indicate that
the cobalt model represents a denervation response in the
production of focal epilepsy (Emson 8 Joseph, 1975).
The activity of tyrosine hydroxylase was dramatically
reduced in both the primary and secondary focus. This
reduction was maximal when the spike activity was at its peak
8 days following cobalt implantation and started to recover by
4 weeks and completely returned to normal activity 10 weeks
after the application of cobalt (Clayton § Emson, 1976).
However, the concentration of noradrenaline in both foci did
not differ using either biochemical methods of estimation
5.
(Clayton 1976) or fluorescence (Emson § Bjorklund, unpublished
data).
Morrel (1964) using histochemical methods, reported that the
ribonucleic acid content was raised in epileptogenic tissues
in cobalt-implanted cats. However, employing labelled
precursors, Dewar et al (1972) showed no change in ribonucleic
acid levels in epileptic foci and the occipital control area of
the same rat brain.
B. CATECHOLAMINE TURNOVER IN THE BRAIN
Each of the biogenic amines has its own peculiar distribution
in the brain. It has been suggested that they serve as synaptic
transmitters or modulators of normal activity in functionally
distinct systems of the brain, namely 5-hydroxytryptamine (5-HT)
in limbic structures, dopamine in the extra pyramidal and limbic system, and
noradrenaline in central autonomic and alerting systems.
1. Synthesis (See Fig. 1)
The precursor amino acid tyrosine, crosses the blood brain
barrier to become hydroxylated by the enzyme tyrosine hydroxylase
at localized intracellular sites to form L-3,4, dihydroxyphenyl-
alanine (L-DOPA). L-DOPA is then decarboxylated by the enzyme
aromatic amino acid decarboxylase to yield dopamine. Dopamine
is then taken up into storage organelles or vesicles, which






















FIG»! Figure showing tha major biosyri111etic pathway
of dopamine and nor''urenaline»
hydroxylases (Moir § Eccleston, 1968., Udenfriend, 1968).
The hydroxylation of dopamine inside these organelles or
synaptic vesicles, leads to the formation of noradrenaline.
It seems now that noradrenaline could be synthesized either
in nerve cell bodies (Carlsson, 1966, Dahlstrom § Fuxe, 1964)
or nerve terminals (Levitt et al, 1965). Vesicles, synthesized
in the cell body, were transported down the axon to nerve
terminals (Dahlstrom § Fuxe, 1964), whereby they would supplement
the vesicle stores replacing the ones lost by synaptic trans¬
mission. Adrenaline, which is present in very small amounts in
the brain, is formed by N-methylation of noradrenaline.
2. Catabolism
The mechanisms available for inactivation of catecholamines
released from nerve terminals are active re-uptake and enzymic
degradation by methylation, catalyzed by catechol-O-methyl
transferase, and oxidative deamination catalyzed by monoamine
oxidase.
(a) Monoamine oxidase
This enzyme was found to be active in oxidative
deamination of catecholamines (Blaschko et al, 1937).
It is, however, not specific for catecholamines and has
a wide distribution in most animal tissues. It is
mitochondrial-bound (Hawkins, 1952) and consists of a
flavoprotein containing 2 moles of FAD per mole of enzyme
(Yasunobu, 1968). Cytochrome CI and copper are co-factors.
Since it is bound to mitochondria, it has an intra¬
cellular location, and is found in nerve cell bodies and
nerve terminals. The enzyme is more active with phenyl-
ethylamine and catecholamine derivatives lacking a $-
hydroxyl group such as tyramine and dopamine than with
noradrenaline and adrenaline (Blaschko et al, 1937.,
Blaschko, 1952) and is stereospecific for the L-form
of the amines (Prakesi § Blaschko,1959).
(b) Catechol-O-methyl transferase
This enzyme causes the transfer of a methyl group
from S-adenosyl methionine to the 3-hydroxyl phenyl
group of catechol (Axelrod, 1957). This enzyme is
found in most cells and is very abundant in liver and
kidney (Axelrod et al, 1959), and has been demonstrated
in the brain, where it is thought to be a soluble enzyme,
but may be membrane bound since it is difficult to purify
free from membrane with enzymic activity.
Little is known about the enzymes which convert the aldehydes
formed by oxidative deamination of the amines by monoamine oxidase
to either the acid or the neutral metabolites. Since the
intermediate aldehyde metabolites have not been demonstrated,
the enzymes causing the further reduction or oxidation are
probably intimately coupled with monoamine oxidase, and hence
probably bound to mitochondria. Breese et al (1969), however,
showed that the presence of a 3-hydroxyl group will facilitate
the formation of the neutral metabolites, whereas its lack will
8.
result in acid metabolite although no real reason is put
forward for this phenomenon.
The metabolic fate of catecholamines in brain, in vivo, had
been shown following the fate of the labelled amine injected
into the lateral ventricle of the rat brain (Mannarino et al,
1963). Three main groups of metabolites were demonstrated
(Fig. 2):-
1. The 4-hydroxy-3-methoxyphenyl metabolites.
2. The 3,4, dihydroxyphenyl metabolites.
3. The sulphate or glucuronide conjugate
of either.
The main metabolites of dopamine in brain tissue and CSF are
3-methoxy-4-hydroxy-mandetic acid (Homovanillic acid, HVA),
(Sharman, 1960, 1963., Anden, Roos 5 Werdinius, 1963a and b), and
3,4,dihyhydroxyphenylacetic acid (DOPAC) (Rosengren, I960.,
Ashcroft et al, 1968). DOPAC is formed by deamination of dopamine
by monoamine oxidase (Fig. 2), and about one half of it is
further 0-methylated to form HVA. There is a large variation
between animal species as the ratio between the concentrations
of DOPAC to HVA differ considerably. In the mouse, the ratio
is about one (Roffler-Tarlov et al, 1971), while in the rabbit
(Anden et al, 1963) and in the dog (Moir § Yates, 1972), there
is about ten times as much HVA as DOPAC.
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in rat and cat brains by analysis of the radioactivity after
intraventricular injection of the labelled amine, was 4-hydroxy-
3-methoxyphenylglycol (HMPG) or its sulphate conjugate
(Mannarino et al, 1963, Schanberg et al, 1968a and b, Breese
et al, 1969). Moreover, Schanberg et al (1968b) showed
that the major metabolite of both labelled noradrenaline and
normetanephrine injected into the lateral ventricle of the
rat was conjugated HMPG. The radioactivity in the combined free
HMPG and vanillin mandelic acid portion was only ten per cent
that of the conjugated fraction. Furthermore, they showed
that the conjugate was probably a sulphate ester since hydrolysis
occurred with sulphatase preparation, whilst B-glucuronidase
preparation was ineffective. Moreover, HMPG was demonstrated
as the major metabolite of noradrenaline in many other species
including man (Schanberg et al, 1969, Sugden § Eccleston, 1971,
Gordon et al, 1973).
The sulphate esters of noradrenaline metabolites are probably
formed using intracellular-located enzyme system described by
Roy (1971) where a two-stage process is thought to be involved
(Fig. 3). The first stage is the activation of sulphate,
itself a two-step process involving the addition of a sulphate
group to adenosine monophosphate and the phosphorylation of the
ribose 3-OH group using ATP. The second stage is the transfer
of the sulphate group to the recipient phenol group.




ATP + S04 ^ APS + PPi
APS-kinaee
APS + ATP * PAPS + ADP
Sulphotransferase
R. OH + PAPS ' ^ ..PAP + R. OSO"4
APS — adenosine S'-sulphatophoaphate
PAPS = 31 phosphoadenylylsulphate
PAP =* 31 phosphoadenosine-5iphosphata
PPi — pyrophosphate
rig. 3 Fijure showing the- various stances of suipbatioa
of phenolic compounds in the liver. Similar
mechanisms are th.ou.rht to occur in brain.
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(Roffler-Tarlov et al, 1971) and from noradrenaline (Braestrup
§ Nielsen, 1975) are produced intraneuronally in the brain
while the O-methylated/deaminated metabolite is formed mostly
outside the nerve terminals.
Thus, dopamine is first deaminated inside the neuron into
DOPAC and this is later O-methylated extraneuronally into HVA.
However, a small part of HVA can be formed inside the neuron.
Dopamine, released into the synaptic cleft, may first be 0-
methylated to form methoxydopamine (3-methoxytyramine) which
is immediately deaminated inside the neuron into HVA. Moreover,
both steps may take place intraneuronally as the enzyme catechol-
0-methyl transferase has been shown to be also associated with
nerve terminals (Broch S Fonnum, 1972), Similarly, nor¬
adrenaline is first O-methylated by catechol-0-methyl transferase
extraneuronally to form norrnetanephrine which diffuses immediately
inside the neuron to be deaminated by monoamine oxidase to form
HMPG. A small amount of HMPG might be formed by O-methylation
of 3,4-dihydroxyphenylglycol (DHPG), formed by deamination of
noradrenaline inside the noradrenergic neuron.
HMPG, thus formed inside the neuron in the brain, is free
and can diffuse freely outside the neuron into the blood or
CSF. However, in the rat brain, most of this free HMPG is
conjugated intraneuronally to form HMPG-sulphate. These
major metabolites of dopamine and noradrenaline so formed must
then cross barriers to either CSF or blood (Werdinius, 1967.,
Meek § Neff, 1972) (Fig. 4).
FigL
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3. Methods of studying catecholamine turnover
Attempts were made to measure noradrenaline turnover in
the brain as a possible clue to its functional importance.
Since both catecholamines were restricted from entry into
the brain by blood brain barrier (Weil-Malherbe et al, 1959),
other ways of measuring turnover were described
1. Measurement of the rate of disappearance of endogenous
noradrenaline after synthetic blockade using tyrosine
hydroxylase inhibitor such as alpha-methyltyrosine.
3
2. The rate of disappearance of H-noradrenaline or
^H-dopamine injected into the lateral ventricle.
3. Measurement of the rate of disappearance of labelled
noradrenaline or dopamine synthesized from labelled
precursor, tyrosine, injected intravenously.
Using these methods, it was found that the turnover rate of
catecholamines, as with their endogenous concentrations, was
different in various brain regions, being highest in areas of
low concentration of each amine and vice versa (Udenfriend, 1963.,
Burach § Draskoszy, 1964., Iversen § Glowinski, 1966).
4. Metabolite estimation
Another way of estimation of catecholamine turnover in
the brain would be to look at changes in the major metabolite
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level. These changes are measured either by:-
A. A change in the specific activity of the main
metabolite following labelling of the endogenous
amine stores,
and
Bo Assuming that the main metabolite itself cannot
enter the brain from the blood, then the concentration
of these metabolites in brain regions might be
expected to provide an index of turnover of the parent
amine.
However, two criteria must be satisfied:-
(a) Defining the major metabolites of dopamine and
noradrenaline in the brain, and this has already
been shown to be HVA and HMPG, respectively.
(b) Determination whether changes in the level of these
metabolites reflect the turnover of the corresponding
amine.
HVA and HMPG, which are the main metabolites of dopamine and
noradrenaline, respectively, will not enter the brain readily
from the circulation (Werdinius, 1967., Chase et al, 1973).
Intravenously administred HVA did not enter the brain or CSF of
the rabbit (Bartholini et al, 1966) or CSF of the dog (Guldberg
14
§ Yates, 1968). Moreover, intravenously administred C-HMPG
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does not readily enter the CSF of man (Chase et al, 1973).
HVA and HMPG sulphate are eliminated from the brain by
enzymemediated saturable transport mechanism (Werdinius, 1967 .,
Meek § Neff, 1972). Thus, these metabolites pass into the
CSF and reach equilibrium with those of brain tissue. In
normal tissue, blocking the transport system of these metabolites
by probenecid would impair the passage of the metabolites from
the brain to the circulation leading to their accumulation in
the brain of the rat and cat (Werdinius, 1967., Sharman, 1967.,
Meek § Neff, 1972) and CSF of rat and dog (Guldberg et al, 1966.,
Meek $ Neff, 1972, Ashcroft et al, 1975). In man, however,
probenecid will lead to increase in CSF levels of HVA but not
HMPG (Gordon et al, 1973., Korf et al, 1971., Chase et al, 1973).
This probably is because HMPG in human brain is only 20%
conjugated in contrast to 90% and 80% in the rat and dog brain,
respectively (Schanberg et al, 1968b).
Local stimulation of the locus coeruleus, where nor-
adrenaline-containing neurons originate (Ungerstedt, 1971)
produced a significant increase of 60% in total HMPG in pooled
right and left cerebral cortex (Walter § Eccleston, 1974),
indicating the increased turnover of noradrenaline in the
stimulated rats.
It was also shown that the rate of HVA formation in the
brain reflected the rate of dopamine formation and turnover in
the brain (Sharman, 1966, 1967).
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Moreover, estimation of HVA levels in different regions of
the brain was used in attempting to localize central dopaminergic
fibers and is quite a reliable method since HVA is relatively
stable in post-mortem tissue (Hornykiewicz et al, 1968).
C. AIM OF THE WORK
Previous workers observed that the concentrations of 3-methoxy-
4-hydroxyphenylglycol (HMPG) and homovanillic acid (HVA), the main
metabolites of the catecholamine noradrenaline and dopamine,
respectively, were altered in brain tissue taken from rats with
cobalt-induced epilepsy. It is well known that alteration in the
levels of these metabolites reflect changes in the turnover of their
respective catecholamine precursor. Increased levels of HMPG were
found in the epileptic cortical foci and striatum 8 days after
cobalt implantation reaching 5-6 folds of the control levels, in
contrast to HVA levels which showed a marked reduction in the striatum
at that period (McQueen § Emson, unpublished results). This is
in comparison to the high levels of HMPG and HVA in frontal cortex
and striatum respectively, reported by Clayton (1973) after cobalt
implantation, together with the reduced tyrosine hydroxylase
activity in these structures.
The present work was done to confirm and possibly extend the
findings in these metabolite changes, reflecting the turnover of
their parent catecholamine.
These metabolites were first estimated 8 days following cobalt
15.
implantation when epileptic activity was well established and any
change in catecholamine turnover might be anticipated. Furthermore,
post-mortem alteration of both metabolite levels were measured to
determine the extent to which it might have contributed to the high
levels already observed. It is hoped that this work could help
in the extension of the role of catecholamine turnover in the focal




Male Piebald Virol Glaxo (PVG) rats, 200-250 g in weight,
were used.
2. PREPARATION OF COBALT-GELATIN STICKS FOR IMPLANTATION
This was prepared according to the method of Fischer et al (1967).
Metallic cobalt powder (Mesh 200) was used. To 5 ml of cobalt
powder, 7 ml of 5% aqueous gelatin solution, warmed to 56°C was added,
mixed and stirred at 56°C in a beaker.
After sedimentation of the suspended powder and decantation of
the supernatant gelatin solution, the mixture was poured on a horizontal
slide to form a layer about 0.75 mm thick. After cooling, the solidified
cobalt-gelatin film (still on the slide) was dehydrated in acetone for
2 hrs, then kept in formaldehyde for 2 hrs for fixation. It was then
washed with distilled water and kept in 80% alcohol.
Before use, the alcohol was allowed to evaporate. On the slide,




A. Cobalt implantation into the right frontal cortex
The following procedure concerning the operation and
subsequent electrocorticographic (ECoG) recording from cobalt
implanted rats were all carried out in the MRC Brain Metabolism
Unit, Edinburgh University, using the method of Dow et al (1962,
1972).
All surgical procedures were done under aseptic conditions.
Male PVG rats (250-300 g) were anaesthetized with halothane
(Fluothane, ICI) in oxygen (2.5 lt/min)„ A halothane concen¬
tration of 4% was used for induction and 2% for maintanance of
anaesthesia. The scalp of the animal was shaved with an
electric hair trimmer and then it was swabbed with 2% iodine
solution in ethanol. A straight midline cranial incision
(2-2.5 cm long) was made on the scalp and the underlying fascia
was reflected to expose the outer surface of the skull. After
locating the coronal and sagittal sutures, the skull was
trephined, the hole was placed 2 mm from each suture in the
right anterior quadrant. The hole was made with a dental drill
(Renta model RA/21) and a round No. 6 burr (Ash),care being taken
not to damage the underlying dura.mater. Haemorrhage from the
skull could be easily controlled and did not constitute a
problem. The cobalt implant was made into the frontal cortex
as follows:-
At the site of the implant, the dura was split with the tip
of sterile 23-gauge needle. Using fine forceps, one mm
cubes of the cobalt-gelatin stick was inserted perpendicularly
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into the cortex so that its tip was flush with the cortical surface.
The hole in the skull was then sealed with bone wax and the whole
operative field was sprayed with antibiotic (Polybacterin). The
incision was then closed with Michel clips (Aescular 12 x 3 mm)
or silk (Mersilk). The whole procedure took about 15 mins.
Control animals refer to both unoperated litter mates of the
experimental animals and to sham operated animals. The latter .were
operated upon exactly as the experimental animals, but no cobalt was
placed into the cortex. The types of controls used in each
experiment is stated in the methods and the results.
B. Fixation of recording screws to skull
In cases of an animal whose EcoG was to be recorded, the operation
procedure was modified so as to include the fitting of permanent
recording electrodes. Using the same equipment and preoperative
procedure as above, a curved cranial incision (2-2.5 cm) was made
through the scalp close to the left eye. The skull was cleaned and
the coronal, sagittal and naso frontal suture located and used as
landmarks to ensure consistent placement of the recording electrodes.
The skull was trephined, pairs of holes were centered 2 mm on each
side of the sagittal and coronal sutures. Cobalt gelatin implant¬
ation was carried out into the right frontal cortex as described
above.(See Fig. 5A).
Specially constructed stainless steel screws (8BA, about 8 mm
in height, made in the Department) were inserted into the holes to
act as recording extradural electrodes.
18a.
Fig. 5 A
Rat skull - dorsal aspect




Site of cobalt implant
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The screws were secured to the skull by cold-curing acrylic
resin (Simplex), and to aid this purpose, a groove had been cut around
the body of the screw.
One of the screws was placed directly over the implant and one
in each of the other three holes. Fig. 5B shows the design of the
screws and their placement in the skull. The operation area was
then sprayed with Polybactrin and the skin flaps replaced after
four holes had been punched in it so that it fitted over the
electrodes and allowed them to protrude externally for recording.
The wound was then closed with Michel clips or silk. The whole
procedure took 20-25 mins.
C. Post-operative management
No special post-operative care was necessary. Skin wounds
healed quickly, and Michel clips removed after 7 days of operation.
Drug-treated rats in a particular experiment were always kept separate
from controls. Not more than 4 rats were placed in a cage, food
and water were allowed ad libitum.
Rats were checked daily for the early epileptic manifestations.
Few rats might have loose screws in the early post-operative period.
These were fixed again with acrylic under aseptic conditions in
the operating theatre. Older rats with loose screws were discarded
from the experiment.
4. ELECTROCORTICOGRAPHIC (ECoG) RECORDINGS









FIG 58 Placement of the hollow stainless steel screw in the skull.
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5. COLLECTION AND STORAGE OF BRAIN SAMPLES FOR BIOCHEMICAL ASSAY
Groups of experimental rats were stunned, and decapitated between
3 and 11 days after cobalt implantation. The brains were removed
quickly, placed on a mixture of solid CO2 and crushed ice. As
dissection was completed, the tissue samples, placed in polythene
bags, were stored in liquid nitrogen (-195°C)„ No tissue sample
was left in liquid nitrogen for longer than 3 weeks before being
assayed.
6. DISSECTION OF BRAIN TISSUE SAMPLES
The brain was placed on its ventral surface on a glass plate
resting on a mixture of solid CO-, and crushed ice. The cerebellum
was removed, and the forebrain bisected. The curved tip of a
micro-spatula was introduced into the lateral ventricle and passed
caudally and rostrally, reflecting the cerebral cortex laterally.
Tissue portions were taken from the following brain regions, using
fine forceps
(a) Right frontal cortex (RFC)
This contained the site of the implant. All visible
pieces of cobalt gelatin as well as any calcified tissue
were removed, before the sample was taken.
21.
(b) Left frontal cortex (LFC)
This area is the site of the secondary (mirror) focus in
cobalt implanted rats. No gross changes could be seen.
From each frontal cortex, tissue samples were taken quickly and
frozen on solid CO2 before storage.
(c) Occipital cortex (OcC)
Larger tissue blocks were taken from this area, since
it was used to estimate the tissue recovery of HMPG. This
area was reported to show no biochemical or ECoG changes after
cobalt implantation and so can be used as internal control for
the same animal.
(d) Right striatum (RS)
(e) Left striatum (LS)
The striatum was identified as bilateral masses of gray
matter in the floor of the lateral ventricle with the expanded
head of the caudate nucleus anteriorly and its body and tail
tapering posteriorly. Care was taken during dissection of the
striatum to avoid including any portion of the adjacent cortex
or white mater.
The average dissection time for each rat was 2 mins. For each
area, tissues were pooled from two rats to constitute a sample.
Samples weighed 80-100 mg for cortex and 30-50 mg for striatum.
Tissue samples were immediately stored in liquid nitrogen until being
assayed.
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Corresponding tissue samples fron control and cobalt implanted
rats were taken together for biochemical analysis.
7. BIOCHEMICAL ASSAY OF HMPG AND HVA
A. HMPG IN BRAIN
HMPG was estimated by the micromethod of Ashcroft et al
(1975) which is used for tissues of 100 mg and less and is
essentially based on that of Walter § Eccleston (1974). The
micromethod, however, allows the simultaneous estimation of HMPG
and either HVA or 5-HIAA in brain tissue samples and CSF.
In principle, the method for HMPG assay depends on hydrolysis
of the conjugated HMPG with the enzyme 'Helicase' followed by
extraction of the total HMPG with ethyl acetate and subsequent
production of the electron capturing derivative, namely acetyl-
trifluoracetyl-HMPG (acetyl-TFA-HMPG) for its quantitative
estimation by gas liquid chromatography (GLC).
The maximum number of tissue samples that could be processed
in one run was twenty. In every group of tissues to be
assayed, two or four tissue samples were over 0.1 g in weight.
The extracts of these heavier tissues were divided into two equal
portions, one of which was used as a recovery for authentic HMPG.
Reagents
The following reagents were used in the assay:-
0.4 M Perchloric acid (Analar), 1 M sodium acetate buffer, pH5,
Ethyl acetate(CT grade), 1.65 M potassium bicarbonate (Analar),
Dichloromethene (BDH redistilled), Anhydrous sodium sulphate (Analar),
Acetic anhydride (Analar), Trifluoro-acetic anhydride (Sigma), 1 mg
HMPG base/ml using 4-hydroxy-3-methoxyphenylglycol (HMPG)-bis-piperazine
salt (Sigma), HCH hexachlorocyclohexane (HCH BDH), and Helicase
(Industre Biologique Francaise). Acetic anhydride and some of the
ethyl acetate (used for injection into the gas liquid chromatograph),
were distilled before use, using a fractionation column.
Helicase is an enzyme preparation composed of a mixture of
sulphatase (1.5 x 10? Roy Units/g) and glucuronidase (1 x 10^ Fishman
Units) and consisted of a lyophilized preparation of the gastric juice
of Helix pomatio. The pH optimum of sulphatase was stated by the
manufacturer to be 5. Using tritiated HMPG sulphate it was found
that a mean of 87% i 9% S.D. of HMPG sulphate was hydrolyzed by the
enzyme and extracted into ethyl acetate in comparison to less than 2%
extracted without the enzyme (Pullar, 1971).
Crude enzyme, as supplied, was found to give high background
fluorescence during HMPG estimation which was markedly reduced by
acetone purification (Pullar, 1971). Accordingly, the crude enzyme
was purified by acetone as follows, before employing it for the
GLC estimation of HMPG:-
One vial of Halicase was dissolved in about 30 ml distilled water
and chilled in the fridge. Acetone (BDH) was also chilled. A
magnetic follower was then placed in the 'Helicase' solution and about
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300 ml of cold acetone was steadily poured into the agitated solution.
The solution was then filtered immediately through a Buchner funnel
and washed with further 100-200 ml of cold acetone. The precipitated
enzyme was dried overnight in a dessicator over pellets of sodium
hydroxide and then stored in the fridge.
A 50 mg/ml solution, freshly prepared, should be clear, and not
cloudy, although brown. It was shown that the maximum activity
of 9 mg/ml 'Helicase' solution was obtained after 8 hrs incubation
(Walter,1973). The activity of each enzyme preparation was
ascertained and compared to that of a previously treated enzyme as
described later, before being employed in the assay.
ASSAY PROCEDURE
The brain tissue samples were removed from liquid nitrogen on to
a piece of weighted aluminium foil and the tissue weight quickly
determined. The tissue was kept on a tray of solid COg (-75°C)
after weighing and before it was homogenized, to avoid its thawing,
1„ Homogenisation and precipitation of proteins and lipids
Tissues of 0.1 g and less in weight were homogenised in 1 ml
of chilled 0.4 M perchloric acid in a chilled homogenizer
(Jencon's). The homogenate was poured into a chilled 3.5 ml
polythene centrifuge tube and the homogenizer washed with 0.2 ml
of the acid which was added to the homogenate. All samples
were placed on ice.
Tissues of more than 0.1 g, to be used for recovery, were
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homogenized in the same way, but using 2 ml and 0.4 ml of
perchloric acid, respectively.
The homogenate was centrifuged in an MSE high speed 18
centrifuge at 3,000 g for 10-15 mins at 4°C.
2. pH Adjustment
The supernatant was decanted into a 5 ml beaker, a 1 cm
long magnetic follower added and the pH adjusted using a pH
meter and a magnetic stirrer, to about 5-5.5 by the careful
addition of 5 N, 1 N, and 0.02 N K0H. 1 N Hcl was kept at
hand for addition if too much K0H was added.
The solution was poured into a chilled conical (15 ml)
stoppered test tube, the beaker washed out with a few drops
of distilled water added to the extract in the tube.
The sample was then placed in the deep freezer for 15 - 50
mins to ensure maximum precipitation of potassium perchlorate.
It was then allowed to thaw and centrifuged in an MSE Mistral
at 3,000 g for 5-10 mins at 4°C. The supernatant was then
decanted into a 15 ml conical test tube and the volume made
up to 4 ml with distilled water.
3. Separation of HMPG and HVA portions
The solution was divided into two portions, each of 2 ml
for the estimation of HMPG and HVA respectively. The HVA
portion at about pH 5 was stored in the deep freezer overnight
for subsequent assay.
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4. HMPG tissue recoveries
The supernatant volume from the heavier tissues of the
occipital cortex, adjusted to 4 ml with distilled water as above,
was divided into two equal portions. Standard amounts of
20 mg and 50 mg HMPG were added to one portion of each of such
four or two extracts, respectively.
4. Aqueous standard solutions
Standard HMPG solution of 20, 20 50 and 50 mg HMPG were
freshly prepared, the volume of each being adjusted to 2 ml with
distilled water. For the duplicate blanks, distilled water was
used to a volume of 2 ml.
6. Hydrolysis of conjugated HMPG
To each sample, 100 pi of 1 M
sodium acetate buffer pH 5, 50 pi Helicase 50 mg/ml freshly
prepared, and a drop of chloroform (to prevent bacterial growth),
was added. The sample was incubated overnight in a water bath
at 37°C for about 17 hrs.
7. Extraction of glycol metabolites
Samples were taken out of the water bath. Each sample, of
pH about 5, was shaken twice for 5 mins each time, with 4 ml and
3 ml ethyl acetate (CT grade). The layers were separated by
centrifugation, and 3 ml and 3,5 ml respectively, of the ethyl
acetate layer, which contains the glycols, were removed into a
10 ml glass test tube. The pooled ethyl acetate extracts were
evaporated to dryness in the test tube by blowing nitrogen in a
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heated block at 56°C.
8. Acetylation of glycols
The residue was taken up in 0.4 ml water and acetylated by
the addition of 50 yl acetic anhydride (redistilled) and 0.6 ml
of 1.65 M potassium biocarbonate solution, and the reaction
allowed to proceed for 35 mins. The acetylated HMPG was
extracted by shaking for 1 min with 1.5 ml dichloromethane
followed by centrifuging.
9. Achieving anhydrous conditions
1.3 ml of the lower organic layer (containing the acetylated
derivatives of the alcohol metabolites) was shaken in an
Ependorff tube, with a little anhydrous sodium sulphate. The
dichloromethane extract was carefully decanted into a 3 ml hard
glass test tube and evaporated by blowing nitrogen at 56°C.
10. Trifluoroacetylation
The residue was taken up in 0.5 ml trifluoroacetic (TFA)
anhydride mixture (prepared by mixing 1 part TFA plus 5 parts
ethyl acetate (CT), prepared fresh).
The test tube is then stoppered and heated at 56°C for
15 min to convert the acetylated HMPG into its fluorinated
derivative. After this 15 min, the solution was evaporated
carefully to dryness under nitrogen at 56°C.
11. Addition of internal standard
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Using Pasteur glass pipette, the residue was tkan up in
0.2 ml ethyl acetate (CT grade, redistilled) containing 15 ng/ml
hexachlorocyclohexane (HCH), as internal standard. The solution
was transferred by Pasteur pipette into a GLC micro-vial. This
can be stored for several days in the refrigerator before being
put on the machine, as long as the vial cap is firmly closed.
12. The quantitative estimation of HMPG by gas liquid
chromatography (GLC)
In the present work, the procedure was performed using a
63
Perkin-Elmer 900 gas liquid chromatograph fitted with a Ni
electron-capture detector (Fig. 6)„ The carrier gas was Argon/
methane (90%/10%) flowing in one eighth inch copper piping at
a pressure of 70 lb/sq inch. The pressure in the cylinder
head should be at least 10 lb/sq inch greater than the pressure
setting in the GLC, and it was usually set at 100 lb/sq inch.
The injection head was screwed on the machine with a gas-
tight joint, to a 5 ft long Perkin-Elmer column, 4 mm internal
diamter. The stationary phase was 2.5% methyl-silicone gum
rubber (E 301) on a chromosorb support (GAW-DMCS) 80-100 mesh.
The powder was kept in position with a spun glass yarn plug.
The flow rate in the GLC was measured as 60 ml/min with a soap
bubble flow meter at exit.
Samples were introduced into the system by on-column
injection of the ethyl acetate solution using 10 pi glass micro-
syringe with a 5 cm long needle. An automatic injection device
(Hewlett-Packard) delivering 2 pi or 4 pi was used with minimum
28a.
A schersatic diagram ahowiag the erpariiaental system
FIG 6 for l-£3 chromatography. The column oven and
detector oven uov/er supply and temperature control
unite have been omitted for the saico of clarity.
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wash-out. The time between the injection of consecutive samples
was 60 min to allow for the maximum clearing of the gas from
the machine, thus reducing the chance of contamination with
vapours from the previous sample. The needle was pushed
quickly through the rubber septum at the injection port head,
the sample injected and the needle quickly withdrawn. The
speed of the chart paper was set at 1 cm/min. The Perkin-
Elmer electron-capture detector consisted of a cylindrical source
of 63j\[i at the periphery of a small chamber, through which the
carrier gas and sample vapour passed surrounding a centrally-
placed probe. The steady state current across the chambers
from the source to the probe was maintained by electron capture
supply unit using a direct current supply.
The final settings with the approximate temperature equivalents
were as follows:-
Setting Temperature (°C)
The column temperature was set to give a retention time of
2.2 min and 3.8 min for HMPG and HCH (internal standard) respectively.
«o
Calculations
For each sample, the height of each acetyl-TFA-HMPG and HCH
peak (in min) was measured and the ratios of the former to the















Amount of HMPG in
_ sample ratio x recovery x 10
each sample (ng) mean ratio equivalent to
10 ng HMPG in aqueous standard
solution
HMPG concentration
_ Amount of HMPG in samples (ng)
(ng/g) tissue weight (g)
HVA IN BRAIN
The concentration of HVA in brain tissue was estimated by
the micromethod (Ashcroft et al, 1975). The method requires a
minimum weight of 15 mg of striatal tissue for estimation of the
metabolites. In principle, the method is based on extraction
of HVA into butyl acetate and followed by back extraction into
0.15 M sodium borate buffer and subsequent fluorophore production.
Reagents
1. Redistilled butyl acetate (BDH reagent grade)
saturated with water.
2. Ascorbic acid 3 mg/ml, freshly prepared.
3. 2 N HCL with 87 ml of concentrated HCL (about 13 N)
were made up to 500 ml with distilled water.
4„ 0.15 M borate buffer, pH 8.5 - Add 1 M NaOH (4 g in
100 ml distilled water) to 0.15 M boric acid (9.28 g/lt
until the pH reached 8.6. 250 ml were prepared at a time
and stored in the refrigerator.
5. Alkaline potassium ferricyanide (K3Fe (CN)6),
freshly prepared. A fresh solution containing 11 mg K3Fe
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(CN)6/ml was prepared. Before use, 12.2 ml concentrated
ammonia (BDH containing 35% NH3) was mixed with 12.8 ml
distilled water and then 100 pi K3Fe (CN)6 (11 mg/ml) was
added to the mixture.
6. Cysteine solution, 1.75 mg/ml, was prepared freshly
before use.
7. Homovanillic acid (HVA) (Calbiochem, A grade), stock
standard, 1 mg/ml, in distilled water, was prepared and
stored in the refrigerator. This was renewed every 4 weeks.
ASSAY PROCEDURE
1. Extraction of HVA
To the 2 ml extract of tissue samples in a 15 ml conical
test tube, 25 pi ascorbic acid (2 mg/ml) and 50 pi of 2 N HCl
were added and the solution saturated with sodium chloride.
The acid metabolites were extracted by shaking twice, for
5 min each time, with 5 ml redistilled butyl acetate,
saturated with water. The samples were then centrifuged
and 4 ml and 5 ml of the upper butyl acetate layer removed
into another 15 ml conical test tube. The acids were then
re-extracted into 0.7 ml of 0.15 M borate buffer, pH 8.5,
by shaking for 5 min. The samples were centrifuged and the
upper butyl acetate layer aspirated off using a water pump.
0.5 ml of the lower aqueous layer was then taken with Eppendorf
pipette for the assay of HVA.
Aqueous standard solutions containing 20, 50, 100 and
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200 ng HVA, respectively and in duplicates, were extracted
and assayed with each batch of samples. Recovery samples
were not required in HVA assay in different brain regions
due to the high recovery of added HVA taken through the
method.
2. HVA fluorophore production
To each 0.5 ml sample in an Eppendorff tube, 200 yl
alkaline K3Fe (CN)6 solution was added. Exactly 4 min
later the reaction was inhibited by the addition of 50 yl
cysteine solution (1.75 mg/ml).
3. Spectrophotofluorimetric assay of HVA
The fluorescence was read on a Perkin-Elmer spectrophoto
fluorimeter MPF—3A within 1-2 hours, using an excitation
slit of 2 and an emission slit of 16. No filter was required.
The emission wavelength was set at 418 nm and the excitation
scan run between 250 nm and 380 nm. The fluorescence
due to HVA fluorophore was measured by the vertical distance
from the top of the peak at an excitation wavelength of 320-
325 nm to a line drawn between two depressions at about 280 nm
and 350 nm respectively.
Calculations
For each tissue sample, the peak height of HVA fluorophore was
measured (in mm) at 320 nm. The peak height due aqueous standard
amount of HVA taken through the same method was also measured. From
the latter, the average height equivalent (in mm) for 10 ng HVA was
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calculated. Hence
Amount of HVA in each
tissue sample (ng)
Sample peak height x 10
Peak height equivalent for
10 ng in aqueous solution HVA.
Knowing the tissue weight, the concentration of HVA in the tissue
sample could then be calculated:-
8. EXPERIMENTAL DESIGN
A. LINEARITY OF THE MICROMETHOD FOR HMPG AND HVA
1. Determination in pure solutions, of the linearity of the
electron capturing derivative formation of HMPG for
estimation by GLCo
Ten solutions, each of 2 ml and containing 10 ng, 20 ng,
50 ng and 100 ng HMPG in duplicates, respectively, were freshly
prepared. To each sample, 100 yl sodium acetate buffer,pH5 50 yl
of Helicase solution (50 mg/ml, freshly prepared) and one drop of
chloroform were added. All samples were then incubated overnight
at 37°C for the subsequent extraction, acetylation and trifluoro-
acetylation of HMPG and consequent GLC estimation as described
above.
2. Tissue recovery of added HMPG processed through the micromethod
HVA cone, (ng/g wet
tissue weight)
Amount of HVA (ng)
Tissue weight (g)
The brain of a male PGV rat was quickly dissected out and
weighed after separation of cerebellum. Homogenization with 0.4 M
perchloric acid (1 ml/100 mg) was done, as described. After pH
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adjustment with potassium hydroxide and centrifugation, the
volume of the supernatant was about 22.5 ml which was divided
into ten portions each of 2.2 ml. Standard amounts of 10,
20, 50 and 100 mg HMPG, freshly prepared, were added to these
portions, in duplicates, respectively. The remaining portions
served as tissue standard duplicates. To each sample 100 yl of 1 M
acetate buffer pH 5, 50 yl of freshly prepared helicase, 50 mg/ml
and 1 drop chloroform were added. Samples were then incubated
overnight (17 hrs) in a water bath at 37°C for subsequent
extraction and estimation of HMPG by GLC as described before.
Calculation of the per cent recovery of HMPG was done as
follows:-
The ratio of acetyl-TFA HMPG peak to that of HCH was
determined for each sample. The average ratio equivalent to
10 ng HMPG added to brain tissue samples was determined.
Similarly, the average ratio equivalent to 10 mg HMPG in aqueous
standard solution calculated. Hence:-
% recovery of Ratio equivalent to 10 ng HMPG added x 10
added HMPG Ratio equivalent to 10 ng HMPG in aqueous
standard solution.
3. Determination, in pure solution, of the linearity of HVA
fluorophore formation
Ten solutions, each of 2 ml and containing standard amounts
of 20, 50 and 100 ng HVA in duplicates respectively, were freshly
prepared.
All samples were then taken for HVA extraction twice with
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butyl acetate, back extraction with borate and eventual
fluorophore formation as described before.
4. Tissue recovery of added HVA processed through the m'icromethod
The striatum from 5 male PVG rats, about 12 weeks old, was
quickly dissected out after decapitation and pooled before being
weighed. Homogenization was done with 0.4 M perchloric acid
using 1 ml for each 100 mg tissue weight as described before.
After pH adjustment with potassium hydroxide, the supernatant
volume was 17.2 ml, and it was divided into 8 portions each of
2.1 ml. To these portions standard amounts of 20, 50 and 100 ng
HVA standard were added in duplicates, respectively. The
remaining portions served as tissue standard duplicates. All
samples were then subjected for HVA extraction and estimation
as described above. Determination of % recovery of HVA added
to brain tissue was done as follows
The HVA fluorophore peak height (in mm measured at 320 nm)
was measured for each sample. The mean peak height (in mm)
equivalent to 10 ng HVA added to brain tissue was determined.
Similarly, the mean peak height (in mm) equivalent to 10 ng HVA
in aqueous standard solution was calculated. Hence:-
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Peak height (in mm) equivalent to 10 ng
% recovery of added _ HVA added to brain tissue x ^qq
HVA to brain tissues Peak height (in mm) equivalent to 10 ng
in aqueous standard solution.
SPECIES VARIATION OF HMPG AND HVA.
Ten male Wistar rats, 12 weeks old and weighing 180 - 250 g,
and 10 male PVG rats,of similar age and weight, were used.
From each rat the stratium was dissected on each side and portions
of frontal cortex were taken from each side after decapitation
as described before.
From each side, frontal cortex or striatum was pooled from
two rats to constitute a tissue sample for that region. Thus, 5
samples of frontal cortex or striatum were obtained for the right
and left sides from ten rats in each group. Portions of occipital
cortex were also pooled from 6 rats for estimation of tissue
recovery of HMPG. Frontal cortex samples, recovery samples, as
well as freshly prepared aqueous standards of HMPG were taken
through the micromethod for the estimation of HMPG levels by GLC
as described above.
Tissue samples from striatum, together with freshly prepared
aqueous solutions containing standard amounts of HVA were taken
through the micromethod for assay of HVA levels as described
above.
B. HMPG AND HVA LEVELS IN COBALT-IMPLANTED RATS
1. HMPG and HVA levels in unoperated and sham operated
controls 8 days after operation
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Ten PVG rats were used in the experiment of which 5 were
operated controls.
Under halothane anaesthesia, these rats were operated upon
exactly like cobalt-implanted litter mates, but after trephining
the skull with No. 6 burr over the right frontal cortex 2 mm in
front of coronal suture and 2 mm lateral to the sagital suture,
these rats received no cobalt implant. The hole in the skull
was closed with bore wax and after spraying the operative held
with polybacterin, the skin was sutured with silk.
No special post-operative care was necessary. None of the
animals displayed clinical jerks in the post-operative period.
At time of sacrifice, 8 days after operation, the rats were killed
by decapitation and their brain quickly removed on solid CC>2
and crushed ice mixture. Portions of the frontal cortex and
striatum from each side were quickly dissected and taken to
constitute a sample. No pooling of tissues was done. Tissues
were quickly stored in liquid nitrogen. Thus, five samples from
each cortex were available for HMPG estimation and five samples
from each striatum for HVA assay from the 5 sham operated rats.
A similar number of samples for cortex and striatum were taken
from the 5 unoperated control rats.
Samples were assayed within 3-4 days of storage in
liquid nitrogen. Samples of both groups of rats were taken
together for biochemical assay.
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2. HMPG and HVA levels at
8 days after cobalt implantation
Thirty-two PVG rats were used of which 16 animals served
as unoperated controls.
Under halothane anaesthesia, 16 of these rats received cobalt
implants as described previously. No special post-operative care
was necessary.
Eight days after implantation, when contralateral forelimb
jerks and whisker twitches were well established, the rats were
killed by decapitation, and their brains quickly dissected out
and put on a mixture of solid CO2 and crushed ice. After the
cerebellum was removed, tissue portions were taken from the right
frontal cortex (RFC) (after enucleating any excess cobalt and,
sometimes, calcium deposits), left frontal cortex (which is the
site of mirror focus), the right striatum (RS), left striatum (LS)
and occipital cortex (OC). Tissues were pooled from 2 rats to
constitute a sample for the particular area.
Control rats were treated in the same way after decapitation.
Thus, 8 tissue samples were available for each region studied in
16 cobalt implanted rats and a similar number from 16 unoperated
controls. Tissue samples from both groups of animals were taken
together for homogenization and biochemical estimation of HMPG and
HVA.
3„ HMPG and HVA levels at 3, 7 and 11 days after cobalt
implantation in PVG rats
The absence of any significant changes in the major cate-
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cholamine metabolite levels 8 days after cobalt implantation,
when epileptic manifestations were marked, contrasted with the
changes in these metabolites previously reported. Thus, it
was desirable to follow the changes in these metabolites as
indicies of their parent catecholamine formation and turnover
at different stages of development of focal epilepsy in cobalt
implanted rats.
This was done at the following time periods:-
A. 3 days after cobalt implantation.
At this time, both primary and secondary
foci were early in development.
B. 7 days after cobalt implantation.
The epileptic activity from both foci was
maximal.
C. 11 days after cobalt implantation.
The epileptic activity from both foci was
still prominent.
For this purpose, sixty male PVG rats were operated upon,
of which twenty-four rats served as sham operated controls.
Of the thirty-six cobalt-implanted animals, eighteen rats
received cobalt implant into the right frontal cortex and had
four recording screw electrodes fixed to the skull, while the
remaining rats had only cobalt implants into the right frontal
cortex.
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Of the 24 sham control rats, 12 animals had the dura
mater over the right frontal cortex incised and 4 recording
screw electrodes fixed to the skull, while the remaining rats
had only the dura mater over the right frontal cortex incised
without the fixation of any screw electrodes„
The operative procedure for cobalt implantation and the
fixation of screw electrodes is already described in the
Methods.
Electrocorticographic (ECoG) recording was done from rats
with fixed electrodes at 3, 5, 7, 9 and 11 days after cobalt
implantation. Each ECoG recording was for 10 min and simult¬
aneously recorded on a magnetic tape (Tandberg Series 100)
for computer spike analysis (Hill § Townsend, 1973). The ECoG
instrumentation, recording technique and spike analysis is
described in Section II (Methods).
Rats were sacrificed at 3, 7 and 11 days after cobalt
implantation. During each of these days, 12 cobalt implanted
rats were sacrificed, half of which had recording screws
fixed to the skull, while 8 sham controls were killed, half of
which were with electrodes.
After decapitation, the brain of each rat was quickly
dissected out onto solid CO2 and crushed ice mixture and
cerebellum removed. Tissue portions were taken, using sterile
forceps, from right frontal cortex (RFC) which is the site of the
primary focus,left frontal cortex (LFC) which is the site of the
41.
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secondary focus, the right striatum (RS), left striatum (LS),
and occipital cortex (OcC) . The technique of dissection is
described in the Methods.
Tissues were pooled from each of two rats in a group to
constitute a sample for each of the above brain regions, one rat
with electrode and the other without electrode.
Thus, 6 samples were available for each of the above brain
regions from 12 cobalt implanted rats sacrificed on each of the
days mentioned above in contrast to 4 samples for each brain region
from 8 sham operated controls sacrificed at the same time.
The frozen samples on solid COg were taken quickly for storage
in liquid nitrogen. Subsequent biochemical analysis was completed
within 3-4 weeks of storage.
C. STUDY OF THE POST-MORTEM STABILITY OF HMPG AND HVA IN BRAIN TISSUE.
The usual method of handling rat brain tissues was to dissect
the brain out quickly onto solid COg (-75°C) after decapitation and
to take the brain tissue as soon as possible to liquid nitrogen
storage (-195°C) until the beginning of the assay (Clayton, 1976).
At the time of the assay, the brain tissue was taken out of
liquid nitrogen onto solid CO2, weighed and then homogenized for
the estimation of HMPG and HVA. So, two time periods were involved,
namely:-
A. The time between death and storage in liquid
nitrogen (-195°C), i.e. before freezing.
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B. The time between the removal of brain tissue from liquid
nitrogen (-195°C) and the starting of the assay, i.e.
after freezing.
Since HMPG and HVA are formed by the enzymatic degradation of
noradrenaline and dopamine respectively, it was conceivable then that
changes in environmental temperature as well as the duration of time
required for each step of tissue handling might alter the rate of
formation and consequently the concentration of these metabolites
in the brain. So, it was desirable to investigate the effect of
these factors, namely, time and temperature, on the brain concentration
of both metabolites.
For both time periods mentioned above, changes in environmental
conditions were induced by exposing the brain tissue to:-
1. Immediate homogenization and assayc
2. Solid C02 (-75°C).
3. Ice (0°C).
4. Room temperature (20°C).
I. HMPG POST MORTEM STABILITY
A. BEFORE FREEZING IN LIQUID NITROGEN
Twenty PVG rats were used. As mentioned above, variation in
environmental conditions were instituted by exposing the brain
tissue to the following:-
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1. Homogenized immediately for assay.
2. Immediately to liquid nitrogen storage (-195°C).
3. Ice (0°C) for 30 min. Tissue from frontal cortex
was put on ice for 30 min before being taken
quickly to nitrogen storage.
4. Room temperature (20°C) for 30 min.
The decapitated head of the rat was put on the
bench for 30 min before dissecting the brain tissue
quickly for storage in liquid nitrogen.
Each tissue sample was obtained by pooling portions of
the frontal cortex on each side of one rat. Each tissue sample
weighed at least 200 mg before assay for duplicate estimates of
HMPG, as described above.
For each condition, five tissue samples were assayed from
the rats used in the experiment.
B. AFTER FREEZING IN LIQUID NITROGEN
Twelve PVG rats were used. Pooled frontal cortex, weighing
at least 600 mg taken from the brain of 2 decapitated PVG rats
was distributed into three, polythene bags and quickly placed in
liquid nitrogen. Before the start of the assay, these tissue
samples were taken out of liquid nitrogen storage and each sample
was exposed to a different environmental condition as follows,
before homogenization:-
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1. Solid C02 (-75°C) for 5 min.
2. Ice (0°C) for 5 min.
3. Room temperature (20°C) for 5 min.
Here the tissue sample was put on the bench.
Each sample weighed at least 200 mg before assay. Thus,
for each condition, six tissue samples were processed from the
rats used in the experiment.
After homogenization and centrifugation and pH adjustment,
duplicate estimates of HMPG were made on the supernatent of
each tissue sample as described before.
In all HMPG assays, duplicate aqueous standards of 10, 20,
50 and 100 ng HMPG, respectively in buffer and with Helicase, were
processed with the above tissue samples.
For tissue recoveries, frontal cortex was pooled from 2
rats and homogenized with perchloric acid for duplicate
recoveries of 10, 20, 50 and 100 ng HMPG respectively.
II. HVA POST-MORTEM STABILITY
A. BEFORE FREEZING IN LIQUID NITROGEN
Twenty male PVG rats were used. After dissection, the
striatum was exposed to the following conditions, as with HMPG:-
1. Homogenized immediately for assay.
2. Immediately to liquid nitrogen storage (-195°C).
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3. Ice (0°C) for 30 min before being taken to liquid
nitrogen.
4, Room temperature (20°C) for 30 min.
The decapitated head was put on the bench for 30 min
before dissecting the striatum quickly out for
storage in liquid nitrogen.
For each condition, 5 tissue samples were used. Each tissue
sample was obtained by pooling the right and left striatum of
one male PVG rat after decapitation and dissecting the brain out.
Each tissue sample weighed between 40-50 mg, before assay.
After homogenization and centrifugation and pH adjustment,
the supernatant of each sample was assayed for duplicate estimate
of HVA as described above.
B. AFTER FREEZING IN LIQUID NITROGEN
Fifteen PVG rats were used. The right and left striatum
were pooled from 3 rats, weighing between 120-140 mg and quickly
distributed into 3 polythene bags for each condition. Samples
were quickly frozen in liquid nitrogen.
At the time of assay, tissue samples were taken out of
liquid nitrogen, weighed, and exposed to the following conditions
before homogenization:-
1. Solid CO2 (-75°C) for 5 min.
2. Ice (0°C) for 5 min.
3. Room temperature (20°C) for 5 min.
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Thus, for each condition, 5 tissue samples were obtained
from rats used in the experiment. Each sample was assayed
for duplicate estimates of HVA as described above.
For all HVA assays, duplicate aqueous standards of 30, 40,
50 and 100 ng HVA respectively, were processed with the above
samples.
Precision
An estimate of precision was obtained from a consideration of the
differences between duplicate estimations . This is expressed as standard
Where d is the difference between two resultsderivation, S.D. =
Ed2
2N.
in a duplicate determination and N is the number of duplicate determinations
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In the GLC estimation of HMPG by the micromethod, and under the
GLC settings described in the method, acetyl-TFA-HMPG and HCH
retention occurred at 2.2 and 3.8 min, respectively, after the
injection (See Fig. 7).
In pure solution, the formation of the derivative acetyl-TFA-
HMPG was linear with different amounts of HMPG. A linear calibration
graph was obtained when aqueous standard amounts of 10, 20, 50 and
100 ng HMPG were assayed (Fig. 8).
The formation of the electron capturing derivative, acetyl-TFA-
HMPG was also linear when different amounts of HMPG were added to
brain tissue homogenates.
The results from assay of 10, 20, 50 and 100 ng HMPG added to
supernatent from brain tissue homogenates are shown in Table 1.
The % recovery of added HMPG to brain extracts was 77.4%.
The sensitivity of the method was equivalent to 2 ng HMPG per
tissue sample, (which is equivalent to 200 ng/g of wet tissue weight).
In the estimation of HVA by the micromethod and subsequent
spectrofluorimetry, the peak of HVA fluorophore appeared at 320 nm
and the height of the peak measured as previously described (Fig. 9).
In pure solutions, HVA fluorophore formation was linear with
different amounts of HVA standards over the range of 20-100 ng
(Fig. 10).
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Retention of acetyl-TFA-HMPG, and that of the internal standard,
HCH, Retention at 2.2 and 3.8 min. respectively, as detected
by the Perkin-Elmer electron capture detector of the GLC
(column temperature 170° C). Gas flow was 60 ml/min.
Paper speed = 1 cm/min. HMPG and HCH retentions are measured
by the vertical distance from the top of either peak to a line drawn
between two depressions at the beginning and end of each retention,




Showing the linear relation between the different concentrations of
HMPG and the formation of acetyl-TFA derivative of HMPG as
measured by the ratio of the peak height of the derivative to that of
the internal standard, HCH. The line is a regression line. Each
point represents the average of two determinations
TABLEl.THRECOV RYOFHMPGDD DPO LERATRAINANTAKROUGHHEIC METHODF REXTRACTION, PURIFICATIONANDCETYL-TFADERIVATIVEFORMA ION SampleAcetyl-TFA HMPGpeak height (mm)HCH peak height (mm)Ratio of HMPGpeak HCHpeak
Ratio eqivalent
toheamount ofHMPG addedtotissue homogenate
Ratio eqivalent
to10ngHMPG addedtoissue homogenate
TissueStandard1235 "11850 Tissue+10ngHMPG2548 +"14152 Tissue+20ngHMPG1384 "+14550 Tissue+50ngHMPG17648 "+16546 Tissue+100ngHMPG5732 +"1523
2.32 2.36 2.600 26. 2.610 27 2.880 54.27 2.900 56.28 3.671 330 26 3.581 240 5 4.902 560 25 4.752 410 24
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Activation spectrum (between 260 and 360 nm) of the fluorescence
due to HVA fluorophore in extracts of striatum, as read in Perkin-
Elmer MPF-3A, spectrophotofluorimeter. Emission wavelength is
set at 418 nm. The fluoroescence of the HVA fluorophore is measured
by the vertical distance from the top of the peak, at an excitation





Showing the linear relation between the different concentration of HVA and
the formation of HVA fluorophore, as measured by the spectrofluorimetric
peak height of the fluorophore at 320 nm. The line is a regression line.
Each point represents the average of two determinations.
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TABLE 2
THE RECOVERY OF ADDED HVA TO POOLED RAT STRIATUM AND TAKEN THROUGH THE
MICROMETHOD FOR EXTRACTION AND HVA FLUOROPHORE FORMATION
Sample
HVA fluorophore
peak height (in mm)
measured at 320 nm in
spectrofluorimetric scan
HVA fluorophore
peak height (in mm)
equivalent to amount of
HVA added to brain extracts
Tissue Standard 88 _
It it 92 -
Tissue + 20 ng HVA 112 22
It + II 114 24
Tissue + 40 ng HVA 134 44
It + II 138 48
Tissue + 50 ng HVA 146 56
It + II 150 60
Tissue + 100 ng HVA 200 113
II + II 207 117
The table above shows a linear relation of the extraction procedure coupled
with fluorophore formation for different amounts of HVA added to brain
homogenates.
Each 10 ng HVA added to tissue extract is equivalent to an average peak
height of 11.48 mm. In aqueous solutions 10 ng HVA is equivalent to
an average peak height of 11.9 mm (see Figure 10).
% recovery of HVA added to brain homogenates = 96%.
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Similar linearity was obtained with brain tissue homogenate to
which was added varying standard amounts of 20, 50 and 100 ng HVA,
respectively (Table 2).
The % recovery of HVA added to brain extracts was 96%.
The sensitivity of the method was 20 ng HVA per tissue sample,
which is equivalent to 400 ng/g and 300 ng/g wet tissue weight for
cortex and striatum, respectively.
Since the recovery of HVA was so high, no correction of
concentrations for recovery was made in subsequent assays and this
is one of the advantages of the method.
Furthermore, employing the micromethod, the concentration of
either HMPG and HVA in the frontal cortex or striatum respectively,
of either Wistar or PVG rats, were not statistically significant
(P = 0.5 - 0.6, and P = 0.4 - 0.5, respectively). (Tables 3A and 3B).
The reported normal level of HMPG in the rat frontal cortex was
68 ng/g tissue weight (1 25 S.D.) (Braestrup § Nielsen, 1972, Yates -
unpublished data), while that of HVA in striatum was 700 ng/g tissue
weight t 150 S.D. (Westerink § Korf, 1975).
HMPG AND HVA LEVELS IN COBALT IMPLANTED RATS
The controls used for biochemical assays in cobalt implanted rats
were either unoperated or sham operated control rats.
On the 8th post-operative day in sham-operated control rats, HMPG
concentrations in the frontal cortex on both sides were not significantly
different when compared to those of unoperated controls.(Table 4A).
Furthermore, HVA concentrations in the striatum were not significantly
different between both groups (Table 4B). Moreover, on the 8th day
following cobalt implantation, HMPG concentrations (Table 5A) in the
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TABLE 3A
HMPG CONCENTRATIONS IN FRONTAL CORTEX OF WISTAR AND PVG RATS
- values are expressed as ng/g wet tissue weight
Sample Wistar Rats PVG Rats
Right frontal Left frontal Right frontal Left frontal
cortex cortex cortex cortex
1 75 78 72 69
2 82 84 86 79
3 77 75 78 88
4 70 68 82 80
5 84 86 75 78
Mean 77 78 79 78
+ S.D. 6 8 5 6
The differences between both groups of rats were not statistically
significant (Student's-t-'test, two-tailed, with Bessel's correction)
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TABLE 3B
HVA CONCENTRATIONS IN THE STRIATUM OF WISTAR AND PVG RATS
- values are expressed as ng/g wet tissue weight
Sample Wistar Rats PVG Rats
Right striatum Left striatum Right striatum Left striatum
1 941 844 - 588
2 801 673 628 721
3 790 745 856 831
4 665 739 622 692
5 659 698 692 638
Mean 771 740 700 694
+ S. D. 104 59 94 82
The differences between both groups of rats were not statistically
significant (Student's-t-test, two tailed, with Bessel's correction)
(-) = sample lost during the assay
TABLE 4A
HMPG CONCENTRATIONS IN FRONTAL CORTEX OF
UNOPERATED AND SHAM OPERATED RATS ON THE
8TH POST-OPERATIVE DAY






























Mean 75 78 77 81
+ S.D. 12 11 14 5
RFC = Right frontal cortex
LFC = Left frontal cortex
The differences in respective concentrations
between both groups of rats were not
significant (Student's-t-test, two-tailed,
with Bessel's correction)
(-) = sample lost during the assay
TABLE 4B
HVA CONCENTRATIONS IN THE STRIATUM OF
UNOPERATED AND SHAM OPERATED RATS ON
THE 8TH POST-OPERATIVE DAY

























Mean 811 831 828 838
+ S.D. 34 41 56 17
RS = Right striatum
L'S = Left striatum
The differences in respective concentrations
between both groups of rats were not
statistically significant (Student's-t-test,
two-tailed, with Bessel's correction)
(-) = sample lost during the assay
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regions of the primary focus (right frontal cortex), secondary focus,
left frontal cortex), and striatum on both sides were not significantly
different when compared to controls, in spite of the tendency towards
increases in the concentration in the treated rats. Similarly,
the levels of HVA in the striatum on both sides showed a tendency
towards reduction, but this was not significant when compared to
controls (Table 5B). The absence of any changes in these metabolites
contrasts with the marked motor epileptic manifestation experienced
by the cobalt-implanted rats.
HMPG and HVA levels were also measured in cortical foci and
striatum at different stages of development of epileptic in cobalt-
implanted rats. The rats developed epileptic foci within 3 days of
the application of cobalt to the right frontal cortex. The spike
frequency of these foci was marked after 7-9 days, and was still
prominent 11 days following cobalt implantation. Spike frequency was
greater in the secondary focus than in the primary focus. Sham
control rats showed no epileptic motor manifestations and no
persistent ECoG changes. (Fig. 11).
HMPG and HVA levels were measured in the rat brain at 3, 7,
and 11 days after the application of cobalt. The results of HMPG
levels at these time periods are shown in Tables 6A, 7A and 8A,
respectively.
At 3 days, the differences in HMPG levels in frontal cortex and
striatum on both sides were not significantly different when compared
to those of sham operated controls.
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TABLE 5A
HMPG CONCENTRATIONS IN DIFFERENT BRAIN REGIONS 8 DAYS AFTER COBALT-IMPLANTATION
INTO THE RIGHT FRONTAL CORTEX OF PVG RATS
- concentrations are expressed as ng/g wet tissue weight
S.D. = standard deviation
Samp1e Cobalt- implanted. Rats Unoperated Controls Rats
RFC LFC RS LS OcC RFC LFC RS LS OcC
1 103 95 150 131 57 55 53 - 83 70
2 89 135 120 103 80 - 88 88 96 54
3 88 75 71 106 67 89 92 69 86 50
4 - 114 - - 95 - 87 89 68 92
5 90 123 108 130 68 78 87 92 95 88
6 98 103 110 - 82 - - - -
Mean 94 108 112 118 75 77 82 79 90 71
+ S.D. 7 19 25 13 13 16 19 13 7 19
The differences in concentration between respective brain region of Cobalt-
implanted and control rats were not statistically significant (Student's-t-test,
two-tailed, with Bessel's correction)
RFC = Right frontal cortex (site of primary focus in Cobalt-implanted rats)
LFC = Left frontal cortex (site of secondary focus " " " " )
RS = Right striatum
LS = Left striatum
OcC = Occipital cortex
(-) = sample lost during the assay
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TABLE 5B
HVA CONCENTRATIONS IN THE STRIATUM 8 DAYS AFTER COBALT-IMPLANTATION INTO
THE RIGHT FRONTAL CORTEX IN PVG RATS
- concentrations are expressed as ng/g wet tissue weight
S.D. - standard deviation
Sample 8 Days Post-Cobalt
Implantation Unoperated Controls
RFC LFC RS LS RFC LFC RS LS
1 N.D. N.D. 807 - N.D. N.D. 889 941
2 ft ft 921 839 ft ft 869 -
3 ft ft 605 940 ft ft 821 864
4 ft ft 674 727 ft ft 752 743
5 ft ft 816 753 ft ft 854 841
6 ft ft 796 68 ft ft 806 -
Mean N.D. N.D. 770 788 N.D. N.D. 831 847
+ S.D. - - 153 102 - 50 82
The differences in concentrations between respective brain regions in
both groups of rats were not statistically significant (Student's-t-test,
two-tailed, with Bessel's correction)
N.D. = Not detectable by the sensitivity of the method (i.e. below
20 ng/tissue sample)
49c.
Development of Epileptic Activity in Cortical Foci






















































□ Cobalt-implanted rats ^ Sham-operated control' S
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HMPG concentrations, however, tended to be higher in frontal
cortex and striatum at 7 days, following cobalt implantation, but
the differences were not significant when compared to those of control
rats.
Moreover, no significant changes in HMPG levels between both
groups of rats were found 11 days after cobalt implantation.
The results of HVA levels at similar time periods are shown in
Table 6B, 7B and 8B„
There was no significant change in HVA levels in the striatum
after 3 days of cobalt implantation in comparison to that in sham control
rats.
The concentrations of HVA, however, tended to be lower in the
striatum 8 days after cobalt application but the differences were not
significant when compared to controls. Moreover, there was no sig¬
nificant change in HVA levels in striatum between both groups of rats
11 days after cobalt implantation. At these stages of development of
epileptic foci, the variance of HVA levels was increased in cobalt
implanted rats in comparison to controls. Furthermore, HVA could not
be detected by the method in either the primary and secondary cortical
foci during the different stages of their development. The normal
concentration of HVA in the cortex is about 150 ng/g which is below
that which could be detected by the sensitivity of the method. However,
if there was an increase in dopamine turnover in these epileptic sites,
it might be reflected by increased HVA levels within the range that could
be estimated by the method.
50a.
TABLE 6A
HMPG CONCENTRATIONS IN DIFFERENT BRAIN REGIONS 3 DAYS FOLLOWING COBALT-
IMPLANTATION INTO THE RIGHT FRONTAL CORTEX OF PVG RATS
- values are expressed as ng/g wet tissue weight
S.D. = standard deviation
3 Days Post-Cobalt 3 Days After Operation in
Implantation Sham Controls
RFC LFC RS LS OcC RFC LFC RS LS OcC
1 101 84 86 104 - 83 99 83 82 53
2 97 96 83 107 74 88 76 99 94 46
3 73 82 108 99 82 78 96 91 95 71
4 66 50 106 100 68 51 52 85 83 62
5 89 94 100 86 50
Mean 85 81 97 99 69 75 81 89 88 58
+ S.D. 14 17 10 7 12 17 19 7 7 11
The differences in co.ncentrations in respective brain regions of both groups
of rats were not statistically significant (Student's-t-test, two-tailed,
with Bessel's correction)
(-) = sample lost during the assay
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TABLE 6B
HVA LEVELS IN THE STRIATUM 3 DAYS AFTER COBALT-IMPLANTATION INTO THE
RIGHT FRONTAL CORTEX IN PVG RATS
- concentrations are expressed as ng/g wet tissue weight
S.D. - standard deviation
Sample 3 Days Post-Cobalt
Implantation
3 Days After Operation
Sham Controls
t in
RFC LFC RS LS RFC LFC RS LS
1 N.D. N.D. 687 772 N.D. N.D. 574 536
2 tf »! 547 480 tf tf 599 675
3 ft tf 402 497 tf ft 717 698
4 It ft 597 496 tf ft 575 629
5 ft ft 796 796
Mean N.D. N.D. 606 608 N.D. N.D. 615 634
+ S.D. - - 133 143 - - 59 62
The differences in concentrations between respective brain regions in
both groups of rats were not statistically significant (Student's-t-test,
two-tailed, with Bessel's correction)




HMPG CONCENTRATIONS IN DIFFERENT BRAIN REGIONS 7 DAYS FOLLOWING COBALT-
IMPLANTATION INTO THE RIGHT FRONTAL CORTEX OF PVG RATS
- values are expressed as ng/g wet tissue weight
S.D. = standard deviation
7 Days Post-Cobalt 7 Days After Operation in
Implantation Sham Controls
RFC LFC RS LS OcC RFC LFC RS LS OcC
1 120 105 - 99 - 86 95 82 90 85
2 102 99 121 132 88 55 68 79 71 65
3 95 98 55 98 92 93 80 74 79 89
4 - 118 98 98 51 85 83 91 80 51
5 83 115 95 88 97
6 88 125 102 107 78
Mean 98 110 94 104 81 80 82 82 80 73
+ S.D. 14 20 24 15 18 15 11 7 8 15
The differences in concentrations in respective brain regions of both groups
of rats were not statistically significant (Student's-t-test, two-tailed,
with Bessel's correction)
(-) = sample lost during the assay
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TABLE 7B
HVA LEVELS IN THE STRIATUM 7 DAYS AFTER COBALT-IMPLANTATION INTO THE
RIGHT FRONTAL CORTEX IN PVG RATS
- concentrations are expressed as ng/g wet tissue weight
S.D. - standard deviation
7 Days Post--Cobalt 7 Days After Operat ion in
OcLlIip 1 C Implantation Sham Controls
RFC LFC RS LS RFC LFC RS LS
1 N.D. N.D. 472 437 N.D. N.D. 608 582
2 ! 1 If 444 494 it .. 7o2 667
3 ft ft 534 604 " 558 562
4 tf If 639 741 " " 599 658
5 f I ft 615 551
6 t! If 663 531
Mean N.D. N.D. 561 560 N.D. N.D. 615 617
+ S.D. 91 96 52 46
""
The differences in concentrations between respective brain regions in
both groups of rats were not statistically significant (Student's-t-test,
two-tailed, with Bessel's correction)




HMPG CONCENTRATIONS IN DIFFERENT BRAIN REGIONS 11 DAYS FOLLOWING COBALT-
IMPLANTATION INTO THE RIGHT FRONTAL CORTEX OF PVG RATS
- values are expressed as ng/g wet tissue weight
S.D. - standard deviation
11 Days Post-Cobalt 11 Days After Operation in
Implantation Sham Controls
RFC LFC RS LS OcC RFC LFC RS LS OcC
1 75 94 98 110 54 77 87 100 90 85
2 - 99 105 111 76 93 85 88 88 78
3 92 115 60 - 76 72 74 84 73 89
4 82 77 115 92 72 74 79 78 72 48
5 60 96 97 103 70
6 99 88 97 87 59
Mean 82 95 95 101 68 79 81 88 81 75
+ S.D. 14 12 17 11 8 10 5 8 10 19
The differences in concentrations in respective brain regions of both groups
of rats were not statistically significant (Student1s-t-test, two-tailed,
with Bessel's correction)
(-) = sample lost during the assay
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TABLE 8B
HVA LEVELS IN DIFFERENT BRAIN REGIONS 11 DAYS AFTER COBALT-IMPLANTATION
INTO THE RIGHT FRONTAL CORTEX IN PVG RATS
- concentrations are expressed as ng/g wet tissue weight
S.D. - standard deviation
Sample 11 Days Post-Cobalt
Implantation
11 Days After Operation in
Sham Controls
RFC LFC RS LS RFC LFC RS LS
1 N.D. N.D. 502 458 N.D. N.D. 570 551
2 ft " 448 625 ff f f 580 656
3 ft " 499 884 ft ft 752 698
4 ff " 906 731 ft ft 660 673
5 ft " 769 675
6 ft " 606 581
Mean N.D. N.D. 622 659 N.D. N.D. 641 645
+ S.D. - 164 132 - - 73 56
The differences in concentrations between respective brain regions in
both groups of rats were not statistically significant (Student*s-t-test,
two-tailed, with Bessel's correction)
N.D. = Not detectable by the sensitivity of the method (i.e. below
20 ng/tissue sample)
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POST-MORTEM STABILITY OF HMPG AND HVA
1. HMPG STABILITY IN POST-MORTEM BRAIN TISSUE
A. Before freezing in liquid nitrogen
Exposure of the frontal cortex to different environmental
conditions of time and temperature resulted in the following
HMPG concentrations (ng/g tissue wet weight t S.D.) on
subsequent assay (see Table 9 for details):-
1. Immediate homogenization and assay.
The mean concentration in this condition was 81 ng/g
t 9 S.D. (n = 5).
2. Immediate freezing and storage in liquid nitrogen.
The mean HMPG concentration in this condition was
88 ng/g t 12 S.D. (n = 5).
3. Ice, for 30 min.
The mean HMPG concentration in this condition was
144 ng/g i 23 S.D. (n = 5). This increase in
concentration was significant when compared to
conditions (1) and (2) above (P = 0.001 - 0.005).
and,
4. Decapitated head on the bench.
The mean HMPG concentration in frontal cortex tissue
was 166 ng/g 1 39 S.D„ (n = 5)„
Again, the increase in concentration was significant when
compared to conditions (1) and (2) above (P = 0.001 - 0.005).
Differences in concentration between condition (3) and (4) were























































not significant. Moreover, delay and exposure to higher
temperatures than solid CO2 before freezing in liquid nitrogen
resulted in increased variability of HMPG estimates in brain
tissue as revealed in the increased standard deviation in
conditions (3) and (4) when compared to (1) and (2).
B. After freezing in liquid nitrogen
Before homogenization, exposure of frontal cortex to
different conditions yielded the following HMPG levels (ng/g wet
tissue weight t S.D.). (For details, see Table 10):-
1. Solid CO2 for 5 min.
In this condition, the mean concentration of the
metabolite was 86 ng/g t 16 S„D. (n = 6).
2. On ice, for 5 min.
The mean HMPG concentration was 163 ng/g t 46 S.D.
(n = 6). This increment in concentration was
significant at P = 0.001 - 0.005 when compared to
condition (1). Besides, the variability is also
increased at this higher temperature compared to that
due to (-75°C) of solid CO2.
and,
3. Room temperature, for 5 min„
The mean HMPG concentration at this condition was
172 ng/g t 48 S.D. (n = 6). Similarly, the increase
in concentration was significant at P = 0.001 - 0.005,
when compared to condition (1) above. Besides, the
variability was also increased (S.D. = 48) when
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TABLE 10
HMPG CONCENTRATIONS IN FRONTAL CORTEX OF PVG RATS UNDER DIFFERENT
CONDITIONS AFTER FREEZING IN LIQUID NITROGEN
- values are expressed as ng/g wet tissue weight. Each value
is the average of a duplicate estimate








1 95 165 227
2 105 227 186
3 84 220 239
4 83 122 125
5 62 119 140
6 86 123 117
Mean 86 163 * 172 *
+ S.D. 16 46 48
Statistical evaluation was done using the Student' s-t-test with Bessel's
correction
k
Significantly higher when compared to condition 1 at P 0.001-0.005
TABLE 11
PRECISION OF DUPLICATE ESTIMATES OF HMPG CONCENTRATION AT SELECTED RANGES
HMPG Concentration
6Q _ n(J Q _ Q _ >
(ng/g wet tissue weight)
Total number of








between all duplicates 11.1% 10% 9.5% 11.6%
in a group
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compared to that of solid CO2 (S.D. = 16).
Precision of HMPG duplicate estimates
In the present study, and under the different conditions
described above, there was a wide range of HMPG concentrations. The
variance between duplicate estimates was found to increase in a
direct proportion to the mean. In spite of the increased variance
(S.D.) with higher concentrations, the average percentage variability
or error was but little altered, indicating precision of duplicate
HMPG estimates by the micromethod over a wider range of detectable
concentrations of the metabolite.
Table 11 shows the standard deviation of the difference between
such duplicate estimates calculated at intervals of 50 ng over the
entire concentration range together with the % error between
duplicates in each group.
2. HVA STABILITY IN POST-MORTEM BRAIN TISSUE
A. Before freezing in liquid nitrogen
Exposure of the rat striatum to different environmental
conditions of time and temperature resulted in the following HVA
concentrations (mean ng/g tissue wet weight t S.D):-
1. Immediate homogenization and assay.
The mean concentration in this condition was 804 ng/g
t 61 S.Do (n = 5).
2. Immediately to liquid nitrogen storage.
The mean concentration in this condition was 815 ng/g
TABLE12 HVACONCENTRATIONSIRASTRIATUMADIFFE E TCONDI IOB FOREFRE Z GLIQUIDT OG N












































Thedifferencesbetweent4conditio srnotstat sticallyignifica t(Student's-t- test,woailed,ithBess l'scorr ction) Thevariabilitywasincre sed,ho ev rthigh rtemper ures
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! 71 S.D. (n = 5).
3. Ice for 30 min.
The mean concentration was 875 ng/g t 158 S.D. (n = 5).
and,
4. Decapitated head on bench for 30 min.
The mean concentration was 932 t 210 S.D. (n = 5).
(For details, see Table 12)»
Although there was a trend to increasing concentration with
delay and higher temperatures than solid COg (-75°C), there was
no significant difference in striatal HVA concentrations between
any of the conditions of treatment above. However, the variab¬
ility was more marked at increasing temperature. The S.D. in
conditions (3) and (4) were I 158 ng/g and t 210 ng/g respect¬
ively, in comparison to t 51 and t 71 of conditions (1) and (2)
above, respectively.
B. After freezing in liquid nitrogen
Exposure of the rat striatum to different temperatures gave the
following HVA levels (mean in ng/g wet tissue weight t S.D.).
For details, see Table 13.
1. On splid COg for 5 min.
The mean HVA concentration at this condition was 821 ng/g
t 78 S.D. (n = 5).
2. On ice for 5 min.
The mean concentration at this condition was 906 ng/g * 198
S.D. (n = 5).
54a
TABLE 13
HVA CONCENTRATION IN RAT STRIATUM AT DIFFERENT CONDITIONS AFTER STORAGE
IN LIQUID NITROGEN
- all concentrations are expressed as ng/g wet tissue weight








1 864 982 982
2 924 848 687
3 821 1174 996
4 720 632 592
5 778 893 958
Mean 821 906 843
S.D. 78 198 170
The differencesbetween the 3 conditions were not statistically significant
(Student's-t-test, two-tailed, with Bessel's correction)
The variability was increased, however, with higher temperatures
55.
3. Room temperature for 5 min.
The mean HVA concentration at this condition was
S4'3 ng/g 1 170 S.D. (n = 5).
Again, the differences in HVA concentrations were not signif¬
icant in comparison to condition (1) above. However, the variabil¬
ity was increased at higher temperatures. S.D. at 0°C and 20°C
was t 198 and t 170 in comparison to ± 78 at -75°C.
Precision
An estimate of precision was obtained from consideration of the
variance between duplicate estimates.
The variance between duplicate estimates was also found to
increase in a direct proportion to the mean. This is illustrated in
Table 14, which shows the standard deviation between such duplicate
estimates calculated at intervals of 200 ng/g wet tissue weight over
the entire range of concentrations.
In spite of the slightly increased variance between different
concentration ranges, the percentage error or variability between
duplicates in any range of concentration was but little affected,




PRECISION OF DUPLICATE ESTIMATES OF HVA CONCENTRATION AT SELECTED RANGES
HVA Concentration
(ng/g wet tissue weight)
600 - 800 800 - 1000 > 1000
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HMPG and HVA concentrations were measured in various brain regions
during the development of cobalt induced epilepsy in rats. The metab¬
olite levels can be utilized in normal conditions as criteria reflect¬
ing noradrenaline and dopamine turnover of the catecholamine system,
respectively.
Assay method
A micromethod used by Ashcroft et al, (1975) was used for this
assay. The method allows the estimation of HMPG and either HVA or
5-hydroxyindole acetic acid (5-HIAA) in brain tissue or CSF. The
results of the present work confirmed the claims of the method in
being useful, accurate and precise for measurement of both HMPG and
HVA levels in small amounts of brain tissue.
For HMPG in brain, the method is used for tissues of 100 mg and
less in weight, and the minimum amount of tissue required for fluori-
metric estimation of HVA by the method was 15 mg of striatum and 100 mg
of frontal cortex of the rat brain.
For HMPG estimation, the method employed the formation of the
electron-capturing derivative, acetyl-TFA-HMPG, for its GLC estimation
and was quite sensitive for measuring the small amount of
HMPG in small amounts of brain tissue. The method was quite
sensitive for measuring the small amount of HMPG as that found in the
rat brain. This is in contrast to the spectrofluorimetric method
of Antun et al (1971) which has a sensitivity equivalent to 200 ng
HMPG and is reproducible for micrograms HMPG/g brain tissue
weight which makes it unsuitable for the small amounts of HMPG found
in the rat brain.
The micromethod showed a linear relation between the formation of
the electron capturing derivative of HMPG and the various amounts of
HMPG in pure solution or extracted after being added to brain homogen-
ates. The percentage recovery of the method (77.4%) was more than
that reported for the GLC method employing the formation of hepta-
fluorbutyryl HMPG (64%) (Sharman, 1969). The sensitivity of the
method was equivalent to 2 ng HMPG per tissue sample and its specif¬
icity by paper chromatography was shown by Walter (1973).
For HVA estimation, the micromethod employed the formation of HVA
fluorophore, and showed a linear relation between fluorophore formation
and the different amounts of HVA extracted from aqueous solutions or
added to brain homogenates. The percentage recovery of added HVA
by the method was very high (96%). Thus, for subsequent HVA assays
in brain extracts, no correction for tissue recovery was essential,
and this is one of the advantages of the method. In contrast,
correction of HMPG concentrations for tissue recoveries was always
required.
The sensitivity of the method for HVA estimates was equivalent
a
to that of 20 ng HVA per tissue samples. This makes it more suitable
for tissues rich in dopamine such as the striatum. However, the
fluorimetric estimation of HVA by the micromethod might be useful for
measuring dopamine turnover in tissues of lower dopamine content such
as the frontal cortex if an adequate amount of tissue is used, or if a
marked increase in dopamine turnover or accumulation of its metabolite,
HVA, is anticipated. The HVA estimation by this method has a high
degree of specificity (Ashcroft et al, 1968), as was shown by paper
chromatography.
The epileptic changes following cobalt application
Following the implantation of cobalt into the right frontal cortex
of the rat, a primary epileptic focus developed in the nervous tissue
around the implant and a secondary focus is formed in the corresponding
area of the contralateral cortex, as measured in the ECoG. Spike
activity appeared in both foci in 3 days and increased in frequency
reaching a maximum in 8 - 12 days after the implantation. This same
pattern was reported by other workers (Dow et al, 1972, Emson & Joseph,
1975). The frequency of spiking in the secondary focus was almost
always greater than in the primary focus.
It was difficult to separate the causative epileptiform mechanisms,
since neuronal damage alone in the cobalt-implanted area and in the
secondary focus might be sufficient to initiate epileptic activity,
similar to cases of post-traumatic epilepsy. Some workers claimed
that the cobalt ion is the critical factor (Dow et al, 1962, Willimore
et al, 1975). Willimore et al (1975), employing a 100 mMol cobalt
chloride solution in an iontophoretic study, demonstrated that the
cobalt ion did possess a potent epileptogenic effect. This was
observed after micro-iontophoretic transfer of at least 100 yg of ionic
cobalt onto the pial surface of the sensorimotor cortex. These workers
reported that with this method, no histological evidence of cell damage
was found and that although about 75% of the cobalt was found in layer
1, the neurons and their processes were intensely stained in layers
II and III of the cortex. Thus, epileptiform discharge originated
from neuronal aggregates that have selective affinity for ionic
cobalt at the focal site in the upper layers of sensorimotor cortex.
Some workers pointed out that the formation of a meningeal
cicatrix also contribute to the development of epileptic activity
(Payan, 1971., Fischer et al, 1968).
Moreover, glass implants, which could cause some meningeal damage
and gliosis, did not initiate epileptic activity (Dow et al, 1972).
However, it seemed that both factors, the general cell damage and cobalt
toxicity, contributed towards the epileptic phenomena. The importance
of contribution of each factor varied at different stages of the epilep¬
tic process. The fact that cobalt ion was found in primary and second¬
ary cortical foci as well as striatum and occipital cortex on both sides
as early as 6 days after implant and was still found in considerable
concentration after 3 weeks (Clayton, 1976), suggests that both factors
are operating during the development of spike activity in cortical
neurons. However, the epileptic activity after 10 weeks of cobalt
implantation, when cobalt ion was cleared from all brain areas except
the primary focus (Clayton § Emson, 1975), probably reflects the cell
damage which is largely permanent. These workers used atomic absorpt¬
ion spectrophotometry (which allows unequivocal estimation of cobalt
ions) and heavy metal histochemistry in showing that cobalt ion spread
widely from the site of the implant. Cobalt ions might spread by
diffusion or by being transported away from the original lesion to
establish a gradient of cobalt throughout the brain. Spread of ionic
by the bloodstream might also be possible0.However,the amount of cobalt
spreading by diffusion is unlikely to be so extensive outside the
primary lesions. Systemic spread of cobalt ions from the side of implant
by bloodstream would have lead to its deposition in other organs,
particularly those of the reticulo-endothelial system such as the liver
and spleen, which is not the case. Thus, it is probable that the
majority of cobalt was spread to the rest of the brain by axonal trans¬
port. In agreement with this suggestion, the levels of cobalt ion
in the contralateral caudate were found to follow closely those in the
overlying cortex with which it had definite fiber connections (Clayton
§ Emson, 1976). Furthermore, it is well known that cobalt salts could
be used to trace axonal pathways (Pitman, Tweedle & Cohen, 1972).
Catecholamine turnover in cobalt-implanted rats
Tyrosine hydroxylase activity was reported to be the rate-limiting
step of catecholamine biosynthesis, and the most specific marker of the
functional integrity of catecholaminergic fibers (Spector et al, 1965.,
Levitt et al, 1965). It is also well known that monoamine oxidase and
catechol-O-methyltransferase are the main degrading enzymes. It was
reported that in this time period, tyrosine hydroxylase activity was
reduced in primary and secondary foci reaching 10% of its value at 6
days, and was still down at 12 days in both primary and secondary corti¬
cal foci, but had partially recovered at 30 days after cobalt implantation
reaching to 30% of its activity (Clayton § Emson, 1975). In the striatum
similar reduction in enzyme activity was observed (McQueen § Emson, 1975,
unpublished data)„ Reduction in the activity of monoamine oxidase and
catechol-O-methyl transferase reaching to 20% and 40% of their control
value paralleled these changes (Clayton § Emson, 1975). However, noradren
aline concentration was found to be normal in cortical foci, using
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biochemical (Clayton, 1975), and fluorescence methods (Emson § Bjorklund,1974 -
unpublished data) of assay. Similarly, dopamine and noradrenaline
concentrations in striatum did not significantly differ from those of
the reported control values.(See Section II : Results : 6-OHDA experiment
in cobalt implanted rats).
These changes might imply that the enzyme changes were a reflection
of local cortical events, induced by cobalt, rather than a general react¬
ion of the catecholamine system in the brain. The finding of normal
tyrosine hydroxylase activity in the locus coeruleus, where most noradren¬
ergic neurons originate (Ungerstedt, 1971, Dahlstrom § Fuxe, 1965), and
in the midbrain in cobalt-implanted rats (Clayton, 1975), tended to
support this hypothesis. Thus, it seemed that the local catecholamine
turnover was reduced at sites where the cobalt ion and its accompanying
cellular change were found, but normal concentration of noradrenaline
in cortex and both catecholamines in the striatum was maintained by com¬
pensatory enzymatic change.
HMPG and HVA levels in cobalt-implanted rats
During the different stages of development of epileptic activity in
the primary and secondary foci in cobalt-implanted rats, HMPG and HVA
levels were not significantly different in comparison to levels in control
rats. However, HMPG levels tended to be higher at 7 and 8 days after
cobalt implantation, when epileptic activity was very marked, in comparison
to those seen earlier after 3 days when epileptic activity was developing
and also in comparison to those levels of the metabolite seen at 11 days
following cobalt application when epileptic activity was still prominent.
HVA levels in striatum remained generally unchanged during these time
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periods although there was a non-significant drop at 7 and 8 days after
cobalt application.
Possible mechanisms
Cobalt implantation in the brain caused large areas of necrosis.
This was marekd in the primary focus. Histological evidence of cell¬
ular degeneration were also reported in the homologous contralateral
cortex in secondary focus, the striatum on both sides as well as in some
regions of the thalamus. It was possible that the enzyme changes
observed might not be specific but due to neuronal degeneration.
Various parameters in the catecholamine nerve terminals involving
synthesis and breakdown of the neurotransmitter, appeared to be sensitive
to toxic effect of cobalt ion, and this was evident in the primary focus.
Thus, one had to assume a fairly rapid transport of ionic cobalt to the
contralateral side to account for the parallel enzymatic changes in
the secondary focus. Cobalt ion was demonstrated in the contralateral
cortex as early as 6 days after implantation (Clayton, 1976). Thus, the
cobalt ion in the cortex, concentrated in the region of catecholamine
nerve terminals might effect a permanent alteration in enzyme function
whether they are synthesizing, catabolising or transport-associated
enzymes. Cobalt ion might produce its toxicity by damaging the enzyme
function, possibly by alteration of structure or by interfering or
inhibiting the action of enzyme co-factors (Pitman et al, 1971, Payan,
1971, Dow et al, 1962). Furthermore, cellular changes might potentiate
the effects of the enzyme changes induced by cobalt.
The finding of unaltered concentration of HMPG in the face of
reduced catecholamine synthetic activity might be explained by increased
noradrenaline catabolism or by a reduction in HMPG transport from the
brain. The presence of normal concentrations of noradrenaline as well
as reduced monoamine oxidase and catechol-O-methyl transferase activity
in epileptic foci tended to exclude the former possibility. However,
this would have resulted in reduced HMPG levels at these sites. Thus,
it seemed reasonable to suggest inhibition of HMPG transport in the
presence of reduced catabolism of noradrenaline, contributing to a normal
or tendency to increased,concentration of the metabolite in cortical
foci and striatum. This block in HMPG transport mechanism could be
attributed to the toxic effect of cobalt on the enzyme system, as descr¬
ibed above, potentiated by the associated cellular degeneration and
membrane damage.
The assay method as used in the present work measured the total HMPG
and did not distinguish free from conjugated HMPG. However, in the
rat brain, about 90% of total HMPG occur as HMPG-SO4.
Free HMPG is thought to be readily diffusible. Some workers
believed that no transport system existed for HMPG since it could diffuse
so easily out of the brain into CSF or blood that no need for transport •
is demanded (Korf et al, 1971). This theory was supported by the find¬
ing of low regional variation of HMPG in the brain. In the rat brain,
only a two-fold maximal regional difference for total HMPG was found, the
highest being in the brain stem and lowest in the cerebellum (Yates -
personal communication). Similarly, a maximal four-fold variance in
HMPG was found in the dog brain (Ashcroft et al, 1975), and similar
results were reported for the human brain (MacKay et al, 1978). This
is in contrast to HVA which showed up to a ten-fold regional variation
reduced catecholamine synthetic activity might be explained by increased
noradrenaline catabolism or by a reduction in HMPG transport from the
brain. The presence of normal concentrations of noradrenaline as well
as reduced monoamine oxidase and catechol-O-methyl transferase activity
in epileptic foci tended to exclude the former possibility. However,
this would have resulted in reduced HMPG levels at these sites. Thus,
it seemed reasonable to suggest inhibition of HMPG transport in the
presence of reduced catabolism of noradrenaline, contributing to normal
or tendency to increased concentration of the metabolite in cortical
foci and striatum. This block in HMPG transport mechanism could be
attributed to the toxic effect of cobalt on the enzyme system, as descr¬
ibed above, potentiated by the associated cellular degeneration and
membrane damage.
The assay method as used in the present work measured the total HMPG
and did not distinguish free from conjugated HMPG. However, in the
rat brain, about 90% of total HMPG occur as HMPG-SO4.
Free HMPG is thought to be readily diffusible. Some workers
believed that no transport system existed for HMPG since it could diffuse
so easily out of the brain into CSF or blood that no need for transport
is demanded (Korf et al, 1971). This theory was supported by the find¬
ing of low regional variation of HMPG in the brain. In the rat brain,
only a two-fold maximal regional difference for total HMPG was found, the
highest being in the brain stem and lowest in the cerebellum (Yates -
personal communication)„ Similarly, a maximal four-fold variance in
HMPG was found in the dog brain (Ashcroft et al, 1975), and similar
results were reported for the human brain (MacKay et al, 1978). This
is in contrast to HVA which showed up to a ten-fold regional variation
and also in contrast to the pattern of localization of monoamine neuro¬
transmitters .
HMPG removal from the brain differed from HVA in being relatively
insensitive to probenecid. Barany (1975) established the existence of
two distinct transport mechanisms in the rat choroid plexus. In addition
to the classical renal-like system, another system could be demonstrated
which was less sensitive to blocking by probenecid. It was possible
for HMPG to be a candidate for the latter system, Eccleston § Ritchie
(1973) have shown that HMPG was readily esterified in the rat brain, in
vivo, and that there was evidence of HMPG-SO4 transport mechanism in
the rat brain (Miner § Heston, 1972, Mrsulja et al, 1975), which
resembles that of HVA and 5-hydroxyindolacetic acid in being inhibited
by probenecid and by ischemia (Meek § Neff, 1972., Miner 5 Heston, 1972,
Mrsulja et al, 1975),
Thus, impairment of transport of HMPG-SO4 out of the brain into
CSF or blood, as induced by cobalt ion toxicity and cellular degeneration
would lead to its retention in brain tissue HMPG„
In the presence of reduced noradrenaline catabolism, HMPG retention,
at the site of primary and secondary cortical foci as well as in striatum
on both sides, could build up to normal or even a tendency to a higher
concentration of the metabolite. This would give a false impression
of normal or increased turnover of noradrenaline at these sites in the
presence of the oppositive effect. However, impaired HMPG-SO4 transport
acting alone would lead to progressive accumulation of the metabolite
in brain tissue, which is not the case. HMPG levels were higher in
cortical foci and striatum at 7 and 8 days when compared to those at 3
days following cobalt implantation, but these levels of the metabolites
were lower after 11 days in comparison to those at 7 or 8 days after
cobalt application. However, at all these time intervals, the
levels were not significantly different from control. Thus there
might be a factor which limited HMPG accumulation and this could be
reduced by HMPG-SO4 formation inside the neuron.
It is also possible that cobalt ion could damage the intracell¬
ular sulphatase enzymes systems, thus impairing the sulphate conjugation
of free HMPG which normally resulted in formation of HMPG-SO4. This
would render a higher proportion of HMPG in the free or diffusible form
in the damaged areas. Since free HMPG readily passes into blood or
CSF, this would prevent or limit the accumulation of higher levels of
the metabolites which might result from impaired transport of its
conjugated form.
It could be possible that the enzyme-mediated transport of HMPG-SO4
is impaired earlier than the intracellular sulphatase enzyme system which
normally conjugated the free form of the metabolite. This could mean
that the non-significantly higher levels of the metabolite at 7 and 8
days after cobalt application was due to mild HMPG-SO4 retention. At
11 days after cobalt-implantation, however, it was possible that a
higher proportion of HMPG existed in the free diffusible form in both
epileptic foci and striatum, hence, the tendency to lower values at
these sites in comparison to those seen at 7 or 8 days following cobalt
application. However, the net result of these changes at these
different times was that the metabolite levels ceased to reflect the
locally reduced noradrenaline turnover in spite of the normal concen¬
tration of noradrenaline.
Similar mechanisms could operate for HVA levels in the striatum
where cellular degeneration and ionic cobalt were reported following
cobalt application to frontal cortex.
Tyrosine hydroxylase activity was also associated with reduced
activity of monoamine oxidase and catechol-O-methyl transferase in the
striatum. Similar to noradrenaline, the concentration of dopamine
in the striatum was maintained in the presence of reduced syntehsis,
by a compensatory reduction in its catabolism. This would have result¬
ed in reduced levels of HVA in the striatum. However, the present
results showed that the levels of HVA were maintained in comparison to
control value. The degenerative cellular changes in addition to the
cobalt-induced enzyme toxicity could impair the active transport of the
reduced amount of HVA formed and this could build up to normal or even
a tendency to higher levels. However, there was no evidence of
increased HVA concentrations with time. Sharman (1967) showed that
a small part of HVA, which corresponded to the small intraneuronally
formed pool, was excreted normally by diffusion into the blood independ¬
ently of and in parallel to the actively excreted part. It might be
possible to suggest that the formation of the intraneuronal diffusible
pool of HVA is proportionately increased to limit possible accumulation
of HVA that might result from progressive mild impairment of active
transport with time. This might explain the absence of significant
changes in the metabolite level in the striatum of cobalt-implanted rats
in the presence of reduced dopamine catabolism.
The absence of detectable amounts of HVA in the primary and
secondary foci in the frontal cortex might reflect the lack of dopamin¬
ergic terminals in these areas. Alternatively, the impairment of HVA
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transport in these areas of cellular degeneration, might not be
sufficient to render it detectable by the sensitivity of the method
which is 20 ng HVA per tissue sample.
These findings implied that estimation of the concentration of the
major amine metabolite is not a good index of amine turnover in the
presence of cellular degeneration and necrosis in comparison to normal
functioning tissue. This was due to the accompanying enzymatic damage
with possible alterations in metabolite active transport mechanism or
even changes in metabolite formation.
Thus, these changes in the metabolite levels might be misinterpreted
to indicate normal or even increased amine turnover in the presence of
the opposite effect.
In this context, it might be worth attempting to explain the contra¬
dictory finding of low tyrosine hydroxylase activity in the presence of
normal noradrenaline concentrations. The following explanations might
all contribute in part to these findings
(a) There might be some compensatory increase in the noradrenaline
concentration in the remaining undamaged neurons.
(b) It is generally accepted that the levels of the transmitter
synthesizing enzymes were in excess to what is required for
normal nerve function, but tyrosine hydroxylase activity
was severely reduced to about 10% of its activity in both
cortex and striatum after cobalt implantation. Thus, this
explanation would seem unlikely.
(c) The activity of tyrosine hydroxylase might be influenced by
local events in vivo which could impair its effectiveness
as a rate-limiting enzyme in the biosynthesis of catecholamines.
MacKay (1974) showed that in the sympathetic ganglion preparation,
no linear relation was found between tyrosine hydroxylase activity and
noradrenaline concentrations. Other workers have reported a dissoc¬
iation between the enzyme activity in vivo and in vitro, and even
questioned its role as the rate-limiting enzyme. It was well known
that the enzyme depended on its activity mainly on the availability of
the reduced folate co-factor (Turner et al, 1974) which was made
available by the enzyme dihydrofolate reductase. It was likely that
local cortical necrosis and devascularization and/or the toxic effect
of cobalt ion would interfere with the local supply of the reduced co-
factor or the affinity of the enzyme for it, thus reducing its activity
in a dramatic manner.
The enzymes L-aromatic amino acid decarboxylase and dopamine 3-
hydroxylase were also involved in the biosynthesis of noradrenaline.
However, the decarboxylase enzyme was reported to be reduced in cortical
foci in cobalt-implanted rats (Emson § Joseph, 1975). Thus, it might
be possible that increased dopamine 3-hydroxylase activity would con¬
tribute to the normal levels of noradrenaline in noradrenergic terminals
in presence of reduced tyrosine hydroxylase activity, provided that it
was not damaged by the pathological changes. It has already been suggested
that when significant levels of dopamine accumulated in the nerve endings,
then dopamine 3-hydroxylase or the intravesicular uptake of dopamine
became rate-limiting in noradrenaline biosynthesis (Landsberg et al,1969).
However, it is well known that alpha-methyltyrosine, which inhibits
69.
tyrosine hydroxylase, causes catecholamine depletion in vivo under
normal conditions. Thus, it seemed that the dopamine hydroxylase did
not compensate enough for the reduced tyrosine hydroxylase activity
under these circumstances and consequently the concentration of nor¬
adrenaline was reduced.
(d) Reduced catabolism of noradrenaline by monoamine oxidase
and catechol-O-methyl transferase might contribute to the
normal concentration of the reduced amount of noradrenaline
synthesized via tyrosine hydroxylation.
Monoamine oxidase and catechol-O-methyl transferase are found mainly
related to catecholaminergic neurons, but also in non-catecholaminergic
neurons and glia (Robinson, 1967, Katz et al, 1969). These enzymes might
be specifically inhibited by cobalt ion or extensive cellular damage
which would not agree with the findings of normal fluorescence of nor¬
adrenergic terminal in cortical foci (Emson § Bjurklund - unpublished
data), or with extent of degeneration and necrosis found histologically.
It was also possible that cobalt ion might have first affected a reduction
in tyrosine hydroxylase activity while the changes in monoamine oxidase
and catechol-O-methyl transferase might be merely a compensatory phenom¬
enon.
From all the above findings one could conclude that cobalt
implantation and its accompanying tissue necrosis reduced the local
catecholamine turnover. However, the normal concentrations of cate¬
cholamines were maintained by compensatory enzymatic mechanism. HMPG
and HVA concentrations, however, did not reflect the turnover of
noradrenaline and dopamine, respectively, due to the degenerative and
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enzymatic changes which could impair the formation or active transport
of these metabolites from their sites of formation in the brain to CSF
or blood stream. Furthermore, the presence of neuronal degeneration
and its local denervation supersensitivity in the epileptic foci might
render the remaining cortical neurons more hyper-excitable or responsive
to the normal concentrations of noradrenaline present, thus contributing
to the resulting process of epileptogenicity.
Using a modification of the cobalt implantation method in immunol-
ogically-suppressed animals, some workers showed that cobalt ion could
produce focal epileptic changes without possible alterations in cate¬
cholamine metabolism and before the onset of substantial cortical and
sub-cortical necrosis with its associated enzyme changes (Altamura et
al, 1978). With this method, the development of epileptic manifestations,
however, was delayed and reached a maximum after 15 days, while tissue
necrosis both cortical and sub-cortical, was less marked and reached a peak
later after 20 days.
This could mean that the biochemical findings in catecholamine
metabolism already described in the present and previous work (Clayton
5 Emson, 1975., Clayton, 1976), were more due to the associated tissue
degeneration and necrosis than to the toxic effect of cobalt ion on
enzyme systems associated with catecholaminergic neurotransmission.
However, the earlier onset of cellular degeneration in cortical foci with
its possible local denervation supersensitivity facilitated the develop¬
ment of epileptic changes. The normal concentration of noradrenaline
acting on the locally supersensitive post-synaptic receptors could have
contributed to the neuronal hyperexcitability at these early stages.
A possible mechanism by which the cobalt ion could initiate
epileptic changes, without producing necrotic changes, might be by
affecting active ion transport through the neuronal membranes. Glial
cells, particularly astrocytes, could act as buffers to protect neurons
against an accumulation of extracellular potassium ion. It might be
that cobalt ion induced a significant modification in oxidative metabol¬
ism of astrocytes characterized by increased dehydrogenase activity,
apart from gliosis, with consequent focal epileptic changes. Such
activated astrocytes have been found in focal epilepsy in man, and
also in cobalt-induced epilepsy in the rat where they appeared before
the first electrical phenomena of epilepsy (Brotchi et al, 1977).
Post-mortem stability of HMPG and HVA
In the time period following decapitation, the present work showed
that exposure of brain tissue to increasing temperatures of 0°C (on ice)
or 20°C (head on bench) for a period of 30 min before freezing and
storage in liquid nitrogen, resulted in a significantly higher and more
variable HMPG concentration on assay when compared to those found in
brain tissue that had been homogenized immediately after decapitation
or frozen in liquid nitrogen before being homogenized.
Similarly, in the time period following freezing the tissue in
liquid nitrogen, HMPG concentration in frontal cortex tended to be
higher and more variable on exposing the tissues to higher temperatures
of 0°C (ice) or 20°C (room temperature) for 5 min when compared to
that in tissues homogenized while being kept frozen on solid CO2 for a
similar period of time.
These observations might be explained by facilitation of the
enzymatic catabolism of noradrenaline occurring with delayed homogen-
ization on higher temperatures either before or after freezing the
tissue in liquid nitrogen or solid CO2. This implied that delayed
freezing of brain tissue allowed the catabolising enzymes, monoamine
oxidase and catechol-O-methyl transferase to act, which effect was
potentiated by higher temperature. This increased catabolism of
noradrenaline (and dopamine) did not occur when the tissue was immediately
frozen or homogenized after decapitation,, Furthermore, HMPG and HVA
concentrations did not differ significantly between tissues homogenized
immediately or those stored frozen.
Furthermore, it implied that freezing inhibited the activity but
maintained the stability of the catabolising enzymes whose activity was
also enhanced by thawing at higher temperatures of ice and the room.
Other workers have also demonstrated the post-mortem stability of
monoamine oxidase and catechol-O-methyl transferase in the rat as well
as the human brain (Ganrot et al, 1962., Vogel et al, 1969., Mackay et al,
1978., Hakanson 8, Owman, 1966). This implied that freezing the tissues
inhibited the activity of the catabolising enzymes, thus maintained brain
dopamine and noradrenaline, respectively. This was supported by the
finding of Walter (1973) that storage of brain tissue for 3 months in
liquid nitrogen depressed the activity of the catabolising enzymes and
did not alter HMPG levels on subsequent assay.
These results also showed that HMPG and HVA levels in tissue
immediately homogenized after death or kept frozen immediately before
being homogenized without thawing, reflected the turnover of their
parent catecholamines, noradrenaline and dopamine, respectively at
the time of death. Furthermore, it showed that this method of tissue
handling was the best method in determining the concentration of major
catecholamine metabolites in reflecting the turnover of their parent
amines at or just before the time of death.
The more rapid thawing of the brain tissue at higher temperature
with its accompanying membrane lysis might result in increased release
of dopamine and noradrenaline with their consequent enhanced enzymatic
degradation, thus contributing to the significantly higher and more
variable concentration of their metabolites. However, studying the
post-mortem alterations of HVA in the rat striatum showed that it was
more stable than HMPG in the altered conditions of time and temperature
described above before and after freezing the tissues in liquid nitrogen.
Noradrenaline and dopamine were known to be prone to a substantial post¬
mortem change (McGeer § McGeer, 1962, Grabartis et al, 1966., Vogel et al,
1969, Carlsson et al, 1974). However, the dopamine metabolite, HVA
seemed to have a much greater post-mortem stability (Hornykiewicz et al,
191j8) „ The present work showed that alteration in time and temperature
did not significantly alter HVA concentration in striatum in comparison
to that which was either immediately homogenized or frozen before being
homogenized, confirmed this stability and suggested that HVA concentrat-
ation at these conditions still reflected the dopamine content at the
time of death. However, the increased variability of HVA content in
brain tissue at higher temperature and with delayed homogenization
either before or after freezing precluded using HVA level under these
conditions as indicating dopamine turnover or just before the time of
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sacrifice.
Some workers found that the noradrenaline content of rat brains
homogenized at increasing time intervals (ranging from 30 min to 4 hrs)
at room temperature were significantly lower than that in control brain
immediately homogenized after death. This loss of noradrenaline did
not occur in brains that were frozen immediately and homogenized without
thawing, indicating that instant freezing generally depressed the activ¬
ity of the catabolizing enzymes and protected brain noradrenaline
(Grabartis et al, 1966). Moreover, brain dopamine and noradrenaline
were reported to be significantly reduced in the brain of rats exposed
at 4°C and 16°C for 16 hrs while monoamine oxidase and catechol-O-methyl
transferase activities showed no significant alterations (Vogel et al,
1969). These changes occurred in spite of the fact that the tissue
showed a considerable decomposition. Furthermore, impairment of
binding and storage of dopamine and noradrenaline might also contribute
to reductions in their levels with exposure of brain tissue to increasing
temperature after death. Maynert § Kuriyama (1964) observed that
tissue slices released dopamine and noradrenaline much faster than 5-HT
during incubation, thus indicating that the concentration 5-HT is better
maintained than the other monoamines in post-mortem preparations (Vogel,
et al, 1969., Mackay et al, 1978).
It might be worth describing briefly the catabolism of dopamine
and noradrenaline under the different conditions above.
The breakdown of dopamine by monoamine oxidase yields DOPAC which
is methylated to HVA. Moreover, the O-methylation of dopamine by
catechol-O-methyl transferase yields 3-methoxytyramine which is
deaminated into HVA by monoamine oxidase.
In contrast, the O-methylation of noradrenaline produces nor-
metanephrine which is deaminated into HMPG by monoamine oxidase.
Moreover, the deamination of noradrenaline yields DHMP which is 0-
methylated into HMPG.
The enzyme monoamine oxidase requires oxygen and its optimum
activity occurs at 37°C. Catechol-O-methyl transferase depended on
its activity on co-factors which are present in surplus in the tissues
and thus the time between death and freezing of tissue or homogenization
is critical before these co-factors are utilized.
It is well known that oxidative deamination, which requires oxygen
stops after death while the tissue is inside the body, and any residual
monoamine oxidase activity was due to the low oxygen content in the
tissue at that time. This explained the enzyme action while the
decapitated head in the experiment was left on the bench for 30 min
before dissecting the brain tissue out. However, in experiments in
which the brain tissue was put on ice or the bench, the atmospheric
oxygen, in addition, contributed to the enzyme action. Exposure of brain
tissue to 0°C (on ice) resulted in elevation of HMPG content while HVA
concentration was unaltered. Thus, it seemed that monoamine oxidase
had more affinity under these conditions for normetanephrine than to
3-methoxytyramine, thus contributing to higher concentrations of HMPG.
However, the concentrations of DOPAC, formed from oxidative deamination
of dopamine was found to increase under these conditions (Nicolaou -
unpublished data). Thus, it also seemed that catechol-O-methyl transfer¬
ase had more affinity for DHPG than DOPAC under these conditions in
contributing to the higher values of HMPG. The fact that these changes
occurred within 5 min of exposure of brain tissue to ice (at 0°C)
emphasized the importance of keeping the tissues frozen on solid CO2
before homogenization in the HMPG assay. The higher levels of HMPG on
putting the tissue on the bench (20°C) indicated the enhancing effect of
temperature on the enzyme changes mentioned above.
However, in conditions where the decapitated head (with brain still
inside) was left on the bench, the catabolism of dopamine and noradrenal¬
ine was mainly by COMT, and the activity of monoamine oxidase depended
on the tissue oxygen at time of death. The increased HMPG content and
normal HVA levels in this condition could also be explained by the mechan
isms already described above, even under the adverse conditions of low
oxygen tension for the action of monoamine oxidase. Moreover it has
been shown that rapid accumulation of 3-methoxytyramine occurred in rat
brain during the first hour after death at 37°C after decapitation, and
this accumulation was enhanced by treatment with pargylline, a monoamine
oxidase inhibitor and was less rapid at lower temperature. The post¬
mortem loss of dopamine from the brain corresponded to the formation of
3-methoxytyramine in pargyline-treated rats, but exceeded this form¬
ation in the non-treated rats (Carlsson et al, 1974) suggesting some
deaminating function by monoamine oxidase, possibly from the residual
dissolved tissue oxygen.
Thus, it might be possible that post-mortem alterations of time and
temperature contributed to high levels of HMPG previously reported in
cobalt-implanted rats. However, these changes are unlikely to alter
HVA concentration which thus seemed to have better post-mortem stability
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The absence of significant changes in HVA levels in striatum at
different times following cobalt implantation contrasted with the
reduced levels of the metabolites observed before (McQueen § Emson -
unpublished data), This could be explained by animal variation in
the different grades of degeneration in the striatum with its consequent
variable effects on active HVA transport as well as other compensatory







A. DOPAMINE AS A NEUROTRANSMITTER
Dopamine (DA), like noradrenaline (NA) and adrenaline, is a
catecholamine,possessing a 3,4-dihydroxy (catechol) aromatic ring and
an amino group. These three biologically active amines are synthetized
in series from 1-tyrosine via L-DOPA. Dopamine was originally consider¬
ed as a precursor, but by the 1950's was recognised to be pharmacologic¬
ally active itself (Blaschko, 1973). Early evidence for the transmitter
role of dopamine was derived from failure of noradrenaline and 5-HT to
reverse some of the effects of the monoamine depleting drug, reserpine,
and the demonstration of very high concentrations of dopamine in brain
areas like the striatum which had low amounts of noradrenaline (Carlsson,
1959). Dopamine was also found to fulfil the criteria of neurotransmitter,
as suggested by McLennan (1963). These included the presence of enzymes
necessary for the synthesis and metabolism of the transmitter and the
release after nerve stimulation. Moreover, local application of dopamine
simulated nerve stimulation (Horneykiewicz, 1973),
Investigation of dopamine mechanisms had been greatly helped by the
recognition of dopamine receptors in the central nervous system and
periphery. Activation of these receptors by dopamine was accompanied
by an increase in cyclic AMP via a dopamine-sensitive adenyl cyclase
(Greengard 8 Kebabian, 1974). Some drugs, like apomorphine, piribedil
and bromocryptine, mimicked the stimulation of the effector tissue.
Conversely, dopamine-receptor antagonists like chlorpromazine,
haloperidol and pimozide, blocked the action of these agonists. The
dopamine agonist and antagonist properties of these drugs had been
confirmed in several models in vivo (Ungerstedt., 1971, Goldberg, 1972).
B. FUNCTIONS OF DOPAMINERGIC PATHWAYS
Fig. 12 shows the principle dopamine pathways in rat brain. Dopamine
appears to produce mainly inhibitory (hyper-polarizing) responses at
its receptors. In some parts of the brain, its effects are much more
powerful than those of noradrenaline. The nigro-striatal pathway is
primarily concerned with motor function, and the infundibular system
with the regulation of hypotholamic releasing-factors (Vogt, 1973).
Although dopamine mechanisms have been implicated in mood and cognitive
functions, the evidence was less direct. Substantial evidence of a
disorder of dopamine pathways in psychosis is derived from the observation
that antipsychotic and neuroleptic activity correlated with dopamine
receptor antagonist properties over a wide range of drugs with different
structure (Matthysse, 1973, Snyder et al, 1974). In addition, amphetamines,
which release endogenous dopamine, might provoke hallucination and
psychosis (Snyder et al, 1974), as did L-DOPA and dopamine agonists
(Calne et al, 1974). It is too simple to suggest that schizophrenia
is a disease of dopamine overactivity in the limbic system (Crow,
Johnstone, Deakin § Longden, 1976). However, it is possible that
functional dopamine overactivity might contribute to the clinical features
of psychosis. Animal experiments implicated dopamine in many other
behaviour patterns including stereotypy (Costall 6 Naylor, 1975), eating,
drinking and autonomic control (Breese, Cooper and Smith, 1974).
The relationship of dopamine system to seizure susceptibility is
still obscure. Stimulation of the caudate nucleus was reported to
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produce arousal (Hensen et al, 1961), and to inhibit seizure activity
in other brain structures (Umbach, 1959, La Grutta, Amato and Avellone,
1972). Moreover, abnormally high concentrations of dopamine in the
brain were associated with arousal (Mantegazzini § Glaser, 1960), or
with irritability and increased motor activity (See Vogt, 1973).
C. DOPAMINE METABOLISM AND CLINICAL EPILEPSY
In general, central catecholamine metabolism in man could be
followed indirectly by findings in the blood, urine and CSF. Shaywitz
(1969) and other workers (Bartolini § Hornykiewicz, 1967., Papeschi et al,
1972), found a reduction of about 50% in HVA concentration in the CSF
of epileptic children. A similar reduction was also found in the CSF
HVA levels of a group of untreated epileptic patients (Shaywitz, Cohen
and Bowers, 1973), suggesting that low HVA concentrations in the CSF
primarily reflected the disease process rather than being the effect of
treatment. However, other workers reported no change in HVA concentrat¬
ion in CSF samples taken from patients with grand mal and temporal lobe
epilepsy (Garelis § Sourkes, 1974), while others reported that CSF
levels of HVA in unmedicated patients as close to control values
(Chadwick, Jenner and Reynolds, 1975). These workers also reported a
correlation between HVA levels in CSF and plasma anti-convulsant
concentrations and suggested that various anti-convulsants raised CSF
HVA levels and that HVA elevation was a manifestation of anti-convulsant
effectiveness.
In these cases L-DOPA treatment was effective in suppressing
epileptic fits (Bernheimer et al, 1966.,BartcOini § Hornykiewicz, 1967).
Similar results have been reached with L-DOPA and decarboxylase inhibitor
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R0-4-4602 (Birkmayer, 1974). These data might suggest that measurement
of CSF HVA levels might have some diagnostic value in some epileptic
patients.
D. ALTERED MONOAMINE METABOLISM IN EXPERIMENTAL EPILEPSY
It has been shown that in audiogenic seizure, the seizure
threshold in genetically susceptible mice varied with age, and this was
correlated with age-induced changes in brain amine levels (Schlessinger
et al, 1959). Some workers found that noradrenaline and 5-HT levels
were 40% and 50% respectively, of their control values in non-sensitive
mice at the time of maximal susceptibility to seizures. Moreover, at
later times, when mice were no longer audiosensitive, their brain amine
levels closely returned to normal values. Similarly, it was suggested
that a similar change in noradrenaline occurred in rubidium chloride-
treated audio-sensitive mice (Alexander 5 Meltzer, 1975). Paradox¬
ically, however, it was then reported that rubidium increased noradren¬
aline turnover in rat brain (Stolk et al, 1970). In cobalt-induced
epilepsy in rats, some workers failed to find changes in either
noradrenaline, dopamine or 5-HT levels in whole brain or a change in
noradrenaline or dopamine turnover (Colosanti 5 Craig, 1970).
Furthermore, noradrenaline levels in cortical foci was found to be un¬
altered in comparison to control unoperated rats (Clayton, 1976).
However, other studies have shown that catecholamine levels were
decreased in the penicillin-induced foci as compared to the contra¬
lateral mirror sites when spike activity was localized in the penicillin
treated cortex; but no difference existed in both catecholamine levels
between both foci when spike activity was fully propagated to the
mirror focus (Kobayashi et al, 1976).
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E. SURGICAL ALTERATIONS IN BRAIN DOPAMINE
The destruction of central catecholaminergic neurons with
6-hydroxydopamine (6-OHDA) (Breese § Traylor, 1971), given intra¬
ventricular^, lowered the seizure threshold in rats (Bourn et al,
1972., Avalone § Samanin, 1977), and was also found to reduce signific¬
antly the anti-convulsant effect of carbamazapine (Quattrone 5 Samanin,
1977), a drug with a pharmacological profile similar to that of phenytoin
(Theobald § Kunz, 1963., Stiener et al, 1970). However, bilateral lesions
in the substantia nigra that produced a 58% reduction in whole brain
dopamine, without affecting noradrenaline or 5-HT, failed to alter the
threshold for minimal electroshock in rats (Adler et al, 1969). These
findings suggested that striatal dopamine was not important in seizure
susceptibility, but they were inconclusive because of the incomplete
removal of striatal dopamine.
F. EFFECT OF DOPAMINERGIC DRUGS ON SEIZURE THRESHOLD
1. Increased dopamine at receptors
(a) Intraventricular administration of dopamine
Dopamine, like noradrenaline, does not penetrate the
blood-brain barrier. Administred intraventricularly to
mice, it was shown to facilitate pentylenetetrazole seizures
at low doses (0.5 - 1 yg) and to antagonise such seizures
at high doses (5 - 100 yg)„ In rats, intraventricular
dopamine was found to have no effect on electroshock seizure
in doses ranging from 4 - 16 yg, while a larger dose




The administration of L-DOPA, the immediate precursor
of dopamine, raised the central catecholamine levels,
particularly dopamine. Boggan § Seiden (1971) reported that
a 200 mg/kg dose of L-DOPA reduced the severity of seizure
in DBA/2 mice. Killiam § Frey (1973) observed that the
same dose elevated the threshold for maximal electroshock
and pentylenetetrazol in both rats and mice. Several
investigators observed that L-DOPA in combination with a
monoamine oxidase inhibitor exerted anti-convulsant effects
(Chen et al, 1968., McKenzie 8 Soroko, 1972). Some of the
strongest evidence that dopamine played a role in seizure
susceptbility was based on the ability of L-DOPA to reverse
or at least antagonise, the seizure facilitating effect of
reserpine (Azzaro et al, 1972., Boggan 5 Seiden, 1971). When
used in combination with monoamine oxidase inhibitor, L-DOPA
appeared capable of elevating a reserpine-depressed threshold
to supranormal levels. These findings favoured dopamine over
noradrenaline as mediator of the effect. However, uncertainty
was interjected by observations that L-DOPA decarboxylation
might occur extraneuronally (Bertler et al, 1966) and in
serotonergic neurons (Chase et al, 1970., 1971). The possibility
that dopamine acted as a 'false transmitter' at adrenergic and
serotonergic sites could also be considered.
(c) Dopaminergic drugs
Increasing evidence suggested that apomorphine specifically
activated dopamine receptors in the CNS (Ernst, 1966, Anden et al,
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1967., Ungerstedt et al, 1969). McKenzie § Soroko (1972)
found that apomorphine markedly elevated the threshold for
maximal electroshock seizures in rats, but not in mice. Stull
and his co-workers (1973) reported marked antagonism of
RO-4-1284-induced facilitation of electroshock seizure by
apomorphine and by intraventricularly administered dopamine.
Since RO-4-1284 is a reserpine-like monoamine depleter, and
the fact that the antagonistic effects of apomorphine and
dopamine were completely blocked by pre-treatment with the
dopamine -receptor blocking agent, pimozide, it was then
suggested that dopamine did exert inhibitory effects in
connection with electroshock seizure. These findings added
apomorphine and dopamine to the reported substances that
elevated seizure thresholds depressed by monoamine depletion
and which included 5-HTP, monoamine oxidase inhibitors and
noradrenaline. Thus, it would appear that almost any
treatment that increased monoamine transmission would restore
seizure threshold. Furthermore, the available information
would suggest that restoration was more readily accomplished
than elevation of a normal threshold to supranormal levels.
Apomorphine, ergocornine and piribedil were also shown to
raise the seizure threshold in audiosensitive mice (Anlezark
8 Meldrum, 1975).
(d) Dopamine-releasing agents
It was shown that low concentrations of amphetamine
released dopamine from the striatum almost as readily as
noradrenaline from all its channels and that higher
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concentrations were necessary to accomplish this effect at
other dopaminergic nerve endings as those in the limbic region
(Azzaro § Rutledge, 1973). It was shown that amphetamine
protected audiosensitive mice from audio shock (Fuxe et al,
1974), and to reduce spike activity in the EEG of cobalt-
implanted rats (Dow et al, 1974)0 However, other observations
suggested that the released endogenous dopamine in brain
might facilitate seizures (Spencer § Turner, 1969., Ellinwood
et al, 1973)„
(e) Effect of monoamine oxidase inhibitors and tricyclic
anti-depressants.
Monoamine oxidase inhibitors, which elevated brain
monoamine levels by inhibiting their catabolism, were found to
raise the seizure threshold. The anti-convulsant action of
monoamine oxidase inhibitors was thought to be mediated, at
least in part, by an increase in the central levels of dopamine
and noradrenaline (Fromm et al., 1973, Jarvik, 1970).
Tricyclic anti-depressants acted by blocking the active
reuptakes of monoamines at the nerve terminals, thus increasing
the effective amine concentration at the synapse. It was
reported that imipramine was effective in the treatment of
some cases of petit mal and minor motor epilepsy (Fromm et al,
1973). However, many monoamine oxidase inhibitors and
tricyclic compounds were too non-specific to permit differ¬
entiation of the effects of monoamine neurotransmitters.
2. Decreased dopamine at receptors
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(a) Inhibitors of dopamine synthesis
Inhibition of tyrosine hydroxylase, the rate-limiting
step in catecholamine synthesis, reduced the brain concentration
of both transmitters. Alpha-methyltyrosine,the best known
enzyme inhibitor, was observed consistently to increase the
seizure susceptibility. Given alone, it lowered the threshold
for tonic seizures in mice (Chen et al, 1968), antagonized the
anti-convulsant action of acetazolamide (Rudzik § Mennear, 1966),
and impaired the restoration of seizure thresholds in reserpine-
treated mice (Wenger, Stitzel and Craig, 1973, Azzaro et al,
1972). These findings supported other evidence that reduced
concentration of catecholamine increases seizure susceptibility
but did not differentiate between the role of dopamine and
noradrenaline.
(b) Dopamine blocking agents
Blockade of dopamine receptors with haloperidol or
chlorpromazine facilitated seizures in low doses, but had an
anti-convulsant effect at high doses (Chen et al, 1968).
However, Killiam $ Frey (1973), reported that haloperidol
failed to influence chemically and electrically-induced seizures
in mice.
(c) It has been shown that reserpine and tetrabenazine, which
reduce the central levels of monoamine, lowered the seizure
thresholds in a variety of models of epilepsy including
pentylenetetrazol ~ convulsions (Jones 5 Roberts, 1968., Pfeiffer
§ Galambos, 1965), electroshock (Azzaro et al, 1972), and
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audio-iogenic seizures (Schlessinger}Boggan and Freedman,
1965., Lehman, 1967., Boggan § Seidell, 1971).
Go CATECHOLAMINES IN DIFFERENT MODELS AND ANIMAL SPECIES OF EPILEPSY.
All these data support the hypothesis that seizure threshold was
linked to central catecholaminergic activity and this was further support¬
ed by microiontophonetic studies, some of which indicated that dopamine
and noradrenaline acted as inhibitory transmitters in the cortex,
(Frederickson et al, 1971, Jordan et al, 1972)= However, some drugs
like reserpine might well exert effects on more than one system. Moreover,
it was established that functional links existed between noradrenaline
and 5-HT systems in certain animals. It was found that sections of
the dorsal noradrenaline bundle in the cat resulted in an increased
cortical and raphe synthesis of 5-HT (Blondaux et al, 1975, Jouvet and
Pujol, 1974). Furthermore, L-DOPA loading raised central levels of
both dopamine and noradrenaline but have also been reported to reduce
whole brain 5-HT in the rat, (Fuller § Penry, 1975). Moreover, drugs
acting on noradrenaline and dopamine systems in brain might have an
effect on intracerebral blood flow and hence might alter the regional
metabolism not specifically related to catecholamine system (Edvinsson,
1975).
Some workers tried to separate the role of catecholaminergic and
serotonergic systems in epilepsy. Kellog et al (1974), using the
technique of catecholamine synthesis inhibition and precursor administr¬
ation, found that seizure threshold in the audiosensitive mouse model
could be raised by increasing and lowered by decreasing central catechol¬
amine levels. Other workers have also reported that inhibiting
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either tyrosine hydroxylase or tryptophan hydroxylase could delay the
recovery of seizure threshold to control values after reserpine,
wherease the simultaneous inhibition of both hydroxylases could prevent
the recovery indefinitely. However, the threshold could be affected
only by a combination of both synthesis inhibitors in normal mice
(Azzaro et al, 1972, Killiam 8 Frey, 1970).
It was suggested that the neuronal substrate to epileptic behaviour
was model-specific or species-dependent, and that the involvement of
the monoamine system might differ widely from one model to another.
In support of this view, it had been reported that audiogenic seizures
in mice could be blocked by clonidine, an alpha-adrenergic antagonist,
but not by apomorphine (Kellog et al, 1974), which stimulate the dopamine
receptors. This is in contrast to the finding that clonidine aggravated
while apomorphine reduced spike activity in cobalt-implanted rat (Ashcroft
et al (1974).This might be related to the fact that morphine had a stimulant
effect in mice, but a sedative effect in rats (Sellstrom et al, 1975).
Other workers also suggested that various monoamine neurotransmitters
played different roles in different models of epilepsy. In the mouse PTZ
(pentylenetetrazol) model, it was shown that seizure threshold could be
elevated by increasing and reduced by decreasing central 5-HT levels but
was insensitive to changes in central catecholamine levels. However, the
electroshock threshold in mice was found to be directly related to central
noradrenaline and dopamine levels but unaffected by altering the seroton¬
ergic activity (Rudzik § Johnson, 1970). Similarly, apomorphine was
shown to protect against maximal electroshock seizures (McKenzie 8 Soroko,
1972), while it potentiated PTZ seizure in mice (Soroko 8 McKenzie, 1970).
Moreover, amphetamine was reported to raise the threshold for electroshock
in rabbits (De Schaepdryver et al, 1962), and mice (Frey, 1964), while
lowering it in the rat (Jurnal $ Regelby, 1968). These observations
suggested that the circuitry of one type of convulsive model might
be species-specific. The concept of model-specific pattern of
neuronal involvement explains why many workers at present disagree
with the early hypothesis of establishing a common biochemical aetiology
whether catecholaminergic (Swinyard et al, 1961., Chen et al, 1968), or
serotonergic (Koe § Wiseman, 1966., Bonnycastle et al, 1957) to all types
of epilepsy.
H. AIM OF THE WORK
Some workers tried to differentiate the role of both catecholamines
noradrenaline and dopamine, in epilepsy in order to provide a more
specific answer. It was shown that phentolamine and sotalol, alpha
and beta-adrenergic blockers respectively, had anti-convulsant effects
in the mouse electroshock model (Navarro et al, 1974). In cobalt-
induced epilepsy in the rat, Ashcroft et al (1974) demonstrated that
apomorphine and amphetamine reduced or abolished spike activity in EEG
of epileptic rats while spiroperidol and clonidine had the opposite
effects. Moreover, the spike suppressant effect of dopamine receptor
stimulants was blocked by spiroperidol, a specific dopamine-receptor
blocker, which also initiated spike activity in control rats. However,
these were few experiments utilizing few animals to demonstrate the
drug effects. The present work was done to elaborate and extend
the above work and to confirm possible aspects of the role of dopamine
system in the cobalt model of focal epilepsy. Other dopamine agonists
were used in the present study that had predominantly a direct stimulant
action on dopamine receptors. The possible mechanism of action of
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these drugs was investigated using some pharmacological and surgical
manipulations of the dopamine system in the rat which might be helpful
in uncovering the aetiological basis of this form of focal epilepsy.
I. PHARMACOLOGICAL ASPECTS OF SOME DOPAMINE AGONISTS AND ANTAGONISTS
1. Apomorphme
It was well established that apomorphine administration to
rats led to the production of stereotyped sniffing, licking and
biting behaviour (Quinton § Halliwell, 1973., Randrup 8 Munkvad,
1968), probably due to stimulation of dopaminergic mechanisms in
the striatum. Furthermore, apomorphine induced contralateral
rotation in rats with unilateral degeneration of the nigro-striatal
pathway induced by 6-hydroxydopamine (6-OHDA) (Ungerstedt, 1971.,
Dray 8 Oakley, 1976., Dray et al, 1975) „ Apomorphine-induced
stereotypy and rotation began within 2-5 min and lasted about
60 min with peak rotation occurring about 30 min after the injection
(Dray 8 Oakley, 1976). Both rotation and stereotypy could be
blocked by the administration of pimozide (1 mg/kg-i.p.) or
haloperidol (0o5 mg/kg.i.p.), either before or after the injection
of apomorphine.
Apomorphine was also known to lower prolactin secretion in
plasma of rats (Horowski et al, 1975), and to stimulate dopamine-
sensitive adenylcyclase (Kebabian 8 Greengard, 1972).
2. Bromocryptine
Bromocryptine or 2-bromo-alpha-ergocryptine is an ergot
polypeptide derivative comprising a lysergic acid residue with a
cyclic polypeptide moeity.
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It was originally characterized as specific inhibitor of
prolactin secretion in all the vertebrates tested including
man (Fluckiger, 1972, Del Pozo et al, 1972). However, Hokfelt
§ Fuxe (1972) found that in the rat, bromocryptine also decreased
dopamine turnover in the median eminence and suggested that it
might interfere with the dopaminergic tuberoinfundibular neurons
which control prolactin secretion.
It was then found that bromocryptine also decreased dopamine
turnover in the neostriatum, an action attributable to direct
stimulation of dopamine receptors at this site (Corrodi et al, 1973).
This central dopaminergic stimulation was assumed to be responsible
for the significant therapeutic action of bromocryptine in Parkin¬
sonism (Calne et al, 1974a and 1974b) and in galactorrhea.
Bromocryptine was shown to induce a dose-dependent stereotyped
behaviour in normal rats. Moreover, it induced a dose-dependent
contralateral rotation in rats with unilateral lesion of the
substantia nigra induced by 6-OHDA (Johnson et al, 1976). These
effects of bromocryptine could be blocked by the prior administration
of pimozide (1 mg/kg, i„p.) or haloperidol, and reduced by pre-
treatment with reserpine or alpha-methyltyrosine (Johnson et al,
1976).
Moreover, bromocryptine stimulated spontaneous motor activity in
normal mice (Johnson et al,1976)in a dose-dependent manner,, Bromo¬
cryptine produced its effects after a latent period of 50 to 70
min (Corrodi et al, 1973, Fuxe et al, 1974, Johnson et al, 1976,
Dray § Oakley, 1976). Bromocryptine (5-20 mg/kg i.p.) induced—
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rotation was fairly constant and persisted up to 240 min and
declined over the next 5-7 hrs depending on the dose (Dray §
Oakley, 1976, Johnson et al, 1976).
Dopamine-receptor stimulation by bromocryptine was also
reflected by a reduction in cerebral dopamine turnover in the
presence of alpha-methyltyrosine-induced synthesis blockade
(Corrodi et al, 1973, Fuxe et al, 1974). The delay in the onset
of action as well as the dependence on presynaptic events differ¬
entiated bromocryptine from the classical dopamine agonists.
Bromocryptine also inhibited dopamine metabolism in man, and this
was reflected by reduction of CSF levels of HVA in treated patients
(Curzon, 1975).
Other neurotransmitter systems, such as 5-HT, were also
affected by bromocryptine (Corrodi et al, 1975). 5-HT release
was reduced, as reflected by 30-40% reduction of brain 5-HIAA in
bromocryptine-treated rats (Snider et al, 1975), and reduction of
5-HIAA levels in CSF of treated patients (Curzon, 1975).
3. Lisuride hydrogen maleate
Lisuride hydrogen maleate is a derivative of isolysergic
acid with strong peripheral anti-serotonin activity (Votava §
Lamplova, 1961). This compound was synthesized by Zikan §
Semonsky (1960) and was used mainly as a prophylactic agent in
migraine.
Lisuride induced stereotyped behaviour in normal as well as
in reserpinised mice. It antagonized the motor depression and
hypothermia induced by reserpine. As with apomorphine, the
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effects of lisuride hydrogen maleate were not impaired by pre-
treatment with alpha-methyltyrosine. In untreated mice, the
substance was very potent in producing a significant hypothermia
with doses as low as 0.1 mg/kg i.p. The stereotyped behaviour
and hypothermia could be prevented by pre-treatment with the
dopaminergic antagonist haloperidol (Horowski § Wachtel, 1976).
These actions indicate that lisuride hydrogen maleate was a potent
dopaminergic agonist with a probably direct action on dopamine
receptors. Furthermore, lisuride at doses as low as 0.1 mg.kg
had a strong serum prolactin lowering effect in rats (Horowski
et al, 1975, and in man (Horowski et al, 1977). In rats, Dlabac
(1973) reported a marked increase in brain dopamine following an
intravenous injection of 0.3 mg/kg lisuride hydrogen maleate and
it was further shown that lisuride lowered the synthesis rate of
dopamine, an effect which was also known for apomorphine (Kehr et al,
1975). In the dopamine-rich areas, the striatum and mesolimbic
forebrain, lisuride (300-100 ug/kg) decreased the rate of L-DOPA
formation in rats after inhibition of aromatic amino acid decar¬
boxylase with NSD-1015, and this was counteracted by haloperidol
(Kehr, 1977)„ In the predominantly noradrenaline-innervated
neocortex, lisuride in doses of 0.3 and 1 mg/kg i.p. increased
dopa accumulation. After inhibition of catecholamine synthesis
with alpha-methyltyrosine, lisuride decelerated dopamine and
accelerated noradrenaline disappearance. In addition, lisuride
caused an increase in 5-HT and a decrease of 5-HIAA concentrations
in the brain. Furthermore, lisuride reduced 3-methoxytyramine
accumulation after monoamine oxidase inhibition with pargyline,
suggesting inhibition of dopamine release. These data support the
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views that lisuride stimulated post-synaptic dopamine and, to
a lesser extent, 5-HT receptors and blocked noradrenaline
receptors in the CNS (Kehr, 1977).
4m CF 25-397 [9,10-Didehydro-5-methyl-8-Beta (2-pyridylthio-
methyl)ergoline].
This is a non-peptide ergot derivative which seemed to
exert some dopamine-like action which differed from the effect of
bromocryptine or L-DOPA and appeared to be more selective.
CF 25-397 induced a dose-dependent contralateral turning in
rats with unilateral lesion in the substantia nigra, induced by
6-OHDA, from a dose of 1 mg/kg i.p. This effect was blocked by
pre-treatment with pimozide (1 mg/kp i.p.) (Jaton et al, 1975).
This indicated that the compound possessed central dopamine
stimulating activity. However, even at high doses (30 mg/kg),
stereotyped behavior was barely detectable. This suggests that
its action on the nigro-striatal system was highly selective
(Jaton et al, 1975). In mice, CF 25-397 inhibited reserpine-induced
catalepsy. However, no motor stimulation was observed. On the
contrary, CF 25-397 (2-5-10 mg/kg i.p.) slightly reduced the motor
activity (Jaton et al, 1975). This drug also induced hypothermia
in cold-acclimatized rats (Silbergeld et al, 1977). Like
bromocryptine, the long latent period between the administration
of CF 25-397 and the induction of its behavioural effects raised
the possibility that the activity depends upon the conversion to
active metabolites. Failure of CF 25-397 in clinical trials to
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elicit any therapeutic effect in Parkinsonism might be explained
by differences in drug metabolism between rats and man.
5. Pimozide
Blockade of dopaminergic receptor sites was widely implicated
in the mechanism of action of various anti-psychotic agents.
Neuroleptics, such as the diphenylbutylpiperidine derivative,
pimozide, appeared to be a selective blocker of the dopamine
receptors (Janssen, 1967., Anden, Butcher and others, 1970).
Studies have suggested that blockade by anti-psychotics of dopamine
receptors in the striatum and the mesolimbic system were closely
related with the anti-psychotic action of these drugs (Anden, 1972,
Anden § Stock, 1973) „
6o 6-hydroxydopamine (6-0HDA)
The stereotaxic injection of 6-0HDA in discrete brain areas
has been widely used to produce selective and specific
degeneration of catecholamine neurons. This method proved a
valuable tool in morphological (Maler et al, 1973, Ungerstedt, 1971)
and functional (Agid et al, 1973.,Lidbrink § Fuxe, 1973.,Ungerstedt,
197),,Arbuthnott, 1970and Ungerstedt? 1970) studies.
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1. ANIMALS
Male Wistar rats (200-250 g in weight) were prepared with cobalt
implants and recording electrodes as already described in Methods of
Section 1.
2. THE STEREOTAXIC FIXATION OF STAINLESS STEEL SCREW CANNULAE
FOR INTRASTRIATAL INJECTION OF DRUGS
In some animals, prior to the implantation of cobalt-gelatin sticks,
two specially constructed stainless steel cannulae (especially made in
the Department) were fixed, one to each side of the skull, so as to
enable injection of drugs into the striatum.
Using the stereotoxic frame, a point (7.7 mm anterior to the
interaural line, and 2.7 mm lateral to the midline), was located on
each side of the skull (Konig § Klippel, 1963). Theslcull was trephined,
and the hole centered at this point, using No. 6 burr. One hollowed
screw cannula was fitted to the skull on each side at this point, and
fixed with acrylic cement (Simplex). Injections were made 3.5 mm
deep to the cortical surface (Konig § Klippel, 1963), using 18 gauge
needle. The solution for injection was freshly prepared and drawn into
a special 2 ml glass syringe (Agla) which was then fitted into a micro¬
meter which will control the volume of the injected solution. The
needle length was such that it could traverse the hollowed screw cannula
and project 4.5 mm below its tip so as to be stereotoxically placed in
the striatum (i.e. A 7.7, 2.7 L, and V 3.5 mm) (Konig § Klippel,
1963).
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3. TECHNIQUE FOR INTRA-STRIATAL INJECTION
Injections of 6-OHDA were made into each side of the striatum in
the anaesthetized rat. One yl of solution was injected slowly. An
interval of 30 sec was allowed before injecting the next 1 yl. This
process was continued until the required volume of solution was given.
For experiments with dopamine agonists, injections were 10-16
days after operation when epileptic foci following cobalt implantation
were well established. At that time, the rat was handled in such a
way that its head was straight and parallel to the plane of the table.
Injections were made into the striatum as described above, care being
taken to prevent movement of the rat head during the injection procedure.
At the end of the recording procedure, and before each injection, care
was taken to avoid blocking of the hollowed screws by blood mixed with
CSF which might have leaked after the injection, clotted and solidified.
4. ELECTR0C0RTIC0GRAPHIC (ECoG) RECORDING
A. Instrumentation
ECoG recordings were made from the unrestrained conscious
rats. Twisted connectors, attached to braided wire, were fitted
into the hollow bore of the recording stainless steel screw
electrodes. The brain activity was amplified and recorded on
a Grass polygraph, (Model 7). During each session,
ECoG recording was done from two rats, one of which was drug-treated
while the other served as a control.
Four channels were utilized and each amplified and recorded the




The right frontal (active) and right posterior (parietal)
electrode.
This would record the potential difference due to epileptic
activity in the right frontal cortex, i.e. the primary focus
of the first rat.
Channel 2:
The left frontal electrode (active) and the left posterior
(parietal) electrode.
This would record the epileptic activity in the secondary
focus in the left frontal cortex of the first rat.
Channel 3:
The right frontal electrode (active) and the right posterior
electrode, i.e. primary focus of the second rat.
Channel 4:
The left frontal electrode (active) and the left posterior
electrode, i.e. secondary focus of the second rat.
Channels 1 and 2 were amplified through direct current (D.C.)
preamplifiers which utilized a transistor chopper with a time
constant of 0.8 sec. Direct current (D.C.) amplification was used
in order to enable the recording of any changes in the character¬
ization of the low frequency component of the ECoG which might have
changed in epileptic rats. All channels had high frequency filters
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set on the driver amplifiers at 35 Hz, and they all utilized a
50 Hz mains filter to block any interference from other equipment.
The final recording sensitivity was 100 uV/cm from all channels,
and the paper chart speed was set at 10 mm/sec. Before each
recording, the polygraph was calibrated from a low frequency oscill¬
ator (SLEE, model 81), producing a balanced sine wave signal so
that all pens were deflecting equally at a frequency of 8 Hz.
Input voltage of 100 uV was fed from the oscillator into each
channel at the level of the grid connections, and the preamplifier
sensitivity adjusted to give 1 cm per deflection.
Calibration was essential so that direct comparisons of the
ECoG amplitudes could be made between all channels.
B. ECoG Recording Technique
The rat, with previously inserted electrodes, was placed in
a perspex box with the recording leads attached. It was allowed
to settle for 10 min in the new environment, a perspex cover was
placed on top of the case to prevent the animal from escaping.
During this settling period, the calibration signal of 100 uV sine
wave, at a frequency of 8 Hz, was recorded for 1 min. The paper
speed was 10 mm/sec. After this settling period, the leads
from electrodes attached to the animal were connected to the grid,
and ECoG recording was done from the conscious unrestrained rats.
These recordings could be made within 24 hrs after the
implantation of cobalt. In order to follow the development of
epileptic activity in cortical foci in the brain, recordings were
done for 10 min either daily or on alternate days in the first week,
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and then on alternate days during the second week after cobalt
implantation, depending on the nature of the experiments.
However, to detect the effect of drugs on the epileptic
activity of cortical foci, long recordings were required. Initially,
a 30 min ECoG recording was done followed by the administration of
the drug. Recording was then continued for 2 hrs or longer after
drug administration, depending on the nature of the drug under
study. Such recordings were made 8-16 days after cobalt
implantation when the motor manifestation and activity of cortical
epileptic foci were prominent.
Recording sessions were standardized as far as possible
particularly with regard to the time of the day and the sequence
of recording the individual animal in any group, since there have
been reports of diurnal fluctation of seizure threshold on various
models of epilepsy (Schreiber § Schlessinger, 1971., Wooley §
Timiras, 1962). In general, ECoG recordings were carried out in
the morning. In drug experiments, the drug injection was normally
given between 9.30 - 10.00 a.m.
During the 10 min recording, the behaviour of the animal and
epileptic motor manifestation were noted. During drug .experiments,
the stereotyped behaviour and'motor epileptic manifestations were
noted every 15 min following the drug injection. However, detailed
behavioural rating was not done. Attempts were made during the
recording to prevent the connecting leads from becoming entangled
as the animal moved about the recording box, by having the 4 leads
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braided into a harness. However, if the rat continued to
circle in one direction, the leads tended to become twisted to
such an extent that recording had to be stopped, the leads removed
and straightened before continuing the recording. For routine
recording, this precaution was very satisfactory, but it was noted
more when animals were treated with dopamine agonists such as
apomorphine. However, this did not interfere to any extent with
the continuation of the recordings.
Sometimes, it was also necessary to prevent the rat from
pulling the leads down with its forefoot, and chewing through them
or actually eating them. This can be prevented by gently poking
the animal with a wooden or rubber stick, or tapping the top of
the cage. Theoretically, this has the disadvantage of changing
the ECoG characteristics by arousing the animal, but in the present
work, this was done infrequently so as to avoid disturbing the
animal to the extent of interfering with the ECoG characteristics.
5. AUTOMATIC ANALYSIS OF ELECTROCORTICOGRAM
A. Instrumentation
The bipolar ECoG recording from each cerebral hemisphere of
the rat were amplified through the Grass polygraph (Model 7), using
35 Hz filters, 0.03 second time constant, and also recorded on
magnetic tape, using a Tandberg I.R. (Series 100) tape recorder,
at a speed of l|"/sec. At this recording speed, the Tanberg
bandpass is from 0-62 Hz. These tapes were used subsequently for
computer analysis and spike counting, according to the method of
Hill § Townsend (1973), which utilizes the criterion of sharpness,
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i.e. peak angles. The signals were then analyzed by replaying
the tape at the recording speed through an analogue low pass filter
with a band width of 25 Hz. The band limited signal was sampled
at a rate of 200 samples/sec/channel, and digitised to a 7-bit
(1%) amplitude accuracy. Gain and offset controls were used to
ensure full utilization of the dynamic range of the analogue
digital computer.
The computer used was an Elliot 905 connected on-line to a
1-16 channel analogue to digital (A-D) and digital to analogue
(D-A) convertor, via a special 8-bit parallel interface (NPL
modified). An Elliot series 20 visual display enabled information
to be displayed an a TSP-212 point plotter was used to produce
permanent graphical records. Input-output was on 8 hole punched
paper tape, and all analyses were carried out in real time.
The recognition of spikes by the computer was done by
separating the recorded phenomena into a set whose members were
'spikes' and a complementary set of 'not spikes'. The rest of the
ECoG like waves, muscle activity and electrical artefacts did not
undergo the same mapping as spikes.
For long recordings, a programme has been designed to monitor
recordings each 5 min, i.e. total spike count per 5 min. For 10
min recordings, the programme averages the spike counts during that
period.
B. Epileptic spike recognition
The main EEG or ECoG features of epilepsy is the spike. The
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International Federation has already defined a 'spike' as a
'wave distinguishable from background EEG activity and having
a duration of one twelfth second or less', and a 'sharp wave, as
a wave distinguishable from background EEG activity, with a
duration of more than one twelfth second and less than one
fifth second'. These criteria fitted the results from the rat
model very well as the frequency of epileptiform episodes occurring
at any given time was much more predictable in the rat than in
recording from epileptic patients (in whom epileptiform spikes
are sparse and unpredictable, and can be easily inhibited). It
has been found that even the process of connecting a patient to
the EEG machine has some inhibitory effect on epileptic phenomena
(Hill § Townsend, 1973). The same inhibitory phenomenon does
occur in rats when one connects them first to the recording leads
before putting them in the recording box. However, this lasts
about 10 min and, since routinely 10 min period was allowed for
the animals to settle, this did not pose a problem.
There have been attempts to utilize computers for the
recognition of epileptic spikes in the EEG and ECoG (Saltzberg
et al, 1971., Carrie et al, 1972). These methods rely on empiric¬
ally-adjusted threshold values and therefore cannot be used easily
as routine procedure. The development of an automatic spike
recognition was itself complicated at the outset by the fact that
there is often disagreement between observers on what is a real
epileptiform activity and what is not when EEG records are inspected
visually. Mosley et al(1972) laid down six guidelines, of which
three were helpful in solving this difficulty. These included:-
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1. Every spike-looking wave is to be regarded as
artefact, unless there are good reasons for
suspecting otherwise.
2. Epileptically significant spikes and sharp waves
are almost always surface negative in polarity
initially, or at least, the sharpest or highest
voltage component of the wave is usually surface
negative. ' *
3. Sharp or spiky events which can be logically explained
by simple alterations in voltage of the background
rhythm or by superimposition of several components
in the background activity of the record should be
ignored.
Taking these guidelines into account, Hill § Townsend (1973)
described a computer programme which allowed the automatic detection
and estimation of the number of spikes in the rat ECoG and human
EEG. This was done by measuring the peak angles of each wave
in the ECoG sample recordings. Spike recognition by measuring
the peak angle required that a criterion should be established
such that waves with peak angles smaller than the criterion angle
were classified as spikes.
In addition to peak angles, other reference features in
classifying spikes are the rise time and fall time (Kooi, 1966).
However, these are difficult to estimate because the precise points
of inflection (at the start and finish) are not easy to define,
since they depend on the form of the underlying activity and its
phase relationship to spikes.
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C. Measurement of peak angles by the computer
The rate of change of potential during the rising and falling
phase of the spike is approximately linear and a straight line can
be fitted by the least squares method to give an accurate estimate
of the gradients. With a sampling rate of 200/sec, it was found
that four points exclude very few spikes and make the method
highly artefact-resistant.
The angle between straight lines which are fitted by the
computer to four points on either side of the peak is the peak
angle (Fig. 13A) „ This angle was computed and its size used in
analysis of ECoG recordings. The effect of low pass filtering is
to round the peak and slightly slow the rise and fall times. The
ease with which two waves can be distinguished by measurement of
their peak angles is dependent upon the gain. This effect is
already known in recognising human spikes, whereas if the gain is
increased or the recording paper speed is decreased, the record
appears more spiky, while conversely at low gains or fast paper
speeds, the spikes may be difficult to recognise. For this
reason, the amplitude value used in calculating the peak angle must
be corrected by reference to a suitable calibration signal.
D. ' Distribution of peak angles
If the statistical distribution of peak angles is examined
by performing a histogram, it is found in the case of records with
clearly visible spikes that the distribution is bimodel (Fig. 13B).
















Fig. 13 A Calculation of Peak Angle of a Wave
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(a) SPIKES - these constitute the small groups on the
left with acute angles.
(b) WAVES - these are the larger groups wTith less acute
angles.
The trough between the two peaks of distribution is then used
to determine the criterion peak angle. Thus, spikes form a
distinct population which can be detected and measured with
suitable accuracy to enable monitoring the ECoG correlate of epileptic
focus during its development and under the influence of drugs.
6. DRUG SOLUTIONS, DOSES AND MODE OF ADMINISTRATION
The following drugs were used during experimentation:-
(a) Apomorphine hydrochloride (Evans)
This was available in ampoules containing 3 mg/ml. It was
used in doses of 0.5, 1 and 2 mg/kg, given by intraperitoneal
(i.p.) injection.
(b) Bromocryptine mesylate (Sandoz)
This drug was freshly dissolved in a few drops of glacial acetic
acid and 0.5% ethanol and the required volume made with 5% glucose
solution so as to give a concentration of 20 mg/ml. The drug
was given i.p. Control rats received an equivalent volume of
the vehicle i.p.
Care was taken that the volume of solution injected was less
than that required for ethanol to produce any sedative effect
or affecting catecholamine metabolism (Carlsson & Lindquist,
1973, Carlsson, Engel, Strombom, Svenson & VJaldeck, 1974).
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Bromocryptine was used in doses of 10 and 20 mg/kg i.p.
(c) Lisuride hydrogen maleate (Schering)
This drug was freshly dissolved in normal saline to make a
final concentration of 1 mg/ml. Lisuride was injected
(i.p.) in doses of 0.1, 0.25, 0.5 and 1 mg/kg.
(d) CF 25-597 (9,10-didehydro-6-methyl-8B-(2-pyridylthiomethyl)
ergoline) (Sandoz)
CF 25-397 powder was freshly dissolved in a few drops of
glacial acetic acid and the required volume made with 5%
glucose water to make a concentration of 40 mg/ml. This
drug was given (i.p.) in doses of 20 and 40 mg/kg.
(e) Pimozide (Janssen Pharmaceuticals Co)
This drug was freshly dissolved in a few drops of glacial
acetic acid, neutralized with one drop of 0.5% ethanol and
the final volume made with 5% glucose water to a concentration
of 2 mg/ml. This drug was injected (i.p.) in a dose of
1 mg/kg.
6-hydroxydopamine (6-0HDA) (Sandoz)
This powder was freshly dissolved in normal saline to make
a concentration of 10 mg/ml, and containing ascorbic acid
(0.5 mg/ml) to avoid its oxidation. This drug was





This powder was freshly dissolved in normal saline to make a
12.5 mg/ml solution, which was used for intrastriatal injection
in a dose of 25 yg (2 yl) in one or both striata.
(h) Apomorphine HC1 powder (Sandoz)
This powder was freshly dissolved in normal saline to make a
solution of 30 mg/ml containing 0.5 mg/ml ascorbic acid to avoid
its oxidation. This drug was injected in a dose of 60 yg (2 yl)
into each striatum.
EXPERIMENTAL DESIGN AND GROUPING OF RATS
A. EFFECT OF DOPAMINE AGONISTS ON FOCAL EPILEPTIC ACTIVITY
OF CORTICAL FOCI INDUCED BY COBALT IMPLANT
1. Effect of apomorphine
Animals were divided into 3 groups, each group of 4 cobalt-
implanted rats for testing the effect of 0.5, 1 and 2 mg/kg of
apomorphine respectively.
ECoG recording was done for a control period of 30 min
from each pair of rats. One rat, then, received the assigned
dose of apomorphine (i.p.) while the control rat was injected
(i.p.) with an equal volume of normal saline. Recording was
continued for 2 hrs following the administration of the drug.
2. Effect of bromocryptine
Eight rats were used, being divided into 2 groups of
four animals each. One dose of bromocryptine mesylate;
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either 10 or 20 mg/kg (i.p.) was assigned to each group to test
its effect on epileptic activity when cortical foci were well
established.
ECoG recording was done for a control period of 30 rain
from each pair of rats. Then one rat received broraocryptine
(i.p.) while the other animal received an equivalent volume of
the vehicle similarly. Recording was then continued every
second half hour for the following 6 hours after the injection,
observing the epileptic and behavioural changes every 15 min.
This is due to the reported latency (50-60 min) for onset and
the prolonged action of bromocryptine in comparison to other
dopamine agonists such as apomorphine. ECoG recordings of
30 min duration were also done after 24 hrs to test whether
the effect of the drug had lapsed.
3. Effect of lisuride-hydrogen maleate on cortical
epileptic foci
Fourteen rats were used. These were divided into 4
groups, two of which were of 3 rats each, while each of the
other two groups contained 4 cobalt-implanted rats. Each group
was used for testing the effect of one dose of lisuride either
0.1, 0.25, 0.5 and 1 mg/kg respectively. The procedure was
the same as that described for apomorphine, except that the
animals received a dose of lisuride (i.p.) after 30 min control
period of ECoG recording.
4. Effect of CF 25-397 on focal epileptic activity
Seven Wistar rats were used, being divided into two groups
of 3 and 4 animals for testing the effect of 20 and 40 mg/kg of
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the drug, respectively. The procedure is the same as that
described for bromocryptine, except that the animals received
CF 25-397 in the assigned dose after an initial 30 min period
of ECoG recording.
B. EFFECT OF DAILY ADMINISTRATION OF BROMOCRYPTINE (20 mg/kg
INTRAPERITONEALLY) ON THE DEVELOPMENT OF SPIKE ACTIVITY IN
EPILEPTIC CORTICAL FOCI IN COBALT RATS
Starting on the first day after cobalt implantation, bromo¬
cryptine was given daily ,20 mg/kg) i.p. to one group of 5 rats,
while the control group received an equivalent volume of the vehicle
daily (i.p.).
ECoG recording for 10 min was done prior to the injection
daily for the first week and then on alternate days until the 12th
day.
C. EXPERIMENTS WITH DOPAMINE RECEPTOR BLOCKER, PIMOZIDE, ON
FOCAL CORTICAL EPILEPTIC ACTIVITY INDUCED BY COBALT
IMPLANTATION
1. Effect of pimozide alone
Three pairs of rats were used for this experiment. ECoG
recording was done for a control period of 30 min. Then
one rat received pimozide (1 mg/kg) i„p. while the control
rat received an equivalent volume of the vehicle (i.p.).
Recording and behavioural observation was continued for 2 hrs
following the injection.
2. The effects of pimozide on the actions of dopamine
agonists
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This was assessed in a series of experiments in which
pimozide (1 mg/kg) or an equivalent volume of vehicle (for
control rats) was given (i.p.) 45 min before the intraperit¬
oneal adminstration of apomorphine (2 mg/kg) or lisuride
(0.1 mg/kg) and 20 min before bromocryptine (20 mg/kg) or
CF 25-397 (40 mg/kg) i.p. ECoG recording and assessment
of the central effects were continued as described above with
each respective agonist.
D. EXPERIMENTS ON THE STRIATUM IN COBALT IMPLANTED RATS
1. Effect of bilateral intrastriatal injection of dopamine
on epileptic activity in cobalt-implanted rats
When cortical epileptic foci were well established after
8-16 days of cobalt implantation, ECoG recording was done for
a control period of 20 min from each pair of rats. One
animal received, then 2 pi (25 pg) of freshly prepared dopamine
solution (12.5 mg/ml) into each striatum, while the control rat
received 2 pi saline bilaterally into the striatum. ECoG
recording and behavioural observation were then continued for
one hour after the injection, noting changes in epileptic
manifestations as well.
2. Effect of bilateral intrastriatal injection of apomorphine
on epileptic activity
The design of the experiment is similar to that described
for dopamine except that the treated rat received 60 pg (2 pi)
apomorphine HC1 solution, freshly prepared, while the control
rat received an equivalent volume of saline into each striatum,
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as described in the Methods.
3. Effect of unilateral injection of dopamine into the
striatum on focal epileptic activity
The experimental design is the same again (1) but the
treated rat received 2 yl (25 yg) of dopamine into the right
striatum while the control animal received 2 yl saline into
the same striatum, as described in the methods.
4. Effect of bilateral destruction of catecholamine terminals
in the striatum with 6-hydroxydopamine (6-OHDA) on the
development of focal epileptic cortical foci in cobalt-
implanted rats,
A. Procedure
Twelve rats received cobalt-implant into the right frontal
cortex. At the time of the operation 2 yl (20 yg) solution of
6-OHDA (10 mg/ml) was injected slowly into each striatum of 6
rats, while the remaining 6 rats received 2 yl normal saline
into each striatum.
The rats were observed daily for behavioural changes and
epileptic manifestation. Many of the rats required supp¬
lementary feeding due to hypokinesia and difficulty in eating
and drinking in the post-operative period.
Daily ECoG recording was started on the first day after
operation, recording was done for 10 min from one drug-treated
and one control animal at a time. Tissues from lesioned and
control rats were assayed together. ECoG recording was
113.
continued daily for the first 8 days and then on alternate
days for the following week.
B. Dissection of striatum
Two weeks after the operation, the rats were killed by
decapitation, their brains quickly removed on a mixture of
solid CO2 and crushed ice. The striatum on each side was
quickly dissected out, as described in the methods. Tissues
were quickly stored in liquid nitrogen for subsequent biochem¬
ical estimation of dopamine and noradrenaline in striatum.
Biochemical analysis was done within 4 weeks of freezing in
liquid nitrogen.
Co Biochemical estimation of dopamine and noradrenaline
Noradrenaline and dopamine were measured in the rat
striatum using the enzymatic isotopic method (Palkowitz et al,
1974), which is a modification of the radiometric catechol-O-
methyl transferase assay for catecholamines described by
Engelman § Portnoy (1970). The reported sensitivity (twice
the blank) of the assay was approximately 15 picograms (pg)
for noradrenaline and 45 pg for dopamine (Palkovitz et al,1974).
Tissues were homogenized in 300 pi of 0.1 N perchloric
(HC104) acid. After centrifugation, the supernatant was
taken into 15 ml glass centrifuge tubes. Blanks contained
300 pi of 0.1 N perchloric acid. Standards were prepared by
adding 50 pi of 0.1 N HCL 04 containing 25 ng dopamine or
noradrenaline (free base) to 300 pi brain extract.
The reaction was initiated by the addition of 100 yl of a
mixture containing 500 yg of dithiothreitol, 0.5 yM magnesium
chloride, 140 yM of tris-HCL (pH 9.6) 25 yl catechol-0-methyl
3
transferase, and 2.5 yl of H-S-adenosyl-l-methionine methyl (SAM).
(Specific activity 500 mCi/mMol, Radiochemical Centre, Amersham).
Incubation was continued for 50 min at 37°C and the reaction was
stopped by the addition of 500 yl of 0o5 M borate buffer, pH 10.
Fifty microliters ( yl) of a non-radioactive carrier solution,
containing 7 yg methoxytyramine, 3 yg normetanephrine, 3 yg meta-
nephrine and 1 mg EDTA, was added to each sample. The O-methylated
products were then extracted into a 9 ml of water-saturated ethyl
acetate:methanol (10:1 V/V) by shaking for 30 sec. The phases were
then separated by a centrifugation at low speed and 8.5 ml of the
organic phase was transferred to another tube containing 0.5 ml of
0.5 M borate buffer, pH 10, to remove the phenolic acids. After
shaking for 30 sec and centrifuging, the organic phase was trans¬
ferred to a third tube containing 0.5 ml of 0.1 N HCL into which
the O-methylated products were extracted into the aqueous phase by
shaking for 30 sec. The tubes were then centrifuged for 5 min,
and the organic phase was aspirated and discarded. The acid phase
was then washed by the addition of 8 ml of water-saturated ethyl
acetate and followed by mixing for 30 sec. After centrifugation,
the ethyl acetate was aspirated and discarded. The tubes were then
transferred to ice bath and 0o5 ml of 0.5 M sodium phosphate buffer,
pH 7.5, was added to each tube.
To separate dopamine from noradrenaline, the side-chain of the
latter was cleaved at the 8-hydroxy-position with 50 yl of freshly
prepared 3% sodium metaperiodate solution,, The reaction was
allowed to proceed for 5 min and was then stopped by the addition
of 50 pi of 10% glycerol. The PH]methyl vanillin was then
extracted into 10 ml of toluene by shaking for 30 sec, followed by
centrifugation to separate the phases. Nine ml of the toluene
phase was then transferred to another tube containing 1 ml of 0.1 N
NaOH for the noradrenaline assay, while the aqueous phase was left
for the dopamine assay.
•Z
The [ Hjmethyl vanillin in the 9 ml toluene phase was extracted
in 0.1 N NaOh by shaking for 30 sec and the organic phase was
removed after centrifugation. The aqueous phase was the acidified
with 0.1 ml of glacial acetic acid and the vanillin was again ex¬
tracted into 10 ml of toluene. Nine ml of the organic phase was
then transferred to a counting vial containing 0.4 ml liquiflour in
scintillator counter. The counting efficiency of tritium was
estimated to be 34%.
The aqueous phase of the metaperiodate reaction was used
for dopamine determination. Five ml of toluene were added to each
tube, mixed for 30 sec, centrifuged and the organic phase aspir¬
ated off. This was followed by the addition of 0.5 ml of 1 M
borate buffer pH 11 and 5 ml of toluene:isoamyl aocohol (3:2 V/V)
to each tube, shaking for 30 sec and centrifuging at low speed to
separate the phases. Five ml of the organic phase were then
transferred to scintillation vial to which 10 ml of scintillant
(NE 260) was added and counted for [%] in scintillation counter.
The important characteristics of this assay are:-
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1. The B-hydroxylated catecholamine (e.g. epinephrine) will
also be measured in the noradrenaline assay. However, since
epinephrine is present in trace amounts in the rodent brain
(Iversen, 1967), this was not a limitation for the assay.
Catechol precursors of noradrenaline, particularly dopamine,
did not cross-react to any marked degree. Furthermore, it
has been shown that both assay procedures exhibited linearity
with amounts of catecholamines ranging between 10 pg and at
least 10 ng (Coyle § Henry, 1973).
2. The toluene wash reduced the contamination of dopamine by
noradrenaline to about 5-7% (i.e. 5-7% of the count number
obtained for a given amount of noradrenaline in the noradren¬
aline assay will be obtained in the dopamine assay). However,
the cross contamination of the noradrenaline assay by dopamine
is about 1%. So, ideally, neither assay should be done in
the absence of the other in order to correct for cross contamin¬
ation of one amine by the other unless one can predict before¬
hand that cross contamination will be insignificant because of
preponderance of one amine to the other. In the striatum where
the assay was done in the present piece of work, dopamine is
present in high concentrations in comparison to the trivial
amounts of noradrenaline; so, the cross contamination
between the amines is negligible.
3. The dithiothreitol should be stored dessicated at 4°C. The
reagent should be weighed and added to the reaction mixture
at the time the latter is prepared. A stock solution of
dithiothreitol should not be used.
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4. It is better to leave behind a small amount of the organic
phase when it is aspirated and discarded, rather than to lose
any of the products present in the aqueous phase.
Sample cpm (counter per min) = Counted cpm minus cpm of reagent blank.
For dopamine, reagent blank ranged between 882 and 974 counts/min and
standard cpm was calculated to be 34334.
For noradrenaline reagent blank ranged between 155 and 216 counts/min
and the standard cpm was calculated to be 15398 counts/min.
Calculations
ng/g wet tissue weight
(dopamine or noradrenaline) dpm of standard tissue weight (mg)
25 x dpm of sample 1000
The estimated counting efficiency for tritium was 34% „
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RESULTS
In all experiments involving periods of long ECoG recording, it
has been noticed that the spike frequency of cortical foci vary
considerably between different animals. This is illustrated in Fig.14
which shows the spike frequency per 5 min of different rats in two
different groups of experiments during an initial control period of 20
min ECoG recording.
This animal variation precluded using the computed spike counts
per 5 min as such for quantitative comparison of the effect of various
drugs on ECoG recorded activity of different rats. This is because
what might have been a spike suppressing effect, induced by a drug in one
animal, would be a normal control epileptic activity in another.
Accordingly, it was important to eliminate this animal variation by
normalising the initial control period of 30 min for all rats. This
was done by expressing the average spike count per 5 min during that
period as a ratio of one for each rat, and then calculating the sub¬
sequent drug effect on each 5 min spike activity of either the primary
or secondary cortical foci as a fraction of one. This will clearly
show the effect of each drug on spike activity in each animal. Besides,
it will allow evaluation of the severity of spikes suppression by various
doses of anti-convulsants. The spike ratios, thus estimated every 5
min, were compared between drug-treated or saline (or vehicle)-treated
controls, using the non-parametric Mann-Whitney-U-test.
However, with experiments involving daily 10 min recordings from
cobalt implanted rats, comparison was done using the actual spike counts
per min and the Kruskal-Wallis non-parametric, one-way analysis of
118a.
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EFFECT OF DOPAMINE AGONISTS
1. Effect of apomorphine on epileptic activity
(See Figs. 15a, b, c, d). Apomorphine produced a significant
suppression in epileptic activity of both primary and secondary
cortical foci induced by cobalt (Mann-Whitney U-test) which was
evident within a few minutes of its intraperitoneal administration.
This effect lasted for 30, 40 and 55 minutes with doses of 0.5, 1
and 2 mg/kg respectively (See Fig. 15), and was found to be signif¬
icantly dose-dependent (Kruskal-Wallis non-parametric one-way
analysis of variance).
For primary focus H = 7.84 P = 0.01-0.02
For secondary focus H = 9.1, P = 0.01-0.02.
This spike suppressing effect was also associated with
suppression of motor epileptic manifestation(whiskers and forelimb
twitches) which paralleled the duration of drug action.
Apomorphine also induced behavioural changes of central
dopaminergic stimulation in the form of increased motor activity,
arousal, and stereotyped gnawing, sniffing, licking, and sometimes
biting which also corresponded to the duration of drug action.
The effect of apomorphine was followed by a period of reduced
motor activity and rebound increase in spike activity of variable
duration. However, this rebound reached significance level with
a dose of 2 mg/kg intraperitoneally ( P = 0.05) in comparison to
saline-treated animals, but generally the animals returned to
normal behaviour after 1.5-2 hrs of drug administration. The
saline-injected controls generally showed a tendency towards an
Legend to Fig. 15
EFFECT OF APOMORPHINE ON EPILEPTIC ACTIVITY IN COBALT-IMPLANTED RATS.
n = number of rats
Each bar represents the mean spike ratio per 5 min t
standard error (S.E.M.).
1. ECoG recording was done for a control period of 30 min. The
average computed spike count per 5 min during that period
from either the primary or secondary focus, was represented
as a ratio of 1.
2. Apomorphine was injected intraperitoneally at 30 min.
Fig. ISA : 0.5 mg/kg apomorphine was injected
B : 1 mg/kg apomorphine was injected
C : 2 mg/kg apomorphine was injected
D : Saline was injected into control rats
(Pooled effect).
3. ECoG recording was continued for 2 hrs after the injection.
During this period of each animal, each spike ratio per 5 min
represents the computed spike count per 5 min from either the
primary or secondary focus expressed as a fraction of its average
count per 5 min during the initial control period of 30 min.
4. Comparison of effect between drug-treated and saline-injected
animals was done with the Mann-Whitney-U-test.
* P <0.002
+ P = 0.002 - 0.02
± P = 0.02
-H- P = 0.02 - 0.05
P = 0.05
5. Kruskal-Wallis one-way anlysis of variance showed the effect
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increase in spike activity of cortical foci, but showed no change
in behaviour.
2. Effect of bromocryptine on epileptic activity
(See Figs. 16a, b and c). Bromocryptine induced a significant
(Mann-Whitney-U-test) reduction in epileptic activity which was
evident within 3 hrs of intraperitoneal administration of 10 mg/kg,
and within 1 hr of giving 20 mg/kg i.p. The effect of bromo¬
cryptine was marked 4 hrs after the injection (See Figs, above),
and was found to be dose-dependent (Kruskal-Wallis one-way analysis
of variance).
For primary focus H = 13.7, P < 0.001
For secondary focus H = 18, P < 0.001.
The effect of bromocryptine was accompanied by a reduction
in forelimb twitches and whiskers in the treated rats, as well as
increased locomotion, arousal, and stereotyped gnawing, sniffing
and licking.
The effect of bromocryptine on epileptic activity and behaviour
was still evident 6 hrs after its administration. However, 24 hrs
after the injection, the drug effect had disappeared.
The vehicle-injected controls showed no alteration in epileptic
activity or behaviour.
3. Effect of lisuride on epileptic activity
(See Figs. 17a, b, c, d and e). Lisuride hydrogen maleate
produced a significant reduction in epileptic activity of primary
Legend to Fig. 16
EFFECT OF BROMOCRYPTINE ON EPILEPTIC ACTIVITY IN COBALT-IMPLANTED RATS
n = number of animals
Each bar represents the mean spike ratio per 5 min t
standard error (S.E.M.).
1. ECoG recording was done for an initial period of 30 min. The
average computed spike count per 5 min during that period from
either the primary or secondary focus was represented as a
ratio of 1.
2. Bromocryptine was injected intraperitoneally at 30 min.
Fig. 16A : 10 mg/kg bromocryptine was injected
16B : 20 mg/kg bromocryptine was injected
16C : Equivalent volume vehicle was injected into
controls (pooled results).
3. ECoG recording was continued every second half hour for the
following o hrs after the injection. Recording was also done
for 30 min after 24 hrs.
During the post-injection period of each animal, each spike
ratio per 5 min represents the computed spike count per 5 rain
from either focus, expressed as a fraction of its average
count per 5 min during initial control period of 30 min.
4. Comparison between drug-treated and control animals was
done with the Mann-Whitney-U-test.
* P = 0.004
+ P = 0.008
* P = 0.016
+F P = 0.028
* P = 0.048
5. Kruskal-Wallis analysis of variance showed the effect of

































































































































































and secondary foci which was evident within 5 min of its admin¬
istration and lasted for 50, 75, 100 and 115 min with doses of
0.1, 0.25, 0.5 and 1 mg/kg, respectively (Mann-Whitney-U-Test).
Using Kruskal-Wallis one-way analysis of variance, this effect
was found to be dose-dependent.
For primary focus H = 18.7, P < 0.001
For secondary focus h = 20.5, P <0,001.
This effect was also associated with reduction in epileptic
forelimb and whiskers twitches, together with signs of dopamine
receptor stimulation in the form of increased locomotation, arousal
and stereotyped behaviour.
The saline-injected controls displayed an increase in spike
activity in both primary one and primary two. Their motor epileptic
manifestations were marked, but showed no other behaviour changes.
4. Effect of CF 25-597 on epileptic activity
(See Figs. 18a, b, c, d, e). CF 25-397 had no effect on
epileptic activity with a dose as high as 20 mg/kg, i.p. However,
with much higher dose of 40 mg/kg, i.p. this drug induced a
significant reduction in spike activity of cortical foci within 1
hr of its administration (Mann-Whitney-U-Test), as well as in the
motor epileptic manifestations. On behaviour, arousal was
increased, locomotion was mildly increased, but stereotyped
behaviour was not seen as with apomorphine, lisuride or bromo-
cryptine.
In general, the effect of CF 25 tended to be milder and of
Legend to Fig. 17
EFFECT OF LISURIDE HYDROGEN MALEATE ON EPILEPTIC ACTIVITY
IN COBALT-IMPLANTED RATS.
n = number of rats
Each bar represents the mean spike ratio per 5 min ±
standard error (S.E.M.).
1. ECoG recording was done- for a control period of 30 min.
The average computed spike count per 5 min during that period
from either the primary or secondary focus, was represented
as a ratio of 1.






0.1 mg/kg lisuride was injected
0.25 mg/kg lisuride was injected
0.5 mg/kg lisuride was injected
1 mg/kg lisuride was injected
Equal volume of saline was injected into
controls (pooled results).
3. ECoG recording was continued for 2 hrs after the injection.
During this period of each animal, each spike ratio per 5 min
represents the computed spike count per 5 min from either the
primary or secondary focus expressed as a fraction of average
count per 5 min during the initial control period of 30 min.
4. Comparison of effect between drug-treated and saline-injected
animals was done with the Mann-Whitney-U-test.
* P < 0.002
+■ P = 0.002 - 0.02
4= P = 0.02
M- P = 0.02 - 0.05
P = 0.05
5. Kruskal-lVallis one-way analysis of variance showed the effect
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Legend to Fig. 18
EFFECT OF CF 25-397 ON EPILEPTIC ACTIVITY.
n = number of animals
Each bar represents the mean spike ratio per 5 min - standard
error (S.E.M.).
1. ECoG recording was done for an initial period of 30 min. The
average computed spike count per 5 min during that period
from either the primary or secondary focus was represented
as a ratio of 1.
2. CF 25-397 was injected intraperitoneally at 30 min.
Fig. 18A : 20 mg/kg CF 25-397 was injected
B : 40 mg/kg CF 25-397 was injected
C : Equal volume of vehicle was injected
into controls (pooled results).
3. Recording was continued every second half hour for the
following 6 hrs after the injection.
During the post-injection period of each animal, each
spike ratio per 5 min was determined as described before.
4. Comparison between drug-treated and control rats was done
with the Mann-Whitney-U-test.
* P = 0.006
+ P = 0.012
P = 0.024





























































































































shorter duration than that of bromocryptine. Some animals seemed
to recover after 7 hrs. However, each animal was back to normal
by 24 hrs after its injection. The vehicle-treated rats showed
no significant alteration in epileptic activity or behaviour.
B. EFFECT OF DAILY ADMINISTRATION OF BROMOCRYPTINE (20 mg/kg i.p.) ON
THE DEVELOPMENT OF EPILEPTIC ACTIVITY IN COBALT-IMPLANTED RATS
(See Figs. 19a, b).
The chronic administration of bromocryptine did not prevent the
appearance of primary and secondary foci in cobalt-implanted rats.
The foci appeared at the same time in comparison to controls. The
early stages of development of primary and secondary foci were not
significantly different from controls. However, after 5-6 days
the spike activity of the cortical foci in the drug-treated rats
were significantly lower in comparison to controls, and persisted
to be significantly lower until the 12th day of observation (Kruskal-
Wallis one-way analysis of variance).
The secondary focus seemed to be more markedly suppressed than
the primary focus by chronic bromocryptine treatment.
C. EXPERIMENTS WITH THE DOPAMINE-RECEPTOR ANTAGONIST, PIMOZIDE
1. Effect of pimozide on epileptic activity
(See Figs. 20a, b). Pimozide, I mg/kg, i.p., induced a
significant increase in epileptic activity on both primary and
secondary foci which was evident for 10-15 min of its injection
(Mann-Whitney-U-Test), and lasted at least 2 hrs after the injection.
The vehicle-treated controls showed no significant changes in
epileptic activity or behaviour.
Legend to Fig. 19
EFFECT OF CHRONIC ADMINISTRATION OF BROMOCRYPTINE ON THE DEVELOPMENT
OF EPILEPTIC FOCI IN COBALT-IMPLANTED RATS0
n = number of animals
Each bar represents the mean spike count per min t standard
error (S.E.M.).
1. Bromocryptine (20 mg/kg) was injected daily, i.p,, into one
group of rats starting on the day of cobalt implantation.
Control rats received an equivalent volume of vehicle,
similarly.
2. Daily 10 min ECoG recording was done from both groups of
rats before the injection.
3. Comparison between drug-treated and control rats were done
using the Kruskal-lVallis analysis of variance.
* p == 0.01 - 0.01
+ p == 0.01 - 0.02
p == 0.02 - 0.05
Fig19A HjBromocryptine-treated
Primaryfocus 12345678 Daysibst-CobaltImpl n
Secondaryfo us
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2. Effect of pimozide on the spike suppressing effect of
apomorphine, lisuride, bromocryptine and CF 25.
(See Figs. 21a and b, Figs. 22a and b, Figs. 23a and b,
Figs 24a and b, respectively). Precreatment with pimozide
(1 mg/kg, i.p.) significantly prevented the effect of these dopamine
agonists on epileptic activity of both primary and secondary foci
(Mann-Whitney-U-Test), as well as the behavioural manifestation
induced by these drugs.
D. EXPERIMENT ON THE STRIATUM IN COBALT-INDUCED EPILEPSY
1. Effect of dopamine
The bilateral injection of dopamine (25 pg into each striatum)
in cobalt-induced epileptic rats produced a significant reduction
in spike activity of both primary and secondary foci (Mann-Whitney-
U-Test) which was evident within 5 min of injection and lasted
for 55 min (Figs. 25a and b). This effect was associated with
suppression of whiskers and forelimb twitches, as well as the
appearance of signs of dopaminergic stimulation of the striatum
such as increased arousal, locomotion and stereotyped behaviour.
Furthermore, the unilateral injection of dopamine (25 pg) into
the right striatum (Figs. 26a and b) reduced significantly the
epileptic activity of both primary and secondary foci (Mann-Whitney-
U-Test), and affected as well a reduction in the motor epileptic
manifestations. This effect was associated with increased
locomotion and turning of the animal towards the left side, i.e.
contralateral to the side of injection. This effect lasted for
about 40 min before disappearing.
Legend to Fig. 20
EFFECT OF PIMOZIDE ON EPILEPTIC ACTIVITY.
n = number of animals.
Each bar represents the mean spike ratio per 5 min i
standard error (S.E.M.).
1. ECoG recording was done for a control period of 30 min. The
average computed spike count per 5 min during that period
in either the primary or secondary focus was expressed as
a ratio of 1.
2. Pimozide (1 mg/kg) was injected intraperitoneally at 30 min.
Control rats received an equivalent volume of vehicle.
3. Recording was continued for 2 hrs after the injection.
During the post-injection period of each animal, the spike
ratio/5 min was determined as a ratio of the computed spike
count per 5 min from either focus to its average count per
5 min during the initial control period of 30 min.
4. Comparison between drug-treated and vehicle-treated animals
was done using the Mann-Whiteney-U-test.
































































































Legend to Fig. 21
EFFECT OF PIMOZIDE ON APOMORPHINE-INDUCED SUPPRESSION OF
EPILEPTIC ACTIVITY„
n = number of rats.
Each bar represents the mean spike ratio per 5 min
t standard error (S.E.M.).
1. ECoG recording was done for a control period of 30 min.
The mean spike count per 5 min during that period from
either the primary or secondary focus was expressed as
a ratio of 1.
2. Pimozide (1 mg/kg, i.p.) was injected at 30 min (Fig. 21A).
Control rats received an equivalent volume of saline (Fig. 21B).
ECoG recording was continued for 45 min after pimozide.
3. Both groups of animals then received apomorphine (1 mg/kg, i.p.)
and recording was continued for 2 hrs after the injection.
During the post-injection period of each animal each spike
ratio per 5 min was determined as described before.
4. Comparison between pimozide-treated and vehicle-treated
animals were done with the Mann-Whitney-U-test.
* P = 0.014
+ P = 0.029
















































































Legend to Fig. 22
EFFECT OF PIMOZIDE ON BROMOCRYPTINE-INDUCED SUPPRESSION OF
EPILEPTIC ACTIVITY.
n = number of animals.
Each bar represents the mean spike ratio per 5 min
_ standard error (S.E.M.).
1. ECoG recording was done for an initial control period of
30 min. The average spike count per 5 min of either the
primary or secondary focus during that period was expressed
as a ratio of 1.
2. Pimozide (1 mg/kg) was injected at 30 min, i'.p. (Fig. 22A).
Control rats received an equivalent volume of vehicle.(Fig. 22B).
Recording was continued for 20 min.
3. Both groups of animals then received bromocryptine (20 mg/kg),
i.p. and recording was continued every second half hour for
the following 6 hrs.
During the post-injection period of each animal, each spike
ratio/5 min was determined as described before.
4. Comparison of effect between pimozide-treated and vehicle-






































































































Legend to Fig,, 23
EFFECT OF PIMOZIDE ON LISURIDE-INDUCED SUPPRESSION OF
EPILEPTIC ACTIVITY.
n = number of animals.
Each bar represents the mean spike ratio per 5 min ±
standard error (S.E.M.).
1. ECoG recording was done for a control period of 30 min.
The mean spike count for 5 min from either the primary
or secondary focus during that period was expressed as
a ratio of 1.
2. Pimozide (1 mg/kg) was injected, i.p., at 30 min (Fig. 23A).
Control rats received an equivalent volume of vehicle
(Fig. 23B).
3. ECoG recording was continued for 45 min after injection
of pimozide. Both groups of animals then received lisuride
(0.1 mg/kg) i.p., and recording was continued for 2 hrs
after the injection.
During the post-injection period of each animal, each spike
ratio per 5 min was determined as described before.
4. Comparison of effect between drug-treated and saline-treated
rats was done with the Mann-Whitney-U-test.






















































































Legend to Fig. 24
EFFECT OF PIMOZIDE ON CF 25-397-INDUCED SUPPRESSION OF
EPILEPTIC ACTIVITY,
n = number of animals.
Each bar represents the mean spike ratio per 5 min 1
standard error (S.E.M,),
1. ECoG recording was done for an initial control period of
30 min. The mean spike count per 5 min from either the
primary or secondary focus during that period was expressed
as a ratio of 1.
2. Pimozide (1 mg/kg) was injected i.p., at 30 min (Fig. 24A).
Control rats received an equivalent volume of vehicle,
i.p., (Fig. 24B).
3. ECoG recording was continued for 20 min more. Then both
groups of animals received CF 25-397 (40 mg/kg) i.p.,
and recording was continued every second half hour for
the following 6 hrs.
During the post-injection period of each animal, the
spike ratio per 5 min was calculated as described before.
4. Comparison of effect between pimozide-treated and controls
was done using the Mann-Whitney-U-test














































































































2. Effect of apomorphine
(Figs. 27a and b). The injection of 60 yg apomorphine into
each striatum significantly and dramatically suppressed the spike
activity of both primary and secondary foci, as well as effecting a
reduction in motor epileptic manifestation. These effects were
more intense than those induced by dopamine and lasted for about
50 min. Behavioural signs of increased locomotion, arousal, and
stereotyped gnawing behaviour accompanied these effects.
3. Effect of destruction of catecholamine terminals in the
striatum on both sides on the development of epileptic activity.
The motor manifestation of bilateral 6-OHDA lesions of both
striata included hypokinesia and difficulty in eating and drinking.
However, rats were maintained throughout the experiment with supp¬
lementary feeding. Other workers also observed these changes with
6-OHDA (Ungerstedt, 1971). The normal reported levels of dopamine
and noradrenaline levels in the striatum are 9200 ng/g tissue weight
(± 700 SEM) and 266 ng/g tissue weight (i 13 SEM), respectively,
(Tassin et al, 1975). The concentrations of catecholamines in
the striatum of saline-injected rats did not differ significantly
from the control values reported above.
The bilateral intrastriatal injection of 6-OHDA (20 yg)
reduced significantly the concentration of dopamine to 10% and 15%
in right and left striata, respectively, in comparison to controls
(Table 15). Furthermore, the concentration of noradrenaline was
significantly reduced in the right and left striata to 26% and 30%
respectively, in comparison to controls (Table 16).
Legend to Fig, 25
EFFECT OF BILATERAL INJECTION OF DOPAMINE INTO EACH STRIATUM
ON EPILEPTIC ACTIVITY.
n = number of rats.
Each bar represents the mean spike ratio per 5 min t
standard error (S.E.M.).
1. ECoG recording was done for an initial control period of
30 min.
2. Dopamine (25 pg in 2 pi normal saline) was injected into
each striatum. Recording was continued for one hour after
the injection.
Control animals received 2 pi saline into each striatum.
3. Comparison of effect between the dopamine-treated and saline
controls was done with the Mann-Whitney-U-test.
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Legend to Fig. 26
EFFECT OF UNILATERAL INJECTION OF DOPAMINE INTO THE RIGHT
STRIATUM ON EPILEPTIC ACTIVITY.
n = number of animals.
Each bar represents the mean spike ratio per 5 min *
S.E.M. (standard error).
1. ECoG recording was done for an initial control period of
30 min„
2. Dopamine (25 yg in 2 yl normal saline) was injected
into the right striatum. Controls received 2 yl saline
into the right striatum. Recording was continued for
one hour after injection.
3. Comparison of effect between the dopamine-treated and
saline controls was done with the Mann-Whitney-U-test.
* P = 0.05.
Fig 26 A
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Legend to Fig. 27
EFFECT OF BILATERAL INJECTION OF APOMORPHINE INTO EACH
STRIATUM ON EPILEPTIC ACTIVITY.
n = number of rats
Each bar represents the mean spike ratio per 5 min
t standard error (S.E.M.).
1. ECoG recording was done for an initial control period
of 20 min.
2. Apomorphine HC1 (60 yg in 2 yl/normal saline), was injected
into each striatum.
Control rats received 2 yl normal saline into each striatum.
ECoG recording continued for one hour after the injection.
3. Comparison of effect between drug-treated and control rats
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The 6-OHDA lesion in striatum on both sides significantly
potentiated the spike frequency of both primary and secondary foci
induced by cobalt implantation in comparison to controls (Kruskal-Wallis
one-way analysis of variance, Figs. 28a and b). This increase in
spike activity was evident within 24 - 48 hrs of cobalt implantation and
persisted throughout the period of observation and was associated with
more frequent forelimb and whisker twitches.
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TABLE 15
EFFECT OF BILATERAL 6-HYDROXYDOPAMINE INJECTION (20 yg IN 2 yl SALINE)
ON THE DOPAMINE CONTENT IN EACH STRIATUM OF COBALT-IMPLANTED RATS
- concentrations are expressed as ng/g wet tissue weight
Rat
No.









R1 8679 8762 355 1473
R2 10421 8278 108 132
R3 10913 11679 1501 4180
R4 8360 7997 1033 830
R5 10205 10382 1767 1656
R6 10890 - - 405
Mean 9911 9420 953 * 1446 *
+ S.E. 416 625 285 445
ie
P <0.001 when compared with the pooled concentration in controls (Student's-t-
test, two-tailed, with Bessel's correction)
(-) = sample lost during the assay
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TABLE 16
EFFECT OF BILATERAL 6-HYDROXYDOPAMINE INJECTION (20 yg IN 2 yl SALINE) ON
THE NORADRENALINE CONTENT OF EACH STRIATUM IN COBALT-IMPLANTED RATS
- concentrations are expressed as ng/g wet tissue weight
Rat
No.






































Mean 301 329 77 * 97 *
+ S.E. 38.7 45.8 19.3 28
P <0.001 when compared with the pooled concentration in controls (Student's-t-
test, two-tailed, with Bessel's correction)
(-) = sample lost during the assay
Legend to Figs. 28A and B.
EFFECT OF BILATERAL 6-OHDA LESION OF STRIATUM ON THE DEVELOPMENT
OF EPILEPTIC FOCI IN COBALT-IMPLANTED RATS.
n = number of animals.
Each bar represents the mean spike count per min t standard
error (S.E„M.).
1. 6-OHDA (20 yg in 2 yl saline) was injected into each striatum
at the time of cobalt implantation in one group of rats.
Control rats received 2 yl saline into each striatum.
2. Daily 10 min ECoG recording was done for the first 8 days,
and then on alternate days until the 14th day.
3. Comparison of effect between drug-treated and saline-treated
rats was done with Kruskal-Wallis analysis of variance.
* P= 0.00.1- OoOl
+ P= 0.01 - 0.02
4F P= 0.02 - 0.05.
Fig28A
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Effect of dopamine agonists and antagonists.
In the present work, the time factor in the development of epileptic
activity matched the previous data in the cobalt model (Emson § Joseph,
1975, Dow et al, 1972), and added more support to the uniformity of the
of the epileptogenic time in cobalt-implanted rats.
All the dopamine agonists used in the present experiments,
suppressed the epileptic activity of both the primary and secondary cortical
foci,an effect reduced by pimozide. Apomorphine is well known to stim¬
ulate the dopamine receptors (Ernst, 1967., Anden, Fuxe and others, 1967).
Apomorphine is a quick-acting dopamine agonist. Its anti-epileptic
activity which lasted about 40 - 50 min with doses used, tended to be
followed by exacerbation of epileptic activity that reached significance
level with a dose of 2 mg/kg (P = 0.05). Lisuride is also a rapidly
acting dopamine agonist (Horowski, 1975., Kehr et al, 1977). However,
its effect on epileptic activity lasted longer than that of apomorphine,
probably due to the more rapid metabolism of the latter.
Bromocryptine is known to stimulate the dopamine receptors directly
(Corrodi et al, 1973)., Johnson et al, 1976). It differs from apomorphine
by the delayed onset of its effects, and that its actions are blocked
by presynaptic depletion of catecholamines whether induced by reserpine
or alpha-methyl tyrosine, which makes bromocryptine behave like a partial
dopamine agonist (Corrodi et al, 1973, Johnson et al, 1976). Moreover,
bromocryptine inhibits dopamine re-uptake (Silbergeld § Pfeiffer, 1977).
It is known that low doses of bromocryptine (less than 1 mg/kg) inhibited
motor function and this effect was attributed to stimulation of dopamine
auto-receptors (Snider et al, 1976). Similar effect was described
with low doses of apomorphine (less than 0.5 mg/kg) (Strombom, 1976).
In contrast to apomorphine, the suppressant effect of 10 and 20 mg/kg
bromocryptine on epileptic activity occurred within 3 and 1 hrs,
respectively, after intraperitoneal injection. The fact that the
latent period was reduced with the larger dose fits with the previous
reports (Snider et al, 1976). In contrast to apomorphine, the anti-
epileptic effect of bromocryptine lasted more than 6 hrs and the
animal had recovered from its effect after 24 hrs.
The lag phase before the onset of action of bromocryptine might
represent the time necessary for the formation of an active metabolite.
It might be that intact presynaptic events are involved in the formation
of such a pharmacologically active moeity. The similarity between
the structure of the bromocryptine molecule and that of L-tyrosine makes
it possible for bromocryptine or one of its peripheral metabolites
to be acted upon by tyrosine hydroxylase to produce an active substance.
Furthermore, presynaptic uptake of bromocryptine might occur by
utilization of tyrosine uptake mechanisms. In this respect, the intra-
neuronal accumulation of the related ergot alkaloid dihydro-ergotoxin
was demonstrated (Meier-Ruge § Iwagnoff, 1976). Moreover, the hypo¬
thermia resulting from bromocryptine in rats, itself a phenomenon thought
to be mediated by dopamine receptor stimulation, was decreased by pre-
treatment with SKF 525A, a potent inhibitor of hepatic microsomal
enzymes. This suggests that bromocryptine depends, at least in part,
on hepatic metabolism for its conversion into active compounds that
possess hypothermic and dopaminergic activity. However, there is no
128.
evidence yet of such active metabolite of bromocryptine.and its
isolation from the urine of rat or man might be of therapeutic value in
treatment of Parkinsonism, endocrine disorders, such as acremegally and
galactorrhea and possibly focal epilepsy. Bromocryptine, however, does
cross the blood-brain barrier and it is known to interact with the acute
effects of apomorphine and amphetamine (Dray 8 Oakley, 1976). Further¬
more, it has been shown to have a direct effect in inhibiting prolactin-
secreting cells of the hypophysis (Pasteels et al, 1971).
The chronic daily administration of bromocryptine attenuated the
rate of development of epileptic activity, particularly in the secondary
foci. This effect suggests that persistent stimulation of dopaminergic
mechanisms might be a useful adjunct in the management and prophylaxis
of focal epilepsy.
CF 25-397 is a dopamine agonist which is thought to be more
selective in stimulating the nigro-striatal system by the fact that it
does not induce stereotyped behaviour, even in large doses (Jaton et al,
1976).
In the present work, this drug was found less effective than
bromocryptine in suppressing epileptic activity. At a dose of 40 mg/kg
given i.p., CF 25 reduced the spike frequency of both primary and
t
secondary foci, while at 20 mg/kg it had no significant effect. Even
at the effective dose, CF 25 did not induce stereotypy thus confirming
its reported selectivity as dopamine agonist. However, the latent
period of its action was shorter than that seen with bromocryptine.
Moreover, its anti-epileptic effect seemed to wear off earlier than
bromocryptine. The formation of active metabolites was also suggested,
in part, as a possible mechanism for its action. However, it has been
shown that inhibition of microsomal hepatic enzymes by SKF 525 reduced,
but did not block, the hypothermia induced by CF 25 in rats (Silbergeld
£ Pfeiffer, 1977).
Pretreatment with the selective dopamine receptor blocker, pimozide,
potentiated the epileptic activity of cortical foci in cobalt-implanted
rats. Moreover, it blocked the anti-epileptic activity induced by all
the dopamine agonists mentioned above.
Thus, it seems that dopamine receptor stimulation inhibited
epileptic activity while blockade of those receptors had the opposite
effect. The finding that the anti-epileptic effects of the different
dopamine agonists was dose-dependent adds more support to this point.
These results also confirm the work of Ashcroft et al (1974), who showed
that dopamine agonists suppressed cortical epileptic activity while
dopamine antagonists potentiated it in cobalt-implanted rats, and con¬
versely adrenergic stimulants increased while adrenergic blockers
inhibited epileptic activity in the same model. Therefore, there seemed
to be a sort of balance in catecholamine neuro-transmitters, with dopamine
tending to inhibit and noradrenaline to increase the excitability of
cortical neurosis.
There is evidence that focal motor epilepsy, the two types of
reflex epilepsies (including audiogenic seizure in mice and photogenic
seizure in the baboon), and the later stages of electro-convulsive shock
are all alike in that propioceptive afferents, mediating impulses arising
from motor activity, play an important role in the evolution of the
seizure response (Chauvel et al, 1975., Naquet et al, 1975., Reguin §
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Pillerd, 1966). Thus, dopamine, apomorphine and other dopamine
agonists may act directly or indirectly on this recurrent system in
inducing their anti-convulsive effects. In the present work and
that of Ashcroft et al (1974), the anti-convulsive effect of dopamine
agonist and antagonists is well demonstrated in the cobalt model of
focal epilepsy. In the reflex epilepsies, it has been shown that
audiogenic seizures are enhanced by pretreatment with reserpine and
this enhancement can be reversed by giving L-DOPA (Boggan § Seiden,
1971). Furthermore, apomorphine and ergocornine prevent or delay
audioshock in the audio-sensitive strain (DBA/2) of mice (Anlezark §
Meldrum, 1972). L-DOPA, apomorphine, and piribedil inhibited completly
the myoclonic response to intermittent photic stimulation in the photo¬
sensitive baboon while haloperidol potentiated it (Meldrum et al, 1972,
1975a). Thus, it seems that epileptic discharges from cortical foci
induce motor epileptic phenomenon and the resulting motor activity
perpetuate, at least in part, these cortical discharges via pro¬
prioceptive afferents. This mechanism tends to involve dopaminergic
control at one stage, hence the suppressant effect of dopamine agonists
and the potentiating effect of antagonists in these forms of sensory
epilepsy.
However, drugs which act as dopamine agonists don't always show
anti-epileptic activity and some species and model variations do exist.
Thus, apomorphine protects against electroshock in rats, but not in
mice (McKenzie § Soroko, 1972), and it may potentiate chemically-
induced seizures by allylglycine in the baboon (Meldrum et al, 1975b),
or pentylenetetrazol - induced seizure in rodents (Soroko § McKenzie,
1970). Bromocryptine, however, seemed to be an effective anti-
convulsant in acute and chronic experiments in cobalt-implanted rats
in the present work; besides, no species or model variation are
reported for this drug yet in experimental epilepsy. Thus the present
findings might justify a limited clinical trial for bromocryptine in
focal epilepsy.
The possibility still exists that changes in the epileptic phenomena
observed in the present work in cobalt-implanted rats as well as those
reported in other forms of 'sensory epilepsy' might be due to drug
interaction other than those on the dopamine system. Apomorphine and
haloperidol inhibit the uptake of gamma-aminobutyric acid by brain
slices (Harris et al, 1973). Bromocryptine and apomorphine also
stimulate 5-HT receptors. The action of dopamine drugs on noradren¬
ergic system cannot be excluded. Nevertheless, the effect of dopamine
agonists and antagonists can most readily be explained in terms of
activation and inhibition of the dopamine receptors respectively, leading
to cortical desynchronization and hypersynchronization, respectively.
Dopamine agonist and antagonists and dopamine receptor binding
Considerable evidence support the view that the turnover of brain
dopamine is regulated in part by postsynaptic dopamine receptors. Thus,
dopamine receptor antagonists have been found to stimulate, and agonists
to inhibit dopamine turnover (Carlsson § Lindquist, 1963., Anden et al,
1967., Nyback 5 Sedval, 1970). Dopamine is known to be a highly
specific stimulant of adenyl cyclase activity in the striatum as well
as other central areas (Kebabian § Greengard, 1971, Horn et al, 1974).
Consequently, adenyl cyclase activation has been considered to be
representative of dopamine receptor response (Kebabian et al, 1972).
[^H] dopamine and [^H]haloperidol bind with high affinity and
selectivity to the post-synaptic dopamine receptors in membrane
preparations of the calf caudate nucleus (Creese et al, 1975). The
binding of these ligands to the dopamine receptor differs from the data
obtained with dopamine-sensitive adenyl cyclase (Kebabian et al, 1972,
Iversen et al, 1975). Butyrophenones represent the clinically most
effective class of neuroleptics as reflected in their high affinity for
pH] haloperidol binding sites. However, they are weak inhibitors of
adenyl cyclase (Burt et al, 1975). These discrepancies indicate that
the recognition site of the dopamine receptor is not identical with
dopamine-sensitive adenyl cyclase.
The binding of both ligands shows marked regional variation with
greatest density in the caudate, putamen, globus pallidus, nucleus,
accumbens and olfactory tubercle, areas that are rich in dopaminergic
terminals (Creese et al, 1975). It has been shown that 6-OHDA lesions
of the nigro-striatal pathway does not alter the binding of these ligands
to the dopamine receptor, thus pointing to a post-synaptic location of
these binding sites. However, more recently, Schwartz et al, (1978)
demonstrated that at least 35% of pH]haloperidol binding in the striatum
is due to binding to presynaptic terminals from fibers originating from
the cerebral cortex, and it was suggested that this binding might
mediate at least in part, the action of anti-psychotic drugs. However,
[%] dopamine binding has not been reported for any presynaptic site
yet. The binding of dopamine agonists and antagonists to these ligands
indicates their selectivity in associating with the dopamine receptor
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TABLE 17A
SELECTIVITY OF BINDING OF DOPAMINE AGONISTS AND ANTAGONISTS
TO THE DOPAMINE RECEPTORS IN CALF BRAIN MEMBRANES
- (From Burt, Creese and Snyder, 1976)
Inhibition of [3h] haloperidol and [^H] dopamine by drugs
Drug Ki









The rate constant of association (Ki) of each drug to
either ligand was calculated by the formula
Ki = IC50
l+C/KD
IC50 = The concentration of drug required to inhibit
specific binding by 50%.
C = The concentration of radioactive ligand (1 to
2 nM for [^H] haloperidol and 5 nM for [^H]
dopamine).
Kp+ = Dissociation constant of the labelled ligand
(2 nM for [^H] haloperidol and 20 nM for
[3h] dopamine)
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(See Table 17A). Drugs lacking dopaminergic properties display
negligible binding. The relative potency of various agonists and
antagonists on the binding of the two ligands parallels their
pharmacological actions at dopamine receptor sites (Burt et al, 1976).
Dopamine agonists have 6-38 times more affinity for [%] dopamine than
[%] haloperidol binding sites. By contrast, dopamine antagonists
have 20-12,000 times more affinity for [JH] haloperidol than [%]dopamine
binding sites. Ergot derivatives have a substantial affinity for
both types of binding (Burt et al, 1976). This difference in substrate
specificity suggests that dopamine and haloperidol label different
portions or states of the dopamine receptor (Creese et al, 1975). There
might be distinct dopamine receptor sites, binding agonists and antag¬
onists, respectively. Alternatively, one dopamine receptor might
inter-convert between conformations which have high affinities for either
agonists or antagonists and this might explain the pharmacological
properties of dopamine agonists and antagonists in terms of their
affinity for the two-state model of the receptor (Snyder, 1975).
According to this model, pure agonists have greater affinity for [^H]
dopamine than [%] haloperidol binding sites while the reverse is true
for antagonists. Mixed agonists-antagonists should have similar
affinities for both binding sites. Table 17B shows the potency of
different agonists and antagonists used in the present work in inhibiting
[3h] dopamine and [^H] haloperidol binding.
Thus, in reducing [%] dopamine binding, apomorphine is the most
potent. It has been shown that the number of apomorphine binding sites
(Seeman et al, 1976), is three times as high as dopamine binding sites.
In the present experiments, apomorphine was found to induce a more
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TABLE 17B
POTENCY OF SOME DOPAMINE AGONISTS AND ANTAGONISTS IN THEIR
BINDING TO THE DOPAMINE RECEPTOR
- (After Creese, Burt and Synder, 1975)
Drug IC50







(-)-Butaclamol 1.300 > 10.000
IC50 values are the concentrations (nM) of each drug
required to inhibit the specific binding of either
5 nM [3h] dopamine or 2 nM of [3h] haloperidol by 50%.
intense inhibition of epileptic activity than dopamine when injected
into the striatum of cobalt-implanted rats.
Bromocryptine is of lower potency than apomorphine in reducing
[^H] dopamine binding. Apomorphine also reduces |^H] haloperidol
binding, butis.only4% as active in this respect than for dopamine
binding. However, bromocryptine is more potent than apomorphine in
reducing [•%] haloperidol binding. These data indicate that both
apomorphine and bromocryptine behave as mixed agonist-antagonist at
dopamine receptor in brain membrane [Burt et al, 1976). Moreover,
apomorphine (Iversen et al, 1975) and bromocryptine (Pagnini et al,
1978), behave as agonist-antagonists on adenyl cyclase. No data are
available for lisuride and CF 25-397 binding to dopamine receptor.
However, like other ergot preparations, they might have mixed agonist-
antagonist properties. In the present work, apomorphine was much
more potent than bromocryptine in suppressing epileptic activity of
cortical foci. The suppression of epileptic activity produced by
2 mg/kg (5.6 pmol/kg) apomorphine was approximately equivalent to that
caused by 20 mg/kg bromocryptine (26.6 ymol/kg).
Lisuride, however, seemed more potent than apomorphine in its
anti-epileptic effect. At a dose of 0.5 mg/kg, lisuride dramatically
suppressed epileptic activity while apomorphine induced only a mild
inhibition at this dose. Lisuride, at a dose of 1 mg/kg suppressed all
epileptic activity, while apomorphine at a dose of 2 mg/kg severely
reduced it and larger doses were used by Ashcroft et al (1974) to obtain
a complete suppression of epileptic activity in cortical foci.
It has been shown that systemically administered apomorphine
accumulates well in dopamine receptor-rich areas, but poorly in the
cerebellum. This may indicate that most of regional apomorphine
accumulation is due to dopamine receptor binding (Melzacka et al, 1978).
This may also apply to other dopamine agonists such as bromocryptine or
their active metabolites.
It has been shown that apomorphine-induced gnawing depends on
striatal concentration of apomorphine (Melzacka et al, 1978). It is
possible that apomorphine elimination, and possibly that of other
dopamine agonists, follows that for a two-compartment open model. The
compartment in which apomorphine has a long half-life probably represents
the drug bound to dopamine receptor, while the compartment from which the
drug is rapidly eliminated represents apomorphine that is not bound or
non-specifically bound. This may explain the differences in the durat¬
ion of action between the short acting apomorphine or lisuride and the
longer acting bromocryptine and CF 25. It has been shown that halo-
peridol prevents the accumulation of apomorphine in the striatum. This
contributes for the antagonistic action of haloperidol to apomorphine
but at least in part, it may he a result of the competition between
the two drugs for the binding sites of the dopamine receptor (Vetulani
et al, 1978). Similar mechanisms could contribute to the antagonistic
action of pimozide to apomorphine and other dopamine agonists.
Behavioural arousal, ARAS, and anti-epileptic activity of dopamine
agonists„
It is noticed during all experiments that increased arousal of the
animal is associated with reduced spike activity, i.e. cortical de-
synchronization while sedation is associated with cortical hypersynchrony.
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The state of alertness or arousal may be regarded as the resultant
state of a number of sub-systems in dynamic equilibrium. These
sub-systems could be specified biochemically, anatomically, or
functionally, which may overlap,and could be manipulated pharmacolog¬
ically, surgically or by alteration of physiological input to the brain,
respectively.
Selfridge (1948), found that in a conducting network, such as that
existing in the brain or the heart, certain types of stimuli could
initiate rhythms of electrical activity synchronizing the firing of
large groups of units. These rhythms could be damped down by the
introduction of new inputs, provided these were not in phase with the
standing rhythms, and strengthened by a reduction of input or by
further in-phase input. The procedures tending to strengthen standing
rhythm could be exemplified by the effects of eye closure on cortical
EEG, namely the appearance of alpha-rhythm in occipital areas and the
11-12 Hz u-rhythm of the motor cortical areas involved. However, if
cortical input is increased by opening the eyes or by arithmetical
mental handling, then these rhythms are disturbed, and the EEG returns
to the more varied waking form.
The ascending reticular activating system (ARAS) exerts a de-
synchronizing tone on the cortex, thus mediating arousal. Stimulation
of the ARAS in cats has been reported to cause increased vigilance with
an increased sensitivity to all sorts of stimuli (Sheard § Flynn, 1965),
while lesions of this system result in a state of hypersomnia and
cortical hyper-synchrony (Lindsley, I960). Koella 8 Czioman (1966),
have demonstrated that raphe activation causes inhibition of ARAS.
The action of the raphe and ARAS on the cortex appear to be diametrically
opposed, and the state of cortical arousal at any one time will be a
reflection of, amongst other things, of the balance between both systems.
The cortical hypersynchrony developed in the four stages of the non-REM
sleep and which are used to characterize each stage, are partly generated
by reduction in the activity of ARAS, the direct synchronizing tone of
the raphe itself, reduction of cortical input as well as abolition of
visual input to the cortex. In the waking state, ARAS in desynchronis-
ing the cortex, increases the data-handling capacity. Thus, a novel
stimulus arising to the cortex is first recognised as novel and then
the cortex sends information to the ARAS which responds by amplifying
this signal and relaying it back to all areas of the cortex resulting
in general arousal which can be caused by non-intense stimuli.
Studies employing anterograde degeneration (Nauta $ Kuypers,1958,
Lynch et al, 1973) and retrograde transport techniques (Robertson
8 Travers, 1975) indicate that the reticular formation sends a small
number of diffusely arranged fibers through the diencephalon towards
the striatum. The cells of origin of these fibers are mainly located
at the caudal mesencephalic and pontine levels. This projection is
suggested to be part of the diffuse ARAS. More recently, it has been
shown that the striatum via the substantia nigra, sends descending fibers
to the reticular formation and superior colliculus (See Fig. 29), from
the latter fiber connection exist to the reticular formation to constitute
the tectoreticular fibers, as well as to the spinal cord, constituting
the tectospinal tract. It is by these descending connections, as well
as by ascending fiber connection to the cerebral cortex, that the
striatum exerts its effect in producing or potentiating arousal, as well
as exerting motor regulatory influence. It is well know that a
major site of action of dopamine agonists is on the dopamine
receptors in striatum and mesolimbic system. Thus, it is likely
that stimulation of the striatal neurons by these drugs might, at
least in part, increase the activity of ARAS Via the fiber connect¬
ions, described above, and augment arousal, thus desynchronizing
the cortex. Moreover, the increased motor activity resulting from
striatal stimulation also increased the data handling with consequent
tendency to desynchronization.
Possible interactions between dopamine and acetylcholine.
It is well known that acetycholine is the main transmitter in
ARAS. Several diffuse cholinergic pathways are the source of
acetycholine from the cerebral cortex (Pepeu, 1973). In particular,
there is one system of fibers that can be stimulated through the
mesencephalic reticular formation, another originates from or passes
through the septum, and there is also an intracortical system. It
has been shown that dopamine agonists stimulate cholinergic neurons,
and thus increased acetylcholine output from the cerebral cortex,
while dopamine antagonists had the opposite effect (Pepeu § Bartolini,
1968, Mantovani et al, 1977). Pepeu § Bartolini (1968), investigating
acetycholine output from the cerebral cortex of the cat, demonstrated
that EEG desynchronization induced by L-DOPA was associated with an
increase in acetycholine output quantitatively similar to that occurring
after amphetamine or stimulation of the reticular formation.
This is in contrast to the situation in the striatum where
dopamine agonists inhibited while antagonists of dopamine stimulated
cholinergic neurons (Stadler et al, 1973). Disturbance of acetyl¬
choline-dopamine balance in the striatum is known to induce various
clinical extrapyramidal syndromes such as Parkinsonism, chorea. Thus,
one might be tempted to believe that such a balance does not occur in
the cerebral cortex, since activation of both systems tends to be in
the same direction, that is, cortical desynchronization. It has been
shown that the putative catecholamine releasers, amphetamine and aman¬
tadine, as well as the amine precursor L-DOPA, not only stimulated
locomotor activity and desynchronized ECoG, but also increased the
acetylcholine output from the cerebral cortex of rabbits, cats, guinea
pigs and rats (Beani et al, 1968., Beani 8 Beanchi, 1973., Mantovani et al,
1977., Pepeu 8 Bartolini, 1968).
It is well known that the ascending reticular pathways from the
brainstem contain acetycholine and are cholinergic (see Shute 5 Lewis,
1967) . It has been shown that administration of the anti-cholinergic
drug,hyoseine, had no effect on spike frequency of epileptic foci and
did not modify the motor epileptic manifestations in cobalt-implanted
rats (McQueen, J. - personal communication). Hyoscine blocks cholin¬
ergic transmission in autonomic and central nervous systems. However, it
will not eliminate the effect of motor movement on cortical activity, Thus
it seems that cholinergic stimulation such as that induced by activation of
ARAS is not the only factor in desynchronizing the epileptic ECoG in the
cobalt model. The lack of effect of hyoscine is in contrast to the
potentiating action of pimozide on epileptic activity, seen in the present
work. An enhancement of the frequency of spiking from epileptic foci
is not uncommonly seen during spontaneous bouts of drowsiness or drug-
induced. sedation (Meldrum 5 Belzamo, 1972). However,
the changes after pimozide were more intense and persistent than
those interposed by spontaneous bouts of vigilance in the normal or
control rats.
Furthermore, there is no definite evidence as to the amine
responsible for stimulation of behaviour and ECoG desynchronization
associated generally with cholinergic activation (Phillis, 1968,
Jasper & Tessier, 1971). Some workers have stressed the role of
noradrenaline (Randrup £ Munkvad, 1968., Bliss § Ailion, 1971., Reiss
et al, 1970). In contrast, others have claimed the involvement of
dopamine (Van Rossum, 1964., Everett, 1970, Costa et al, 1972, Schlechter
§ Butcher, 1972). In agreement with the latter hypothesis, it has
been shown that drugs which increased dopamine to noradrenaline ratio
in brain concomittantly increased acetylcholine output, while the
opposite changes in this ratio reduced it (Beani 8 Bianchi, 1970).
Thus, it seems that dopaminergic activity is an important factor in
controlling the excitability of cortical neurons. The alteration in
epileptic activity of cortical foci induced by dopamine agonists and
antagonists seen in the present work confirm this point.
Which dopamine system?
It is clear from the present work that dopamine receptor stimulants
inhibited epileptic activity and desynchronized the cortical neurons.
This effect was dose-dependent with different drugs used. This would
suggest that different degrees of stimulation of a dopaminergic mechanism
at a particular site is essential in inhibition of cortical hyper-excit¬
ability. Possible sites of action remain to be elucidated whether it
is the dopamine receptors in the cortex or other parts of the dopamine
system.
Substantial biochemical evidence were provided for the existence
of dopaminergic nerve terminals in the cerebral cortex of the rat and
cat (Thierryet al, 1972, 1973). These findings were supported by
fluorescence,histochemical, and pharmacological observations (Hokfelt et
al, 1974., Lidbrink et al, 1974). The increased sensitivity of the
glyoxylic acid method of fluorescence histochemistry allowed visual¬
ization of characteristic network of dopamine containing nerve terminals
ramifying in areas outside the extra pyramidal system including the
frontal and anterior limbic cortices of the rat brain (Lindvall 5
Bjorklund, 1974). Such terminals are found in dorsomedial frontal
cortex, anterior cingulate cortex, the ventral part of entorhinal
cortex and in the pyriform cortex. The results of lesion experiments
showed that the projection to the frontal cortex originates from A 10
cell area of the ventral tegmentum, whereas the projection to the
anterior cingulate cortex arises from A 9 cell areas in the lateral
substantia-nigra (Lindvahl et al, 1974). However, dopamine terminals
have not been found in the motor area of the frontal cortex where both
primary and secondary foci are induced in cobalt-implanted rats (Emson
§ Koob, 1977). Thus, it seems unlikely that dopamine agonists exerted
their effect via stimulation of cortical dopamine receptors.
It is well known that the main site of action of these drugs is
the dopamine receptors in the striatum. Thus, besides stimulating
locomotion and increasing arousal which play at least a part in the
desynchronizing effect of these drugs on the cortex, as described before
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the question still remains whether the striatum does contribute in
controlling motor movements initiated by the motor cortex as well as
desynchronizing any epileptic tendency of the cortex. In this respect,
it might be worth reviewing some of the fiber connections in the
striatum:-
1. Input system of the striatum
It has been shown that the striatum receives strong
projection from the neocortex, intralaminar nuclei of thalamus,
and substantia nigra. Experimental evidence also indicates that
the striatum is also the recipient of fibers from the reticular
formation and one of the raphe nuclei. As regards the cerebellar
input into the striatal circuitry, it has been shown that a larger
number of fibers, originating from the dentate nucleus, leaves the
cerebellum via the brachium conjunctivum, then decussate in mid¬
brain and are distributed profusely to the anterior and lateral
central thalamic nuclei, which are the centres for termination of
the most important outflow channel of the striopallidum (see below).
Experimental evidence has shown that areas of termination of the
dentato-thalamic and pallido-thalamic projections overlap extensively
(Carpenter et al, 1976., Mehler § Naata, 1974). This cerebellar
projection may be considered as forming part of a circuit including
the following centers: Cerebral cortex-pontine nuclei-cerebellar
cortex-dentate nucleus-thalamus-motor cortex. This cerebro-cerebellar
loop shares its thalamo-cortical loop with the principal striatal
circuit (see below).
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Thus, it seems that the thalamus is an important relay-
station, linking the activity of the motor cortex with the
coordinating action exerted by the cerebellum, as well as with the
striatum. This might explain the therapeutic effect of cerebellar
stimulation on suppressing certain mild types of epilepsy and
cortical desynchronization (Wagner et al, 1975, Cook 5 Snider, 1955),
through the ARAS, partly by altering the phasic inhibition of the
thalamus (Yingling § Skinner, 1976).
2„ Output system from the striatum
(a) The principal striatal circuit (cerebral cortex-striatum-
globus pallidus-thalamus-cerebral cortex). (Fig. 29).
This is the most important of all these conndctions. Studies
employing axon degeneration techniques have shown that the
whole cortex sends fibers to the caudate-putamen of each site
and that all parts of the striatum receive fibers from cortical
neurons. The arrangement of this corticostriate projection is
on a simple topographical basis, although there is overlap in
the termination of fibers from different cortical areas (Webster,
1965., Kemp § Powel, 1970). This means that no part of the
striatum is under the influence of one structural or
functional cortical area. However, the projection from the
sensory cortex to the striatum is particularly large, whereas
that of the visual cortex is small. Furthermore, it has been
shown that the sensorimotor cortex and its supplementary areas
project bilaterally to the striatum (Kunzle, 1975). More
recently, it has been shown that about 35% of [^H] haloperidol
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Fiq 29 Diagrams summarizing (a) the classical concept of the pyramidal (PY.)
and extrapyramidal (E.P.) motor systems, and (b) our present1—day knowledge of the
fiber connections of the motor cortex and the striatum. Abbreviations: C., nucleus
caudatus; F.R., formatio reticularis; C.P., globus pallidas; O.P.E., globus
pallidus, pars externa; G.P.I., globus p i.llidus, pars interna; 11.L., lateral
habenular nucleus; I., intralaminar nuclei;!!., motor neuron; p., putamen; R.,
nucleus ruber; S.N., substantia nigra; SlilVi'li., corpus subthalamicum; TECT., tectum
mescr.cephali; THAI,., thalamus; T.P.P., nucleus tegmenti pedunculopontinus, pars




binding of the striatum is localized to presynaptic dopamine
receptors in these cortical terminals (Snyder et al, 1978), and
it was suggested that these afferents might be relevant, at
least in part, in the mechanism of action of the anti-psychotic
dopamine receptor antagonists. Efferent fibers from the
striatum converge towards the globus pallidus. The pallido-
thalamic projection originates from neurons of the internal
pallidal segment to end in the lateral and anterior ventral
thalamic nuclei. The lateral nucleus is connected via the
thalamo-cortical fibers with the motor area of the cortex from
which the pyramidal tract originates. In addition, one
striatum is in connection with the other, via fibers of the
striopallidal and pallidothalamic projection (Powell 8 Cowan,
1956., Mehler, 1966., Jones 8 Levitt, 1974). The existence of
this major circuit between the striatum and the cortex suggests
that the information derived from the cortex is processed in
the striatum, before being fed back via the globus pallidus
and thalamus to the motor and premotor areas of the cerebral
cortex, thus modulating its activity.
(b) Pallido habenular fibers
The globus pallidus projects upon the lateral habenular
nucleus. It is via these fibers that the striatum gain access
to the limbic system (Nauta, 1974).
(c) Nigro tectal and nigro reticular fibers connect the
striatum with the reticular formation and the superior colliculus
from which the reticulo spinal and tecto spinal descending
spinal tracts originate, respectively. Thus, the striatum
seems to exert its motor regulatory influence by way of
both ascending and descending projection.
Based on these anatomical relations of the striatum and their
functional importance, as well as the known pharmacology of dopamine
agonists, it was thought feasible for the striatum to affect cortical
desnychrony as part of its regulatory action on motor activity, as well
as on the excitability of cortical neurons.
The application of the cholinergic drug, carbachol, into the
caudate nuclei of the rhesus or squirrel monkey resulted in the
appearance of secondary generalized seizures which were blocked by
atropine (Cools et al, 1975., Murphey § Dill, 1972). These observations
strengthen the classical hypothesis that subcortical structures such
as the basal ganglia are important for the generalization and propagation
of epileptic attacks (Gestaut § Fiscber-Williams, 1959).
On the other hand, the caudate nucleus inhibits bioelectrical
epileptiform activity in several brain regions including the cerebral
cortex (Amato et al, 1964., Krauthamer, 1963) and amygdaloid nucleus
complex (La Grutta et al, 1971), which are characterized by having a
low threshold to epileptic phenomena (Feinstein et al, 1970., Ajmon-
Marsan fj Abraham, 1964). Micro injections of dopamine into the caudate
nucleus inhibited epileptic activity in the amygdala induced by the
local application of picrotoxin (Stach, 1976). Furthermore, epileptic
activity in mirror cortical foci induced by oubain was inhibited by
dopamine and potentiated by haloperidol injected into the rabbit striatum
(Stach 5 Kacz, 1976). The intrastriatal injection of dopamine
completely inhibited carbachol-induced generalized seizure in rhesus
monkeys (Cools et al, 1975). It has also been reported that the systemic
administration of L-DOPA, with a decarboxylase inhibitor, suppressed
the epileptic activity in penicillin-induced (Kobayashi et al, 1976),
and cobalt-induced (Scuvee-Moreau et al, 1977), cortical foci. It is also
well known that andiogenic, electroshock-induced, and photomyoclonic
seizures are modulated by dopaminergic compounds (Billet et al, 1970 .,
Boggan § Seiden, 1971, Killam, 1973, Meldrum et al, 1975).
In the present experiments, the bilateral intrastriatal injection of
dopamine (25 yg) reduced rapidly the epileptic activity of cortical foci
in the cobalt model. However, the effect was short-lived, lasting for
about 45 min. It is possible that a large amount of the injected dopamine
was eliminated by the catabolising enzymes catechol-O-methyl-transferase
and monoamine oxidase, or by diffusion leaving a portion to reach its site
of action at the synapses in the striatum, thus producing this short-lived
effect. Similar results were obtained with bilateral injection of apo-
morphine (60 yg) into each striatum. However, the anti-epileptic
effect of apomorphine was more intense than that of dopamine. It has
been shown that apomorphine is the most potent dopamine agonist in red¬
ucing [^H] dopamine binding (IC50 = 6 nM) while dopamine is about 30%
as active, ( IC50 = 22 nM). However, like dopamine, the anti-epileptic
effect of apomorphine was short-lived lasting about 50 min, and this
reflects the rapid metabolism,inactivation and elimination of apomorphine.
These experiments do suggest that stimulation of dopamine receptors
in the striatum is a primary event in the action of dopamine agonists in
inhibiting cortical epileptic activity.
Furthermore, the unilateral injection of dopamine (25 yg) into the
right striatum caused inhibition of epileptic activity in both the primary
and secondary cortical foci. This could imply that fiber connections
between the striatum on both sides via pallidum and thalamus remain an
important inter-dependent link whereby the primary focus influences the
activity of the secondary focus and vise versa. It is possible that
dopamine could have diffused to the other striatum to induce suppression
of epileptic activity in the secondary focus. This might have caused
dissociation of the onset of suppression of epileptic activity on both
sides, whereby it would have occurred earlier on the injected side.
However, in this experiment both foci were suppressed rapidly and at a
similar time after the injection, which might rule out diffusion of
in
dopamine to the opposite striatum /initiating the suppression of epileptic
activity on the contralateral side.
The anatomical spread of seizures through the brain depends on the
specific site of cortical discharge, the strength and duration of a
stimulus, and whether the event is new or chronic. With direct cortical
stimulation or the application of topical convulsants, the earliest
signals are detected in the contralateral homotopic cortex and homolateral
subcortical nuclei, particularly the thalamus and caudate-putamen
(Kriendler, 1965., Scheibel § Scheibel, 1966) . This reflects spread by
specific corticofugal pathways,through the corpus collosum to the homo-
tropic cortex, and by internal capsule to the striatum and the thalamus.
It has already been shown that sectioning of the corpus collosum
if carried out within 4 days, prevented the development of secondary focus
in the cobalt-implanted rat, but had no effect at later times (Ashcroft
et al, 1974). This suggests that the secondary focus becomes independent
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of its callosal connections with the primary focus after four days of
cobalt application but remains partly dependent upon it through other
pathways, like the one linking the striatum on both sides with the
thalamus as shown in the experiments described above. Recent experiment¬
al work has emphasized both the medial thalamus-frontal cortex and mid¬
brain reticular formation as important in the mechanism of bilateral
seizure spread, the latter being activated early from foci in motor
cortex (Kriendler, 1965). Other workers using autoradiographic tracer
methods in penicillin-induced foci, suggested that bilateral seizures
develop from a unilateral focus primarily through increasing activation
of intrathalamic circuits (Collins et al, 1976., Collins § Plum, 1975),
In cobalt-implanted rats, contralateral forelimb twitches were evident
and very rarely did the animal develop bilateral or generalized seizure.
However, thalamic spreading depression suppressed the discharge produced
by cortical or hippocampal stimulation in rats (Aquino-Cias § Bures, 1967).
Moreover, thalamic lesions have been used as a therapeutic technique in
patients suffering from intractable seizures (Mullan et al, 1967., Williams,
1965).
The effect of intrastriatal injection of dopamine agonists
demanded looking at the effects of destroying dopamine terminals in
the striatum upon cortical epileptic foci.
The bilateral injection of 6-OHDA (20 yg) into each striatum caused
a significant reduction in the concentration of both catecholamines, in
comparison to controls. However, dopamine concentration was more
profoundly reduced than that of noradrenaline, reaching to 10% and 15%
of control values on the right and left sides, respectively. This
effect was accompanied by potentiation of the development of epileptic
activity in cortical foci, thus adding more support to the assumption
that the striatum exerts an important inhibitory role tending to de-
synchronize cortical neurons. However, if striatal dopamine was the
sole modulator of the activity of cortical neurons, via the major striatal
circuit described before, the increased epileptic activity following 6-OHDA
lesion of striatum would have been much more pronounced. Thus, an
additional factor could augment such inhibition by the striatum upon the
cortex. It has been shown that some gabbaminergic neurons in the
striatum are not functionally related to the striato-nigral system, but
project to the prefrontal cortex (Divac, 1968)„ The intrastriatal
injection of gamma-aminobutyric acid (GABA) was shown initially to
potentiate transiently and then to inhibit the epileptic activity of
cortical mirror foci induced by oubain (Stach 5 Kacz, 1976). The role
of GABA in epilepsy has been extensively investigated (Meldrum et al,1975.,
Woods, 1975). It has been shown that inhibition of GABA synthesis with
consequent reduction in brain GABA concentration lowered the threshold
of animals for convulsions. However, treatments that elevated brain
GABA are not always anti-convulsant. Amino-oxyacetic acid, an inhibitor of
the enzyme metabolizing GABA (GABA-transaminase) has a definite anti¬
convulsant action at doses of 5-20 mg/kg, while at higher doses
it might have a definite convulsant effect (Woods § Pesker, 1973).
Moreover, sodium-n-dipropyl acetate is known to elevate brain GABA and
is used in the treatment of epilepsy (Jeavons § Clark, 1974), yet
this drug was shown to have no effect on cortical epileptic activity
in acute and chronic experiments (Emson, 1976). Thus the anti¬
convulsant action of these drugs is unlikely to be mediated by elevation
of brain GABA levels„
Thus, it seems that the dopaminergic mechanisms in the striatum
play an important role in modulating the activity of cortical neurons,
tending to desynchronize any tendency to epileptic activity.
In conclusion, it could be said that dopamine agonists exerted
their desynchronizing effect on cortical foci at least in part, by
stimulation of dopamine receptors in the striatum as well as augmenting
activity of ARAS as induced by increased arousal and motor enhancement.
Some anti-convulsants, like phenytoin and phenobarbitone have been shown
to increase HVA levels in the CSF of treated patients (Corrodi et al, 1967.,
Chase et al, 1969). Amphetamines which release catecholamines from their
nerve terminals, have been used clinically in the treatment of epilepsy,
including petit mal. Furthermore, they have been reported to enhance
the anti-convulsant action of phenobarbitone and phenytoin in the mouse
electroshock model (Rudzik § Johnson, 1970). Thus, it is possible that
stimulation of dopaminergic mechanism could explain in part the anti¬
convulsant action of these dings.
SECTION 3.
DOPAMINE AND AMYGDALOID KINDLING
(SEIZURES INDUCED BY SENSITIZATION
WITH LOW INTENSITY ELECTRICAL
STIMULATION OF THE AMYGDALA),
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Bromocryptine 20 mg/kg i.p.
tb)
ECoG Record 1: showing the suppressant effect of bromocryptine on the
epileptic activity in cobalt-implanted rats.
(a) A sample of recording during the initial control period of 30 min.
(b) A sample of recording from the same animals 4 hrs after the
intraperitoneal administration of bromocryptine (20 mg/kg) to Rat 2.
Rat 1 received an equivalent volume of vehicle, i.p.
(a) A sample of recording during the initial control period of 30 min.
(b) A sample of recording from the same animal, 20 min after the
intraperitoneal administration of lisuride (0.1 mg/kg) to rat 2.
Rat 1 received an equivalent volume of normal saline, i.p.
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(b) A sample of recording from the same animals 15 min after dopamine


















ECoG Record 4: showing the suppressant effect of apomorphine
administration into each striatum on epileptic activity in cobalt-
implanted rats.
(a) A sample of recording during the initial control period of 20 min.
(b) A sample of recording from the same animals after the administration
of apomorphine (60 yg) into each striatum of rat 2. Rat 1 received
2 yl normal saline.
A. DEVELOPMENT AND MECHANISM OF KINDLING
Periodic bipolar stimulation of a number of sites throughout the
olfactory-limbic system can lead to grand mal development and intensific¬
ation of behavioural convulsions (kindling) in a variety of species
(Goddard, Mclntyre 5 Leech, 1969), even at current intensities that are
initially too low to produce any behavioural or electrographic effect.
The most productive areas in kindling phenomenon involves deep limbic
structures in rats (Goddard, 1967., Racine, 1972a and b), cats (Goddard,
1969, Morrel, 1973, Wada, 1974), rhesus monkeys (Wada, 1974) and
Baboons (Wada 5 Osawa, 1974). For example, if the rat amygdala is
periodically stimulated at a level which produces neither electro-
graphic nor behavioural effects, eventually the afterdischarge threshold
may be reduced to the point where subsequent stimulations reliably elicit
afterdischarge. If stimulations are then continued, mild motor auto¬
matism may appear which increases in severity with each successive
stimulation until motor seizure characterized by facial and forelimb
clonus, weeping and loss of equilibrium can be elicited reliably
(Racine, 1972a).
Although kindling can be produced from a wide variety of olfactory,
limbic and cortical areas, the number of stimulations necessary to kindly
full motor seizures is a function of the site of stimulation (Goddard et
al, 1969). However, since the amygdala has been found to be particularly
responsive, most studies on kindling have employed amygdaloid stimulation.
Regardless of the level of responsiveness of any particular structure,
however, kindling cannot be produced unless stimulations are distributed
over a time. Goddard et al (1969), found the number of stimulations
leading to kindled convulsions to be inversely related to the duration
of the interval between stimulations. It was difficult to kindle
rats with interstimulation intervals of less than 20 min, and inter-
stimulation intervals of 24 hrs or longer were found to be optimal.
In a subsequent study using different stimulation parameters, Racine
et al (1973) confirmed the general inverse relation between the duration
of the interstimulation interval and the number of stimulations required
to kindle full motor seizure, but found that intervals as short as
one hour could be used without significantly retarding the rate of
kindling. Moreover, they found that kindling and not just the expression
of motor seizures was blocked at short intervals, massed stimulations
(15 stimulations administered at 15 min intervals) produced only a slight
reduction in the number of distributed stimulations later required to
kindle full motor seizures.
Racine (1972a) has provided convincing evidence that the elicitation
of afterdischarge at the site of stimulation is a necessary prerequisite
for the kindling of motor seizures. Periodic stimulation maintained at
a level below the afterdischarge threshold did not lead to the development
of motor seizure, nor did it reduce the number of suprathreshold stim¬
ulations, later required for kindling. Moreover, the main electro¬
physiological correlate of the kindling process appears to be the degree
to which the afterdischarges generalise from the site of stimulation to
other neural structures (Racine et al, 1972). During the course of
kindling, spike amplitudes in secondary foci progress from very small
or non-existent to amplitudes as great as those in the primary focus
(Racine, 1972a).
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Racine (1972b) has also reported that an appreciable reduction in
the afterdischarge threshold can occur during kindling, but at least
three lines of evidence suggest that the reduction in the afterdischarge
threshold is independent of the kindling which can occur concommitently.
First, periodic amygdaloid stimulation maintained below the afterdischarge
threshold reduces the afterdischarge threshold without leading to the
development of motor seizure (Racine, 1972a). Secondly, stimulation
of the posterior neocortex does not kindle motor seizures even though it
reduces the afterdischarge threshold (Racine, 1975). And, thirdly, the
reduction of afterdischarge threshold appears to be restricted to the
site of stimulation while kindling of one brain site greatly influences
the degree to which other brain sites can be kindled (Goddard et al, 1969.,
Racine, 1972b*, Racine 1975., Mclntyre § Goddard, 1973).
Perhaps the most important feature of the change in neural function
induced by periodic brain stimulation is that they are enduring, if not
altogether permanent. Goddard et al (1969) rekindled rats after 12
weeks of stimulation-free interval and found a saving of 90% in the
number of stimulations required to elicit a full motor seizure. Similarly,
Racine (1972b) found that the decrease in afterdischarge threshold produced
in rats by repeated hippocampal or amygdaloid stimulation persisted at
least 6 weeks after all stimulation were curtailed.
Although the permanence of the change in motor seizures are more
striking, the changes in afterdischarge threshold are particularly
important since they can be produced by subthreshold stimulation. Even
stimulation levels which produce no obvious electrographic or behavioural
change can produce a lasting increase in the susceptibility of the brain
to later stimulations.
The evidence suggests that the kindling effect does not result
from a localized histological change at the stimulated site, but
depends widely upon disseminated neuro-circuits being constructed trans-
synaptically (Goddard et al, 1969., Racine et al, 1972., Racine, 1972b,
Wada § Sato, 1974, Wada et al, 1974). This view is further supported
by the 'transference' phenomenon, which is the efficient rekindling in
a secondary brain structure after establishing the kindling effect in
the primary structure. Moreover, permanency of behavioural modification
and of electrographic seizure discharge was confirmed in kindled animals
(Goddard, 1972, Mclntyre 6 Molino, 1972, Wada et al, 1974). These
findings strongly suggest that the kindling procedure can lead to second¬
ary functional alterations and predictable organisation of brain function,
culminating in a permanent state of epileptogenic activity that is strikingly
similar to human epilepsy.
A number of reports suggested that the mesencephalic reticular
formation and related structures in mid brain and lower brain stem may
play a prominent role in the spread of afterdischarges in amygdaloid
kindling (McCaughran et al, 1975, Mclntyre, 1975, Wada § Sato, 1974, 1975).
Studies of amygdaloid kindling in rats, cats, rabbits and baboons (Wada,
Sato 6 McCaughran, 1974, Tanaka, 1972) showed progressive involvement of
basal cortical areas as well as the development of spike discharge in the
frontal cortex, associated with complex seizure patterns. As kindling
progressed, the cortical epileptiform activity became independent of the
amygdaloid afterdischarge. Furthermore, studies employing bilateral
aspiration lesions of frontal cortical areas, particularly the prefrontal
and orbital cortex, have shown retardation of the rate of kindling.
Nevertheless, kindling occurred in lesioned rats, indicating that these
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cortical areas are not essential for the development of amygdaloid
seizures (Corcoran et al, 1975).
B. INNERVATION OF THE AMYGDALA
Cholinergic input
The cholinergic nerve terminals in the amygdala originate from the
ascending cholinergic reticular system (Shute § Lewis, 1967). Furthermore,
biochemical and histochemical evidence suggest that the basolateral nuclei
contain more cholinergic nerve terminals than the centro medial nuclei
of the amygdala.
Catecholaminergic input
Noradrenergic terminals have been demonstrated in the amygdala by
fluorescence histochemistry (Fuxe, 1965., Ungerstedt, 1971). Lesion and
radiographic studies indicate that at least a portion of these terminals
originate from the locus coeruleus and reach the amygdala via the dorsal
noradrenergic bundle and stria terminalis (Segal et al, 1973., Ungerstedt,
1971).
The dopaminergic input to the amygdala originate from the substantia
negra and passed through the internal capsule and stria terminalis
(Ungerstedt, 1971). The highest tyrosine hydroxylase activity and
catecholamine concentrations in the amygdala are located in the central
nucleus (Fuxe, 1965., Ben-Ari et al, 1975). Furthermore, a higher tyrosine
hydroxylase activity and catecholamine level were found in the basolateral
than in cortico-medial areas (Ben-Ari et al, 1975), thus supporting the
findings using fluorescence histochemistry studies of the amygdala
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(Hokfelt et al, 1974). Furthermore, regional differences within the
amygdala were much larger for dopamine than for noradrenaline (Ben Ari
et al, 1975).
Neural output from the amygdala
The fiber connection of the amygdaloid complex comprises connections
with the following:-
(a) the olfactory area
(b) the neocortex
(c) the lateral preoptic area and hypothalamus
(d) the dorsal thalamus.
These connections are thus important in the spread of afterdischarge
initiated in the amygdala and, consequently, in the generalization of
subsequent seizure.
C. CLINICAL AND EXPERIMENTAL IMPLICATIONS OF KINDLING
The utility of the kindling phenomenon as a model of epileptogenesis
was the first clinical application to be emphasized (Goddard et al, 1969.,
Morrel, 1973). There are striking parallels between the kindling
phenomenon and the progressive development of epileptic symptoms in human
patients. In untreated clinical cases as in kindled animals, there is
often a progressive development of symptoms within a particular attack as
well as from one fit to the next (Hughlings-Jackson, 1870). By definition,
human epilepsy is a spontaneously recurring, self-sustained, paroxysmal
dysfunction of the brain, but early efforts to kindle rats to the point
where they would display such spontaneous seizures did not meet with
success (Goddard et al, 1969). However, further experiments have
clearly demonstrated that periodic amygdaloid stimulation will eventually
result in the development of recurrent spontaneous seizures in both
rats (Pinal et al, 1973) and cats (Wada § Sato, 1973., Wada, Soto f)
Corcorann, 1974).
In the rat the production of spontaneous seizures simply appears to
be a matter of extending the number of periodic brain stimulations. If
amygdaloid stimulations are continued beyond the point where most kindling
experiments are curtailed, there is a gradual reduction in the day-to-day
variability of the class 5 motor seizure pattern (Racine, 1972a) followed
by the eventual development of two new motor seizure patterns. The first
involves multiple rearing and following sequences and the second can best
be described as a running fit. It appears that the electrographic basis
for the development of spontaneosity is the same for both rats and cats
(Pinel, Mucha, Phillips, 1975., Wada et al, 1973). In both cases the
development and proliferation of interactal spike discharges appears to
be the major electrographic correlate of the epileptogenesis of spontaneous
seizures. Now that it has been well established that repeated local brain
stimulation will eventually lead to the progressive development of epileptic
syndrome, the kindling model should prove to be a valuable tool in the
controlled experimental study of factors associated with epileptogenesis.
The second major clinical application of kindling has been to use
it as a procedure for assessing the convulsant and anti-convulsant prop¬
erties of drugs and other stimuli. Babington 5 Wedeking (1973) studied
the effects of a variety of centrally-active agents on kindled seizures
elicited from the amygdala or sensori-motor cortex. Once the seizures
were stabilised, drug effects on seizure duration were assessed.
Anti-depressive drugs were found to be more effective in suppressing
seizures elicited by amygdaloid stimulation than those elicited from
the cortex, whereas both anti-anxiety and anti-epileptic drugs exerted
non-selective blockade, but the anti-anxiety drugs were more potent.
However, the effect of drugs can be assessed not only on each individual
seizure, but on the progressive intensification of seizures from one
stimulation to the other. By determining the extent to which anti¬
convulsants are capable of blocking the kindling motor seizure, it may
eventually become possible to predict which anti-convulsant will be most
successful prophylactically in a clinical situation (Wada, 1975). Wise §
Chinerman (1974) reported that diazepam and phenobarbitone, but not
diphenylhydantoin^can block the progressive intensification of motor
seizures but not the local decrease in afterdischarge threshold produced
by repeated electrical stimulation of the amygdala.
Electrical current has been applied to the human brain in an attempt
to identify epileptic foci (Adams § Rutkin, 1972), to treat schizophrenia
(Carletti, 1956), to change emotional level of psychotic patients (Heath,
1970) and to relieve chronic pain (Heath § Mickle, 1960). However, it
was argued whether brain stimulation could leave the organism more
susceptible to seizures, not only during the course of treatment (Goddard,
1971), but also to convulsant agents administered long after the electrical
stimulation therapy had been curtailed.
It has been shown that alcohol withdrawal can interact with prior
brain stimulation to intensify epileptic symptoms (Pinel et al, 1975).
Furthermore, withdrawal from barbiturates and many other sedatives or
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tranquillizers can produce convulsions similar to those seen in alcohol
withdrawal (Itil, 1970). Moreover, repeated amygdaloid stimulation,
either above or below the afterdischarge threshold, was found to intensify
the subsequent convulsive reaction to metrazol in rats (Pinel, Skelton
§ Mucha, 1975).
Apart from local brain stimulation which is infrequently employed
as a therapeutic measure, kindling can be produced in response to the
repeated administration of a variety of convulsive agents. Sub-convulsive
doses of metrazol in rats, at 3-day intervals, resulted in the develop¬
ment of minor myoclonic response after four injections, and eventually
grand mal seizures were elicited in some animals (Mason & Cooper, 1972).
Leech (1971) observed that micewhich are initially resistant to audio¬
genic seizures will eventually become responsive to stimulation if they
were exposed to a short bout of audiogenic stimulation daily. Moreover,
the daily injection of carbachol into the amygdala, hippocampus or caudate
in rats, in sub-convulsive doses will eventually elicit motor seizures
(Vosu § Wise, 1975). Repeated electroconvulsive therapy is widely used
in psychiatric treatment, especially in depressive illness. The duration
of the inter-stimulation interval may influence the susceptibility to
electroconvulsive seizures. It has been shown that electroconvulsive
stimulations (ECS) administed at intervals of 3 (Ramer § Pinel, 1974) or
7 (Pollack et al, 1963) days, resulted in increased susceptibility and
intensification of the induced seizure. However, at interstimulation
intervals of 24 hrs or less, ECS series were found to cause a progressive
reduction in seizure threshold and severity (Essig et al, 1961., Ramer §
Pinel, 1974).
D. CATECHOLAMINES AND KINDLING SEIZURE SUSCEPTIBILITY
The role of brain catecholaminergic systems in the neurohumoral basis
of seizure susceptibility has been studied by many workers. It was
reported that catecholamines are inhibitory to seizures in general
(Maynert, 1969). Depletion of central catecholamine levels induced by
reserpine or intra-ventricular injection of 6-OHDA has been shown to
accelerate kindling (Arnold et al, 1973, Coi-coran et al, 1974), while
increased catecholamine turnover, as that induced by stress, was found
to retard the development of kindling seizure. These findings are
consistent with the previous reports that increased seizure susceptibility
occurred when brain catecholamine levels were significantly lowered,
while decreased susceptibility was found when brain dopamine levels were
significantly elevated (Boggan § Seiden, 1971, Bourn et al, 1972, Izumi
et al, 1973, Mackenzie § Soroka, 1972)„ All the above findings suggest
that kindled seizure susceptibility may be dependent upon the depletion
of brain catecholamine levels. Seizure susceptibility, which is based
on marked depletion of both catecholamines, is increased by participation
of activated serotonergic system during slow wave sleep and is decreased
by the physiologically active catecholaminergic system during REM sleep.
Some workers have shown that marked depletion of catecholamines
occurred in both cerebral hemispheres of hippocampal kindled cats (Sato
et al, 1975). Other workers, however, reported a reduction in noradrenaline
levels in the hypothalamus, but found no change in brain dopamine levels
in amygdaloid kindled rats (Callaghan § Schwark, 1975). Using micro-
iontophoretic studies it has been shown that dopamine behaves as inhibitory
transmitter in the amygdala (McCrea, Jordan § Lake, 1973, Ben-Ari § Kelly,
1974). More recently, it has been shown that unilateral lesion of the
stria terminalis, which contains catecholamine inhibitory afferents to the
amygdala, facilitate the development of the early stages of kindling
induced by ipsilateral amygdaloid stimulation (Engel § Katzman, 1977).
Furthermore, the dopamine content was reported to be locally reduced at
the site of the stimulated amygdala in kindled rats (Engel § Sharpless,
1977). These findings suggested that dopamine in the amygdala is
inhibitory to the kindling pi'ocess.
Tyrosine hydroxylase
Tyrosine hydroxylase activity is the rate-limiting step in the
biosynthesis of catecholamines, and the most specific indicator of the
functional integrity of catecholaminergic neurons (Levitt et al, 1965,
Spector et al, 1965) (For Review, see Introduction, Section 1).
It has been shown that two molecular types of tyrosine hydroxylase
exist, controlling the synthesis of noradrenaline or dopamine in their
respective neurons, (Reis et al, 1975). Although brain tyrosine hydroxy-
last is highly localised to catecholaminergic nerve endings, histochemical
studies following lesions of catecholamine neurons have shown accumulation
of catecholamines proximal to the lesion and their disappearance at the
nerve endings (Dahlstrom 6, Fuxe, 1965). This implies a continuous trans¬
port of the enzyme from the cell body to nerve terminal. Nagatsu et al
(1971) investigating the enzyme activity in the bovine caudate nucleus
were unable to produce a linear increase in L-DOPA production with
increasing amounts of tissue unless the enzyme was purified. Using
purified tyrosine preparations, Hendry § Iversen (1971) were able to
estimate the enzyme activity in small amounts of neural tissue, and their
method was quite sensitive. Moreover, brain tyrosine hydroxylase is
responsive to slightly different conditions of pH than the adrenal enzyme
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the optimal activity occurring at pH 6 (McGeer et al, 1967).
E. AIM OF THE WORK
The present work was done in order to follow on the possible role
of the dopamine system in amygdaloid kindling in a manner analogous to
the focal cortical foci induced by cobalt already described. In the
first part of this work tyrosine hydroxylase activity was estimated in
the stimulated amygdala as well as in various brain regions that are
involved or could be implicated in the spread of amygdaloid afterdischarge.
The second part of the present work utilizes the dopamine agonists as
a pharmacological tool in manipulating the possible underlying mechanism
in kindling. This work might help in the understanding of the aetiology
and spread of seizure activity from subcortical foci such as those





During all kindling experiments, male Wistar rats 180-200 g in
weight, were used.
B. DEPTH ELECTRODE
The bipolar electrode was prepared by twisting a suitable length of
nichrome wire and cutting it at the tip, allowing a length of 1 cm for




Halothane (Fluothane, ICI) was used with medical air (BOC).
4% halothane was used for induction, and maintained at a
concentration of 2%. The flow rat was 2.5 litres/min.
2. Surgical procedure for electrode implantation
Under halothane anaesthesia, rats were implanted with bipolar
stimulating electrodes in the basolateral region of their left
amygdalae.
A curved cranial incision, 2 - 3 cm long was made in the scalp,
extending from the region near the left eye backwards towards the
lambdoid suture. After separating the underlying fascia, the
skull was exposed. A hole was drilled, using No. 6 size burr, on
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each side of the skull 2 mm anterior and lateral to coronal and
sagittal sutures, respectively, and then two stainless steel
recording electrodes were fitted to these holes, and fixed with
acrylic cement(Simplex).
Using the stereotaxic frame a point on the left side of the
skull was localized 4.5 mm anterior to the interaural line and
4.4 mm lateral to the midline (which corresponded to the sagittal
suture if the rat is properly positioned)„ At this site, a hole
was drilled, using No. 6 burr, and the dura mater incised with the
tip of a fine needle. Thus, the brain surface was exposed and
viewed in an operation microscope (Zeiss). The bipolar electrode
was then implanted at this point 7.9 mm deep to the cortical surface
into the basolateral region of the left amygdala (Konig and Klippel,
1965) and fixed to the skull with acrylic cement. Haemostasis was
secured and skin closed with silk after spraying the wound with
polybactrin.
3. Post-operative period
No special post-operative care was necessary. Scalp wounds
healed remarkably well. Infection was rarely a problem. The
animals were allowed one week for recovery and daily stimulation was
begun on the 8th day. During that period, the rats were examined
daily, and animals with loose or dislocated electrodes were discarded.
After several weeks animals do lose their electrodes presumably as
a result of getting them stuck in the wire loops of the cage.
However, it was possible to keep some animals in the kindled state
with electrodes intact for as long as 5 months after operation.
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In all experiments, stimulated rats were kept separate from
controls. Sham-operated and unoperated controls were kept separate
from each other. Drug-treated rats were kept separate from saline or
vehicle-treated controls.
Not more than 4 rats in each group were assigned to a cage.
Food and water were allowed ad libitum, except during a period of
a few hours associated with the stimulation and recording procedures.
D. PARAMETERS OF STIMULATION
Beginning on the 8th post-operative day a suprathreshold constant
sinusoidal current ranging between 100-5C0 uA and consisting of 1 msec
biphasic square-wave pulse at a frequency of 60 Hz was delivered to the
stimulated rats for one sec daily via the stimulating electrode, using
a constant current physiological stimulator (Farnell).
Electrical activity from the amygdala was amplified and recorded on
a Grass polygraph (model 7) before and after stimulus delivery. The
recording paper speed was 10 mm/sec. The duration of the ensuing after-
discharge in sees was measured on the recording paper starting from the
point of stimulation.
E. DEVELOPMENT AND STAGING OF MOTOR SEIZURE
Daily stimulation was continued until the rats developed generalized
convulsions after stimulation for 2-3 consecutive days. As the number of
stimulations increased, the rats developed progressive seizure manifest¬
ation of amygdaloid kindling, starting with facial twitching, progressing
to forelimb clonus and finally generalised seizure. This pattern was
previously reported by Racine (1972a). A semi-quantitative estimate of
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the intensity of seizure was done using the scale described by Racine
(1972a) as follows
Stage 0 No seizure
1 Mouth and facial movement
2 Head nodding
3 Forelimb clonus
4 Rearing (Kangaroo posture)
5 Rearing and falling backwards.
Thus, a full motor seizure with loss of postural control is referred
to as class 5 motor seizure. Daily stimulation was continued once daily
until the rats developed generalized seizure for 2-3 days. The duration
of the evoked afterdischarge was measured, and the number of stimulations
required for the development of different stages of seizure were noted
for each rat.
Tissue sections with the microtome showed the electrode tracts in
the region of the amygdala.
F. DESIGN OF EXPERIMENTS
1. DETERMINATION OF AFTERDISCHARGE THRESHOLD DURING DEVELOPMENT
OF KINDLING
Twelve rats were used of which only 7 reached the final stages
of generalized seizure. Starting on the 8th day the minimal current
intensity required to induce afterdischarge was determined daily
until the animals developed generalized convulsions for 2 days. The
number of stimulations required for the development of different
stages of the motor seizure was also noted.
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2. TYROSINE HYDROXYLASE ACTIVITY IN VARIOUS BRAIN REGIONS
IN KINDLED RATS
A. Experimental procedure
Twenty-one male Wistar rats were used in the experiment.
Seven of these rats served as unoperated controls. Under halothane
anaesthesia, the basolateral region of the left amygdalae of 14
rats were stereotaxically implanted with bipolar stimulating
electrodes, as described in the method. Of these animals, 7
were stimulated and 7 served as sham controls.
During the post-operative period and during experimentation,
stimulated rats were kept separate fron controls.
B. Dissection
Four weeks after the last stimulation, rats were killed
by decapitation and their brains were dissected out quickly on
a cold stage at 4°C. The following dissection was done with
the aid of a dissecting microscope:
The whole hippocampus was carefully dissected out from the
overlying cortex on both sides of the brain and was then removed
entirely. Two vertical cuts were then made from the inferior
surface of the brain, the first at the level of the optic
chiasma (A 5500 micronsl(Koning £ Kippel, 1963) and the second
at the level of junction of the cerebral peducles with the base
of the cerebral hemisphere (A 3000 microns), thus dividing the
brain into three parts. From the anterior part, tissue
portions were taken from the frontal cortex and striatum on both
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sides. From the middle part, both amygdalae were dissected
out under the dissecting microscope and care was taken not to
include the adjacent pyriform cortex in the dissection of
the amygdala. Tissue portions were then taken from the thalamus
and hypothalamus with the aid of the dissecting microscope.
Kindled, implanted and unoperated control rats were treated
identically in all phases of sacrifice.
Storage of tissue samples
Tissue samples, placed in polythene bags, were stored
by freezing in liquid nitrogen (-195°C). The duration of
storage was about 35 days before being assayed biochemically for
tyrosine hydroxylase activity. No significant loss of enzyme
activity was found over that period of storage. The enzyme
activity in the brain of control unoperated rats, which was
stored for that period, showed no greater variation than tha.t
in freshly killed rats.
Electrode tracts
The dissection described above did not allow looking for
electrode tracts. However, the pattern and rate of seizure
development and of the elicited afterdischarge strongly indicated
that the electrode tips were in the amygdala.
C. Biochemical analysis of tyrosinehydroxylase activity
Kindled, implanted and unoperated control rats were treated
together in all phases of sacrifice and biochemical analysis.
Homogenates of tissue sample were assayed together in duplicate
for tyrosine-3-hydroxylase activity according to the method of
Hendry § Iversen (1971). The extract of brain was incubated
with pH] labelled tyrosine in the presence of an inhibitor of
aromatic amino acid decarboxylase. At the end of the incubation
period the amount of titrated 3:4-dihydroxyphenylalanine (pH]
L-DOPA) formed was measured. This is proportional to the level
of activity of tyrosine hydroxylase in tissue extracts. The
incubation mixture, containing both pH]-L-DOPA and pH] tyrosine
was passed through an alumina column. pH] L-DOPA was adsorbed on
alumina and thus retained, while pH] tyrosine did not adsorb on
alumina and was washed out with dilute Tris buffer. The retained
pH] L-DOPA was eluted from alumina by glacial acetic acid and a
sample of the eluate was then taken for pH] counting.
Homogenization
Homogenization of weighed tissue was done, on samples which were kept
frozen on solid CO2 (-75°C), with 20 mM potassium phosphate buffer pH 7.4
and containing 0.1% of 1% Triton-X.
For each 1 mg of tissue, 10 pi of buffer was used for homogenization
in an Ependorff tube. pH] 2:3 side chain L-tyrosine (specific activity
22 Ci/mMop Radiochemical Center, Amersham) was purified before use by
incubation for 30 min with alumina equilibrated with 0.5 M potassium
phosphate buffer, pH 7.4. This procedure would remove any pH] labelled
catechol compounds that may have been present as impurities. Thus 100 pi
of the stock pH] tyrosine solution was added to a mixture of 100 pi
alumina suspension (Neutral grade, Sigma) equilibrated with 0.5 M KP04
buffer, pH 7.4 and 200 pi of 5 mM Tris (Tris-hydroxymethyl melamine)»
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buffer, pH 8.6 This mixture was shaken continuously for 5 min using
a mechanical shaking apparatus and with sufficient force to keep the
alumina in suspension. It was then allowed to stand for 30 min. The
supernatant was used as the purified tyrosine substrate for the assay
of tyrosine hydroxylase.
The final substrate solution for the enzyme activity was prepared
by mixing equal volumes of the purified tyrosine solution with 0.2 M
potassium phosphate buffer solution containing 2 mM DMPH4 (2-amino-4
hydroxy-6,7 dimethyl tetrahydropteridine, Roche), 6.25 mM of B-mercaptoe-
thanol and 3.05 nM 3-hydroxybenzyl oxyamine (NSD - 1055, Smith & Nephew),
as the aromatic amino acid decarboxylase inhibitor. This concentration
of NSD-1055 was reported to produce a complete inhibition of decarboxylase
activity. This final substrate solution was used for the reaction and
it containted 66 pmol (1 yCi) [%] 2,3 side chain-1-tyrosine in each
10 yl solution.
Reaction
To start the reaction, 10 yl of the substrate solution described
above, was added to 10 yl of tissue homogenates. The reaction was allowed
to proceed for 20 min at 37°C in stoppered Eppendorf tubes and was
terminated by the addition of 250 yl of 0.4 M perchloric acid containing
2 yg/ml of cold L-DOPA carrier.
Neutralization
The acid solution was then neutralized to pH 8 by the addition of
4 ml solution containing 0.1 M Tris, 0.2 M sodium EDTA and 0.3 M sodium
hydroxide.
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Adsorption of [%] L-DOPA
The solution was then passed through 4 x 0.25 cm columns of neutral
alumina, equilibrated in potassium phosphate buffer, pH 7.4 and washed
with 10 ml of 5 mM Tris buffer, pH 8.6. The unadsorbed, unreacted
[%] tyrosine was washed out of the column by the passage of 40 ml of
5 mM Tris buffer, pH 8.6.
Elution of [%] L-DOPA
The adsorbed [%] L-DOPA on alumina was eluted from the column
using 3 mis of 1 M glacial acetic acid (Analar).
Counting
A sample of 1 ml of the 3 ml eluate was added to 10 ml of the
aqueous scintillant NE-260. The radioactivity of tritium in the samples
was estimated in scintillation counter, the number of counts over a 10
min period being recorded.
Estimating the % recovery of [%] L-DOPA by the method
The recovery of L-DOPA through the whole procedure was measured
as follows:
10 yl of [3H] L-DOPA (specific activity 2.5 Ci/mMol, Radiochemical
Center, Amersham) was added, in duplicate, to tissue homogenate, contain-
ing no [ H] tyrosine, and then passed through the method. The estimated
radioactivity was compared to that counted following the addition of
similar amounts (10 yl) of [^H] L-DOPA directly to the effluent of duplicate
tissue sample processed through the method. The percentage recovery
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ranged between 49 - 52% in all the assays.
Blanks
Tissue and reagent blanks were assayed, in duplicate, simultaneously
with tissue samples. Tissue blanks, in duplicate, were prepared by
heating the homogenate to 80°C for 15 min and then cooled on ice. 10 pi
perchloric acid was then added before the addition of the tyrosine
substrate solution. Reagent blanks, in duplicate,were prepared by
mixing 10 pi of 20 mM KP04 buffer, pH 7.4 containing 1% of 0.1% Triton-X
with 10 pi of the tyrosine substrate solution.
Tissue and reagent blanks gave similar low counts. Tissue blanks
gave counts between 460 - 1000 counts/min and these were used during the
calculation of the enzyme activity.
Nil values were assigned to all tissue samples with less than double
the counts produced by tissue blanks.
Calculations
TOH activity
(nMol [3H1 L-DOPA PPM x Recovery x 9 x 1000
v. . = 49,333,000
per hr per gm wet ' '
tissue weight)
PPM of sample (cpm)
(desintegrations/min) SamPle «=unts/min x efficiency of countingfor Tritium.
Sample cpm = Counted cpm minus cpm of tissue blank.
*7
In the assay, 1 pCi of [ H] tyrosine (equivalent to 2,220,000) was
used in each reaction. This is equivalent to the activity present in
0.045 nMol tyrosine. Thus,
2,220,000 dpm = 0.045 nMol tyrosine
0.045 nMol L-POPA




Estimating the efficiency of counting for [^H]
Ten samples were used. In each sample,
5 pi of [%] toluene (standard activity 20,000 dpm/5 yl) was added
to 10 ml of NE-260 scintillant and counted for 10 min. The estimated
percentage efficiency for tritium ranged between 32-36%, with an average
efficiency of 34%.
3. DOPAMINE AGONISTS AND KINDLING
A. EFFECT OF SOME DOPAMINE AGONISTS ON RATE OF KINDLING
1. Bromocryptine and the rate of kindling
Twenty one male Wistar rats were used in the experiments, of
which 15 rats reached the final stage of convulsions. Eight of
these rats were bromocryptine-treated and 7 rats were vehicle-treated
controls.
The operative procedure for electrode implantation is similar
to that described above. Post-operative care, parameters of
amygdaloid stimulation as well as the staging of motor seizure are
similar to those described above.
Stimulation of the left amygdala was done once daily, beginning
on the 8th post-operative day. Bromocryptine was given daily in a
dose of 20 mg/kg, (i.p.) at 9.30 a.m. Control rats received an
equivalent volume of vehicle intraperitoneally. Stimulation was
done 4 hours after the injection when the effect of bromocryptine
on behaviour was marked. The rats appeared to have recovered
from the effect of bromocryptine after 24 hrs of each injection.
In this experiment the number of amygdaloid stimulations
of
required to elicit the different stages/motor seizure was determined
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for 8 bromocryptine-treated and 7 control rats. Furthermore,
the duration of the evoked afterdischarge was recorded after each
stimulation session (in sees) starting from the point of stimulation
of each rat.
2. Apomorphine and the rate of kindling
Eighteen male Wistar rats were used in this experiment, of which
13 rats reached stage 5 seizure. Seven of these rats were
apomorphine-treated and 6 were saline-injected controls. The
operative procedure, post-operative care, stimulation parameters
and staging of seizure were similar to those described before.
Daily stimulation was begun once daily on the 8th day. Apomorphine
was given daily at 10.00 a.m. in a dose of 2 mg/kg i.p. Control
rats received an equivalent volume of saline, i.p. Stimulation
was done twenty minutes after the injection when the effect of
apomorphine on behaviour was marked. Rats recovered from the drug
effect after 1 hr of its administration. In this experiment also,
the number of stimulations required to produce a generalized seizure
in 7 apomorphine-treated and 6 saline-treated controls was determined.
Moreover, the duration of elicited afterdischarge was measured for
each rat.
B. ACUTE EFFECT OF SOME DOPAMINE AGONISTS ON AFTERDISCHARGE
THRESHOLD AND DURATION
These experiments were done on rats kindled during previous
experiments. At this stage, the afterdischarge threshold is much
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more stable than that seen in the early stages of kindling
stimulation, and any alterations in the level of the threshold
might be more easily detectable.
1. Effect of bromocryptine on afterdischarge threshold and duration
Seven of the kindled rats in the previous bromocryptine
experiment were used for testing the afterdischarge threshold on
6 consecutive days. On the first day the threshold was measured in
the non-drugged stage. On the 4th day the threshold was determined
4 hrs after bromocryptine (20 mg/kg i.p.) administration. On each
of the following two days the threshold was tested in the non-drugged
state. The afterdischarge duration (in sees) was measured after
each stimulation.
The threshold was determined as follows: Each animal was
stimulated several times with 15 min periods of rest between
stimulations. The intensity of the stimulating current was varied
while all other parameters of stimulation remained the same as
in the previous experiment. The current intensity of the first
stimulation train was 40 yA. Stimulation intensity was increased
by 20 yA steps on each subsequent stimulation until an afterdischarge
was elicited. The lowest current at which the afterdischarge was
observed was considered to be the afterdischarge threshold. On
the second day the same procedure was repeated to assess the
stability of the threshold. On the 3rd day, all rats were given
an initial stimulation of their individual afterdischarge threshold.
The current intensity was then raised by 20 yA steps if no after-
discharge was produced, or it was lowered by 20 yA if one was seen.
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This procedure was continued until afterdischarges were evoked
for the ascending series, or were no longer observed in the
descending series. Again, the lowest current at which they were
observed was taken as the afterdischarge threshold.
On these 3 days, once the afterdischarge threshold was deter¬
mined, the duration (in sees) of the ensuing afterdischarge was
measured.
On the 4th day, rats received bromocryptine in a dose of
20 mg/kg intraperitoneally. The same procedure for determination of
afterdischarge threshold as that on the 3rd day was followed 4 hrs
after bromocryptine administration when its effect on behaviour was
marked. The duration of the evoked afterdischarge was also
measured. The same procedure for determination of afterdischarge
threshold and duration was followed on the next 2 days to detect
any recovery or change in the threshold.
2. Effect of apomorphine on afterdischarge threshold and duration
Seven experimental rats that were kindled from the previous
apomorphine experiment were used for testing the afterdischarge
threshold and duration on 5 consecutive days. The parameters of
stimulation and the design of the experiment was the same as that
described with bromocryptine, except that the rats received apomorphine
in a dose of 2 mg/kg i.p. on the 4th day and stimulation was done 20
min after the injection when the effects of apomorphine on behaviour
were marked.
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3. Effect of L-DOPA pretreatment on the afterdischarge
threshold and duration
Six experimental rats kindled from previous experiments were
used for testing the afterdischarge threshold and duration on 5
consecutive days. Essentially, the design of the experiment is
the same as that described for apomorphine. However, L-DOPA was
given in a dose of 250 mg/kg i.p. on the 4th day„ When the
behavioural effects with this dose, i.e. bristling of fur and increased
locomotion, were seen after 20 min, stimulation of the amygdala was




1. AFTERDISCHARGE THRESHOLD AND KINDLING
The rats developed afterdischarge on the first day of stimulation.
The threshold current for afterdischarge showed a progressive reduction
with the progression of kindling stimulations. During the early
stages the threshold was variable between different rats, and in the
same rat at different occasions. However, as kindling progressed, the
threshold became more stabilized with the development of different stages
of the seizure, and was quite stable when generalized convulsion occurred.
Fig. 30A shows the evolution of the afterdischarge threshold in each
of 6 rats in the experiment. Generalized convulsions (stage 5)
occurred after 8 to 12 stimulations.
Stage 1 seizure occurred after an average of 2.5 stimulations
(n = 6), the mean afterdischarge threshold at this stage was 140 yA
*
22 S.EM, (see Fig. 30B).
Stage 3 seizure occurred after an average of 6 stimulations (n = 6)
the mean threshold for afterdischarge at this stage was 86 pA t 16 S.E.M.
(see Fig. 30B).
Stage 5 seizure occurred after an average of 9.5 stimulations (n = 6)
the average threshold for afterdischarge at this stage was 55 pA t 10 S.E.M.
(see Fig. 30B).
2. RESULTS OF TYROSINE HYDROXYLASE IN KINDLING
A. ANIMAL EXPERIMENT
All rats developed afterdischarges on the first day of stimulation
Fig 30A 178a.
Showing the changes in after discharge threshold




















































q Stage 1 = Jaw movement
□ Stage 3 = Contralateral forelimb
clonus




Average Number of Stimulations
Fig 31A 178c.
Number of stimulations required for different stages of seizure
development in kindling n = 7




Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
Stage of Kindling Convulsion
Fig 31 B
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Duration of after discharge (in sec) during the different stages
of seizure development in kindling n = 7
- Rats were subsequently used for tyrosine hydroxylase assay





of the amygdala. The early stages of motor seizures were seen
after few stimulations in most rats. In 2 rats, however, mouth
twitches and head nodding were evident on the first stimulation.
All rats developed generalized convulsions after 9 to 13 days of
daily amygdaloid stimulations. The pattern and rate of seizure
developed and the spread of afterdischarge was similar to that seen
with kindling induced by stimulation of the amygdala. Figures 31A
and 31B show the average number of stimulations required for the
development of different stages of kindling convulsions in this
group of rats, and the mean duration of afterdischarge at these
stages, respectively.
B. BIOCHEMICAL ANALYSIS
Tyrosine hydroxylase in brain area of unoperated control rats
was not significantly different from the normal levels reported by
other workers (Uretsky § Iversen, 1970). The results of tyrosine
hydroxylase activity in the amygdala of the 3 groups of rats studied
are shown in Table 18 and the Summary table. Analysis of variance
showed no significant difference in the enzyme activity in the
right and left amygdalae of both sham-operated and unoperated control
rats. The data, however, showed a persistent and significant red¬
uction in enzyme activity in the left stimulated, but not the contra¬
lateral amygdala of all kindled rats in comparison to controls (Two-
way Analysis of variance, F-distribution, P = 0.05). This
reduction in enzyme activity was significant at the level of P< 0.002
in comparison
(Mann-Whitney D test, two-tailed, u = 3)/to that of the contralateral
side. However, no correlation was found between the reduced enzyme
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SUMMARY TABLE
TYROSINE HYDROXYLASE ACTIVITY (nMol 3H-L-DOPA £ormed/hr/g wet weight)
IN DIFFERENT BRAIN REGIONS IN AMYGDALOID KINDLED RATS
- each value represents the mean activity + S.E. (n)
Right Left
Amygdala
Kindled (7) 1.96 + 0.13 #1.31 + 0.09*
Sham-operated (7) 2.11 + 0.17 #2.10 + 0.15
Unoperated (7) 1.95 + 0.10 1.98 + 0.07
Hippocampus
Kindled (6) 0.36 + 0.02 0.34 + 0.04
Sham-operated (6) 0.38 + 0.03 0.42 + 0.02
Unoperated (6) 0.38 + 0.02 0.40 + 0.03
Hypothalamus
Kindled (6) 4.17 + 0.28 3.58 + 0.28
Sham-operated (6) 4.31 + 0.19 4.45 + 0.25
Unoperated (6) 5.01 + 0.18 4.89 + 0.27
Thalamus
Kindled (6) 1.13 + 0.11 0.82 + 0.16
Sham-operated (6) 0.89 + 0 .10 0.88 + 0.10
Unoperated (6) 1.10 + 0.18 0.92 + 0.16
Striatum
Kindled (6) 23.99 + -1.05 21.79 + 0.68
Sham-operated (6) 25.02+1.63 24.62+1.24
Unoperated (6) 23.99+1.66 25.14+1.85
Cortex
Kindled (7) 0.28 + 0.01 0.26 + 0.02
Sham-operated (7) 0.27+0.02 0.27+0.02
Unoperated (7) 0.27 + 0.02 0.28 + 0.02
# Site of electrode implantation into the left amygdala
* P< 0.002 for comparison of right and left sides (Mann-Whitney-U-test)
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TABLE 18
TYROSINE HYDROXYLASE ACTIVITY (nMol 3h-L-DOPA/hr/g wet tissue weight)
IN THE AMYGDALA OF KINDLED RATS
Kindled Sham-operated Unoperated
]"s"'" Rats Controls Controls
Right Left* Right Left* Right Left
1 2.04 1.58 2.33 2.31 1.85 1.92
2 2.23 1.58 1.83 2.07 1.90 1.94
3 1.65 1.07 1.46 1.66 1.74 1.95
4 1.63 1.03 2.53 2.13 2.31 2.15
5 2.36 1.56 2.43 2.22 2.22 2.16
6 2.38 1.40 2.66 2.82 2.13 2.12
7 1.44 0.97 1.57 1.48 1.51 1.60
Mean 1.96 1.31# 2.11 2.10 1.95 1.98
+ S.E.M. 0.13 0.09 0.17 0.15 0.10 0.07
Two-way analysis of variance showed the enzyme activity to be
significantly reduced in the left stimulated amygdala of kindled
rats (F-distribution, P = 0.05) in comparison to that of the right
amygdala of the 3 groups of rats.
*
Site of implanted electrode (left amygdala)




TYROSINE HYDROXYLASE ACTIVITY (nMol 3H-L-DOPA/hr/g wet tissue weight)








Right Left Right Left Right Left
1 0.02 0.29 0.38 0.42 0.46 0.42
2 0.35 0.28 0.40 0.38 0.38 0.44
3 0.34 0.54 0.51 0.52 0.34 0.52
4 0.34 0.36 0.34 0.42 0.47 0.46
5 0.47 0.30 0.31 0.37 0.32 0.39
6 0.32 0.31 0.39 0.47 0.38 0.41
7 - - - - - -
Mean 0.36 0.34 0.38 0.42 0.38 0.40
+ S.E.M. 0.02 0.03 0.03 0.02 0.02 0.03
The differences in enzyme activity between the three groups of
rats were not statistically significant (Analysis of Variance)
(-) sample lost during the assay
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TABLE 20
TYROSINE HYDROXYLASE ACTIVITY (nMol 3H-L-DOPA/hr/g wet tissue weight)








Right Left Right Left Right Left
1 3.94 3.43 3.71 3.72 4.42 3.66
2 2.99 3.69 3.74 4.11 5.35 5.12
3 3. 80 2.63 4.43 3.83 4.70 4.82
4 4.97 4.52 4.54 4.81 4.96 5.59
5 4.94 2.96 5.05 5.48 5.75 5.56
6 4.36 4.30 4.37 4.76 4.86 4.46
7 - - - - - -
Mean 4.17 3.58 4.31 4.45 5.01 4.89
+ S.E.M. 0.28 0.28 0.19 0.25 9. 18 0.27
The differences in enzyme activity between the three groups of
rats were not statistically significant
(-) = sample lost during the assay
179e.
TABLE 21
TYROSINE HYDROXYLASE ACTIVITY IN STRIATUM OF KINDLED RATS
- enzyme activity in nMol ^h-L-DOPA formed/hr/g wet tissue weight
- S.E. = standard error of the mean
Number of Kindled Sham-operated Unoperated
tissue sample Rats Controls Congrols
Right Left Right Left Right Left
1 24.85 20.86 27.74 27.53 26.00 30.68
2 25.92 23.65 29.31 28.26 20.48 23.93
3 22.61 20.12 22.93 23.02 19.34 21.60
4 23.45 24.52 20.33 19.29
*
21.40 18.91
5 27.58 20.74 25.32 25.99 25.50 24.38
6
7
19.53 20.89 24.48 23.61 31.23 31.34
Mean 23.99 21.79 25.02 24.62 23.99 25.14
+ S.E. 1.05 6.68 1.63 1.24 1.66 1.84
The differences in enzyme activity between the three groups of rats were
not statistically significant (Two-way analysis of variance, F-distribution)




TYROSINE HYDROXYLASE ACTIVITY (nMol 3H-L-DOPA/hr/g wet tissue weight)








Right Left Right Left Right Left
1 0.28 0.22 0.23 0.27 0.26 0.23
2 0.27 0.28 0.31 0.35 0.36 0.41
3 0.37 0.33 0.23 0.22 0.32 0.30
4 0.29 0.20 0.36 0.33 0.36 0.31
5 0.28 0.34 0.26 0.25 0.26 0.27
6 0.21 0.23 0.23 0.25 0.28 0.27
7 0.24 0.25 0.24 0.22 0.20 0.22
Mean 0.28 0.26 0.27 0.27 0.29 0.28
+ S.E.M. 0.01 0.02 0.02 0.02 0.02 0.02
The differences in enzyme activity between the three groups of
rats were not significant (Analysis of Variance)
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TABLE 23
TYROSINE HYDROXYLASE ACTIVITY (nMol 3H-L-DOPA/hr/g wet tissue weight)








Right Left Right Left Right Left
1 1.54 1.63 1.07 1.12 1.34 0.87
2 1.21 0.82 0.73 0.56 1.86 1.61
3 0.76 0.70 0.67 0.58 0. 79 0.67
4 0.88 0.75 0.60 0.83 1.29 1.20
5 1.40 0.61 1.25 1.21 0.54 0.48
6 0.99 0.41 1.01 0.99 0.78 0.69
7 - - - - - -
Mean 1. 13 0.82 0.89 0.88 1. 10 0.92
+ S.E.M. 0.11 0. 16 0. 10 0.10 0.18 0.16
The differences in enzyme activity between the three groups of
rats were not statistically significant
(-) = sample lost during the assay
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activity and the pattern or rate of seizure development or the
duration of the evoked afterdischarge.
No significant differences was found in tyrosine hydroxylase
activity in the hippocampus, thalamus, hypothalamus, striatum
and frontal cortex on the right and left sides of both implanted
and unoperated control rats (see Tables 19-23 and Summary table).
In kindled rats, no significant difference was found in the
enzyme activity in the hippocampus thalamus and frontal cortex on
both sides of the brain. However, although the enzyme activity
tended to be reduced in the striatum and hypothalamus, this
reduction was not statistically significant in kindled rats.
3. EFFECT OF DOPAMINE AGONISTS ON KINDLING
A. EFFECT ON THE RATE OF KINDLING
(Figs. 32A, B 8 C, Figs. 33A, B 5 C), The onset of motor
seizure was not significantly different in drug-treated and control
rats (Mann-Whitney-U-test). The mean number of stimulations required
to elicit stage 1 seizures was 3.6 (n = 8) for bromocryptine-treated
and 2.7 (n = 7) for the apomorphine-treated in comparison to
3.7 (n = 7) for vehicle-treated, and 2.6 (n = 6) for saline-injected
controls, respectively. Similarly, the average duration of after-
discharge at stage 1 was 32.6 (n = 8) sec for bromocryptine-treated
and 47.8 (n = 7) sec for apomorphine-treated, in comparison to 35
sec (n = 7) for vehicle-treated and 43.4 (n = 6) sec for saline con¬
trols, respectively. The differences were not statistically signifi¬
cant (Mann-Whitney-U-test).
The development of stage 3 seizure, i.e. contralateral forelimb
Effectofchronicadministrationbromocryp ne(20g/kgi.p.daily)t enumb rf











Fig 32 B 180b.
Effect of chronic administration of bromocryptine
(20 mg/kg i.p.) on the duration of after discharge
(in sec) during different stages of seizure development




Stage 1 (Mann.Whitney, U = 23, P = 0.306)
" 3 ( " " , U = 20, P = 0.198)
5 (
A






Stage 1 Stage 3













Fig 32 C 180c.
Rate of increase in after discharge duration
following bromocryptine (20 mg/kg i.p. daily)
administration in rats kindled by daily
amygdaloid stimulation.





Day 2 (Mann. Whitney, U = 22, p = 0. 347)
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clonus, was not significantly different in drug-treated and control
rats (Mann-Whitney-U-test). The average number of stimulations
required to elicit this stage of seizure was 5.75 (n = 8) for
bromocryptine-treated and 5„86 (n = 7) for apomorphine-treated, in
comparison to 6,6 (n = 7) for vehicle-treated and 6.33 (n = 6) for
saline controls, respectively.The average duration of afterdischarge
at this stage was 75.6 (n = 8) sec for bromocryptine-treated and
77.4 (n = 7) sec for apomorphine-treated in comparison to 98.3 (n = 7)
sec for vehicle-treated and 66 (n = 6) sec for saline-injected
controls respectively. The differences were not statistically
significant (Mann-Whitney-U-test).
Moreover, the average number of stimulations required to elicit
generalized convulsions (stage 5) was 7.4 (n = 8) for bromocryptine-
treated and 9.86 (n = 7) for apomorphine-treated in comparison to
9 (n = 7) for vehicle-treated and 9.83 (n = 6) sec for saline controls,
respectively. The differences were not statistically significant
(Mann-Whitney-U-test). The average duration of afterdischarge at
this stage was 135 sec (n = 8) for bromocryptine-treated and 117 sec
(n = 7) for apomorphine-treated, in comparison to 160 sec (n = 7)
in vehicle-treated and 134 sec (n = 6) in saline-treated control
rats, respectively. The differences were not statistically
significant (Mann-Whitney-U-test).
It might be worth to mention that in spite of increment in
the afterdischarge duration, it remained variable between rats and
in the same rat as the final stages of kindling convulsions were
approached. This is in contrast to the more stable lowered
afterdischarge threshold at that period, as already seen in the
previous experimentation
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The effect of chronic administration of apomorphine
(2 mg/kg i.p. daily) on the rate of increase in after discharge
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on the afterdischarge threshold.
Moreover, there was no significant difference in the rate of
increase in afterdischarge duration in bromocryptine and apomorphine-
treated rats in comparison to their respective controls. When
compared after an equal number of stimulations, the duration of
afterdischarge was not statistically different between the drug-
treated and control rats (Mann-Whitney-U-test).
Brain tissue sections (30 microns each) showed that the electrode
tracts led to the region of the basolateral amygdala. This was
confirmed in some rats by histological examination of stained sections.
Besides, the pattern of seizure development strongly indicates that
the site of electrode implantation was the amygdala.
B. EFFECT OF DOPAMINE AGONISTS ON AFTERDISCHARGE THRESHOLD AND
DURATION
1. EFFECT ON AFTERDISCHARGE THRESHOLD
The afterdischarge threshold was measured on each of 3
consecutive days and were found to be stable. In the 7 kindled
rats of the bromocryptine experiments, they ranged between 60 to 260
pA with a mean threshold of 142 pA„ In the 7 kindled rats in the
apomorphine experiments, the afterdischarge threshold ranged between
160 to 280 pA with a mean threshold of 203 pA, while in the 6 kindled
rats of the L-DOPA experiments, they ranged between 100 to 240 pA
with a mean threshold of 170 pA„
On the second or third day some rats showed a 20 or 40 pA
increase or decrease while others showed no change in the level of
Fig34A
















































Effect of apomorphine (2 mg/kg i.p.) on the local after discharge
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On the fourth day, the threshold for afterdischarge was
measured 4 hrs after bromocryptine, or 20 min after apomorphine
or L-DOPA, and no significant change was found with either of these
drugs (paired t-test).
With bromocryptine, 3 rats showed no change another 3 rats
showed an increase of 20 pA, while 1 rat showed a decrease of
20 yA in the afterdischarge threshold (see Fig. 34A).
With apomorphine, 4 rats showed no change, 1 rat had a
20 pA increase, while another 2 rats showed a 20 pA decrease in
the afterdischarge threshold (see Fig0 35A).
With L-DOPA 3 rats had no change, 2 had 20 pA increase, while
1 rat had 20 pA decline in afterdischarge threshold (see Fig. 36A).
2. EFFECT ON AFTERDISCHARGE DURATION
The afterdischarge duration (in sec) in the above experiments
was also measured. The afterdischarge duration during the first
3 days of stimulation was less stable than the afterdischarge
threshold. In the 7 kindled rats in the bromocryptine experiment,
the afterdischarge duration ranged between 80 sec and 156 sec, with
a mean duration of 112 sec. In the 7 kindled rats of the apomorphine
experiment, it ranged between 65 sec and 134 sec with a mean duration
of 96 sec, while in the 6 kindled rats of the L-DOPA experiments, it
ranged between 40 sec and 130 sec with a mean duration of 85 sec.
On the fourth day, the afterdischarge duration was also measured
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Effect of apomorphine (2 mg/kg i.p.) on the after discharge duration
in amygdaloid kindled rats
n = 7
* Stimulation was done 20 min
after apomorphine injection
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arousal, stereotypy and pileoerection) were marked. Similarly,
these dopamine agonists produced no significant change in the




, Fig. 37 X Site of electrode implantation into the basolateral
region of the left amygdala (A 4.5 mm, L 4.4mm,
V 7.9 mm), (Konig § Klippel, 1963).
Legend to recorded afterdischarges from the amygdala
Samples of recordings from the stimulated amygdala of
control rats showing the afterdischarge threshold (in
and duration (in sec) during the different stages of
development of amygdaloid kindling.
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Electrographic seizure responses and behavioural convulsions could
be induced by a number of experimental treatments (Purpura et al, 1969).
Some of these treatments would result in permanent alteration in neural
function, and these had been proposed as models for investigation into the
mechanism of neural plasticity (Goddard et al, 1969., Morrel, 1969., Racine,
1972). One such treatment was kindling. At least two independent neural
changes occurred in kindling. First, repeated electrical stimulation
progressively lowered the threshold for epileptiform afterdischarge at
the tip of the electrode., and secondly, once an afterdischarge was generated,
it was propagated with increasing strength to other limbic and motor sites
in the brain (Racine et al, 1972a).
Afterdischarge threshold
In the present work, during the first few stimulations, the after-
discharge threshold in the stimulated amygdala was variable between
different rats at one stimulation session, and in the same rat at different
stimulations. However, later on in the course of kindling development,
there was a progressive reduction in the threshold convulsive after-
discharge, and this was in agreement with the previous work (Racine, 1972a).
This supported the assumption that one of the hallmarks of kindling was
progressive reduction in the convulsive afterdischarge threshold.
The spread of afterdischarge and the motor seizure
The sequence of motor changes induced by amygdaloid kindling included
jaw movements, head nodding, forelimb twitches, rearing,and rearing with
loss of postural control. This sequence was similar to that reported by
other workers (Racine, 1972b). In the present experiments, the duration
of afterdischarge showed a progressive increase with the sequence of
development of motor seizure. This reflected the increased intensity
of spread of the afterdischarge from the site of stimulation to other
motor sites in the brain; hence, the development of different stages of
the motor seizure.
It had been shown that activation of the reticular formation occurred
just before the appearance of generalized seizure in kindling (Wada § Osawa,
1975). Furthermore, electrical changes were detected in the motor cortex
during the early stages of kindling. Similar generalized convulsions to
those triggered by daily amygdaloid stimulation were elicited following
stimulation of the prefrontal cortex in rats (Wada et al, 1974) suggesting
that the cortex participated in kindling convulsions. However, experiments
using aspiration lesions of the prefrontal and orbital cortex showed
retardation of kindling, but did not prevent it, suggesting that these
cortical areas were not essential for the development of generalized
convulsions (McCaughran et al, 1975).
Previous studies showed that the forebrain commissures (corpus
callosum, anterior commissure and hippocampal commissure) are involved in
the propagation of epileptiform activity between various areas of the
cerebral cortices. (Erickson, 1940., Brodal, 1948, McCulloch 8 Garrol, 1941,
Fox 5 Schmidt, 1943, Brodal, 1948, McCulloch 8 Garrol, 1941, Frost et al,
1958, Fox et al, 1948, Simpson, 1952). However, these pathways were
found not critical for amygdaloid kindling in the rat, but they participated
in determining the pattern of seizure development and propagation of after-
discharge to contralateral structures. Sectioning of the corpus callossum
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and hippocampal commissure were reported to produce disruption of the
development of bisymmetrical stage 5 seizure in kindling, and also
caused a severe disruption in the propagation of afterdischarge to the
contralateral frontal and motor cortices. However, the propagation
of afterdischarge to the contralateral amygdala was attenuated only by
bisection of all three commissures. Moreover, regardless of the extent
of forebrain bisection, bilateral discharges were reported in the
mesencephalic reticular formation (McCaughran et al, 1978a). Therefore,
it was possible that limbic-brain stem connections might be more function¬
ally involved in amygdaloid kindling than forebrain commissural pathways.
Furthermore, lesion experiments showed that the non-specific thalamic
regions did not participate critically in amygdaloid kindling (McCaughran
et al, 1978b). Since previous studies established a major role for the
non-specific thalamus in partial epilepsy of neocortical origin, then it
could be suggested that the mechanism that underly seizures of neocortical
origin may differ from those of limbic origin.
Catecholamines and acetylcholine in kindling
Several reports suggested cholinergic circuits were involved in
seizure propagation (Jasper, 1969). Some workers have shown that
the daily injection of subconvulsive doses of carbachol into the amygdala
would eventually elicit motor seizures. Some workers showed that atropine
retarded kindling in rats (Arnold et al, 1973), but this was not confirmed
by others (Wada, 1975 - unpublished data). Depletion of central cate¬
cholamine neuro-transmitters by reserpine or 6-OHDA facilited the electro-
graphic and motor seizure responses evoked by repeated amygdaloid stim¬
ulation (Arnold et al, 1973., Corcoran et al, 1974). Moreover, intensific¬
ation and prolongation of the local amygdaloid afterdischarge was reported
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following reserpine administration (Wilkinson 8 Halpern, 1977). This
evidence indicated that catecholamines are inhibitory in some parts
of the central nervous system and may be inhibitory over some cholinergic
circuits (Bloom et al, 1965., Jasper, 1969-, Stein, 1968).
Tyrosine hydroxylase activity as index of catecholamine production in
kindling.
It seems likely that catecholamine-;depletion facilitated the develop¬
ment of amygdaloid seizures by reducing the tonic inhibition within the
limbic system. It was reported that the enduring focal sensitisation in
kindling was attributed in part to a persistent reduction of post-synaptic
inhibitory influences at the site of stimulation (Burnham § Gardner-Medwin,
1974). The reduced tyrosine hydroxylase activity, together with the
reported lowered dopamine, but not noradrenaline content, in the stimulated
amygdala suggested that a reduction of dopaminergic neurotransmission was
involved during the initiation of focal postsynaptic hyperexcitability
changes in amygdaloid kindling. However, this focal reduction of post¬
synaptic inhibition might involve other neurotransmitter systems in
kindling initiated from other sites, such as the hippocampus which virtually
lack dopaminergic innervation . Moreover, the presence of tissue necrosis
at the electrode tip would have inhibited amygdaloid kindling (Goddard et
al, 1969).
Furthermore, no change in tyrosine hydroxylase activity was found in the
contralateral amygdala.hypothalamus as well as the frontal cortex and
thalamus on both sides, which are involved in the spread of amygdaloid
afterdischarge in kindled rats. Similarly, no significant alterations
in enzyme activity was found in the hippocampus which is closely involved
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in amygdaloid kindled afterdischarge (Wada 8 Sato, 1974), but incapable
of producing generalized seizure when stimulated in kindled animals
(Burnham, 1975). The absence of any significant change in catecholamine
production in all brain regions studied, apart from the stimulated
amygdala, does suggest that the mechanisms of spread of afterdischarge
are different from those initiating the focal hyperexcitability in
kindling convulsions. It could consequently be concluded at this stage
that kindling induced a definite, long-lasting reduction in tyrosine
hydroxylase activity at the site of stimulated amygdala.
It might be possible that reduction in tyrosine hydroxylase activity
might reflect damage at the site of the implanted electrode. The lack
of alteration in enzyme activity at a similar site in the sham-operated
control rats would render this explanation unlikely. It is also unlikely
that the low intensity current, used in the stimulation procedure, to
have caused tissue damage. Tissue damage might reduce the local activity
of other transmitter synthesizing ensymes besides that of tyrosine hydroxy¬
lase However, no change in choline acetylase or glutamic acid decarboxy¬
lase were observed at the site of the stimulated amygdala in kindled rats
in comparison to controls (Blackwood, 1976 - unpublished results).
Moreover, no histological evidence of degeneration was reported in the
stimulated amygdala in kindled rats (Brotchie et al, 1978) and no local
evidence of tissue degeneration was seen at the site of stimulation in
the present work with drug experiments.
Some dopamine agonists and kindling
To follow further on the dopamine system in kindling, the effects of
dopamine agonists were assessed. Kindling had been related to systems
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such as the amygdala, hippocampus, cingulate and frontal cortex,
caudate-putamen, nucleus accumbens, olfactory bulb and the septum. All
these areas were post-synaptic to catecholaminergic innervation.
Therefore, it was possible that kindling seizures result from activation
of systems that were normally inhibited by ascending catecholamine
projections. This was in contrast to the self-stimulation procedure
sites which contained either the cell bodies or axonal projection of the
catecholamine system, and in which self-stimulation reward was not com¬
pounded with seizure development.
The dopamine agonists bromocryptine and apomorphine produced no
significant effect on the rate of development of amygdaloid kindling.
Furthermore, dopamine agonists had no effect on the threshold as well as
the spread of afterdischarge. The lack of effect of dopamine agonists
in kindling seemed paradoxical to the expected inhibitory role of dopamine
in the amygdala (Ben-Ari § Kelly, 1976), and the reduced tyrosine hydroxy¬
lase activity seen in the present work. This was also in contrast to the
anti-epileptic effect of dopamine agonists on cortical foci, reported in
Section II of this thesis.
Activation of striatal neurons by dopamine agonists mediated at least
in part the inhibitory effect of dopamine agonists on cortical epileptic
foci induced by cobalt application (Section II). It had been shown that
the caudate nucleus inhibited bioelectrical activity in several brain
regions including the cerebral cortex (Amato et al, 1964) and amygdaloid
nucleus complex (La Grutta et al, 1971), both of which possessed a low
threshold for epileptic phenomena. The striatum gained access to the
limbic system via the lateral habenular nucleus with which it was
connected by pallido-habenular fibers. Moreover, the hippocampus,
amygdala and pyriform cortex project to islands of cells which were
located anterior to the head of the caudate nucleus in the nucleus
accumbens, and the nucleus stria terminalis0 However, the ineffective¬
ness of dopamine agonists, as well as the unaltered tyrosine hydroxylase
activity in the striatum suggested that the striatum neither inhibited
nor did it participate in reducing the focal inhibition at the site
of stimulation in the amygdala. It seemed that sensitization by low
intensity stimulation of the amygdala caused alterations of the postsynaptic
receptor population in the stimulated amygdala which rendered then un¬
responsive to striatal stimulation as induced by dopamine agonists.
Dopamine receptors and kindling
Dopamine receptors had been involved in the regulation of tyrosine
hydroxylase activity and consequently dopamine synthesis and turnover
by the dopaminergic neurons. A post-synaptic location of these
regulating dopamine receptors assumed that their blockdade inhibited a
feed back neuronal loop which when activated reduced the activity of
dopaminergic neurons (Carlsson § Lindquist, 1963, Bunney et al, 1973a and
b). An alternative hypothesis assumed that the dopamine receptors which
regulated the activity of tyrosine hydroxylase were located presynaptically
ac dopaminergic terminals (autoreceptors). Without involvement of inter¬
mediate synaptic relay (Kehr et al, 1972) small doses of dopamine agonists
bind to those autoreceptors in producing their inhibitory behavioural
effects, as well as reducing the activity of tyrosine hydroxylase. Larger
doses, however, bind to post-synaptic receptors in producing their enhanced
behavioural effects as well as effecting a further reduction in tyrosine
hydroxylase activity (Carlsson et al, 1976).
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Some workers suggested that dopamine sensitive adenyl cyclase
located in dopaminergic axonal terminals regulated the kinetic state of
tyrosine hydroxylase in the striatum. This view was based on in vitro
findings that cyclic adenosine monophosphate (c AMP) increased dopamine
synthesis when added in high concentrations to striatal slices or
synapotosomes, probably by increasing the affinity of tyrosine hydroxy¬
lase to its pteridine co-factor (Harris et al, 1974). However, in vivo
experiments failed to support this theory (Zivkovic et al, 1975). It
is possible that the state of membrane polarization or the frequency of
membrane polarity changes might influence the kinetic state of tyrosine
hydroxylase through a change in the cyclic AMP content in the nerve
terminal cytosol.
The reduction of dopamine content in the stimulated amygdala in
kindled rats reported by Engel § Sharpless (1977) could be due to increased
dopamine release and inactivation or to reduced catecholamine production.
The finding of reduced tyrosine hydroxylase activity in this region
supported the latter possibility. Furthermore, since the noradrenaline
content was reported to be normal in the stimulated amygdala, it seemed
that this reduction affected the enzyme activity in dopaminergic neurons.
This manifested itself as about 30% reduction in total enzyme activity in
catecholaminergic terminals in the stimulated amygdala as measured by the
present method of assay, in comparison to the contralateral side and to
controls.
It could be possible that repeated stimulation by low intensity
current affected reduction in tyrosine hydroxylase activity and dopamine
production by stimulating the pre-synaptic dopamine autoreceptors and/or
affecting the polarization of axonal membrane. Activation by the
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stimulating current of post-synaptic and/or internuncial neurons involved
in the post-synaptic feedback neuronal control of dopamine synthesis might
also be a contributory factor. It is well known that neuronal activity
at any one time depends on the net balance exerted upon it by inhibitory
and excitatory influences (Goddard et al, 1969). Since dopamine is an
inhibitory transmitter in the amygdala (Ben-Ari & Kelly, 1976), then a
reduction in dopaminergic neuro-transmission post-synaptically would
contribute, at least in part, to the persistent hyperexcitability changes
in post-synaptic neurons at the site of stimulation. These changes would
be manifested by lowering of the afterdischarge threshold between successive
stimulation, as well as the development of interictal discharges between
stimulations. Thus, the reduction of tyrosine hydroxylase activity could
be secondary to alteration in pre-synaptic events with more contribution
from post-synaptic feedback mechanisms as the post-synaptic neurons become
progressively hyperexcitable with possible alteration in receptor mechanisms,
resulting from repeated stimulations.
However, if reduced dopamine release and transmission was the only
factor, then it would be expected for dopamine agonists to exert some
inhibitory effect at the post-synaptic receptors, which is not the case.
It might be worth, at this stage, to describe the dopamine receptor
binding in the amygdala.
Using [^H] dopamine and [^H] haloperidol it was shown that [%]
haloperidol binding in the amygdala was about 30% of that of the striatum
and 50% of that of the olfactory tubercle, while [^H] dopamine binding
sites were much less abundant (Creese et al, 1975). This suggested that
dopamine receptor binding in the amygdala existed mainly in the antagonistic
state. Thus, it might be possible that repeated sensitization with low in¬
tensity
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current could have altered the structural configuration and/or
reduced; the agonist binding sites post-synaptically so as to interfere
with their binding or response to endogenous or exogenous dopamine and
dopamine agonists. This could also explain the reported lack of effect
of amphetamine on amygdaloid afterdischarge in kindling (Kamei et al, 1977).
It could also be possible that the antagonistic state of the dopamine
receptors had been augmented by repeated stimulation. This assumption
might be supported by the finding that the dopamine receptor blockers,
chlorpromazine and haloperidol, increased the duration of afterdischarge
and reduced its threshold in amygdaloid kindled rats (Kamei et al, 1977.,
Schmitt, 1967).
It is well known that if kindling stimulations were continued,
spontaneous convulsions would be initiated (Goddard et al, 1969). This
might be due to severe reduction in post-synaptic inhibition associated
with marked hyperexcitability of post-synaptic membranes which might lower
the threshold for afterdischarge to the extent that normal excitatory
impulses arriving at the hyperexcitable synapses would initiate epileptic
changes and thus motor seizure. These impulses could be mediated by
cholinergic and possibly noradrenergic neurotransmission. Moreover, it
might also be possible that changes of local post-synaptic receptor
mechanisms might lead to the acquisition of self-stimulating properties by
post-synaptic neurons. Some workers have already suggested that in any
kindling process, an excitatory-inhibitory coupling, together with
excitatory self-stimulation should be searched for (Morrel q Tsuru, 1976,
Lieblich § Amari, 1978)„
Another important feature is the facilitation of synaptic transmission
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which accounted for the spread of afterdischarge in multiple neuronal
circuits in kindling. This was referred to as enhanced electrical
fluidity. At pathologically high levels of electrical fuidity, an
electrical event occurring at any point in a neuronal matrix would be
transmitted throughout that matrix, such that every cell would be
stimulated by every other cell. It might also be that the learning
process and memory consolidation resulted from a controlled increase of
electrical fluidity in specific neuronal circuits, thus mimicking the
kindling phenomenon to some extent.
It was reported that tricyclic anti-depressants inhibited the local
afterdischarge in kindling. These drugs would inhibit the active re-uptake
of the released catecholamines and 5-HT into the axonal terminals. It
could be possible that their effect was mediated by 5-HT mechanisms, since
the amygdala is also known to contain high concentrations of this neuro¬
transmitter. However, there is no evidence yet of any specific alteration
in 5-HT neurotransmission in amygdaloid kindling.
Functional linking hypothesis and kindling
Some workers described a first approximation model which accounts
for the strongest phenomena defining kindling (Lieblich § Amari, 1978).
This model was based on excitation-inhibition coupling of neural aggregates,
to which a self-stimulation element of the excitatory aggregate was added.
The functional linking hypothesis viewed the representation of kindling
as a process of gradual transition through structural changes from a stable
system to a system showing stability for small pertuberations and
oscillatory orbit for larger pertuberations, and finally to a persistent
p ely oscillatory system. The anatomical linking hypothesis considered
the main neuronal systems involved in the kindling phenomenon to be
located in the amygdaloid pyriform complex (where kindling is initiated),
the hypothalamus, and the hippocampal-septal-preoptic system, respectively.
It is well known that the amygdala is connected via the central amygdalo-
fugal pathway and stria terminalis to the hypothalamus, the inhibitory
aggregate representing the hippocampal-septal-preoptic system and the
self-stimulating element of the excitatory aggregate as representing the
amygdaloid pyriform complex.
Stimulation of the hypothalamic aggregate (or reducing its threshold)
in this system retarded kindling from the amygdaloid aggregate, while
reduction of its stimulation potentiated kindling. In addition, the
model showed that kindling would not be possible from the hypothalamus even
with drastic reduction of threshold. Moreover, Callaghan § Schwark (1975)
demonstrated a reduction in noradrenaline content in the hypothalamus
of kindled rats. However, tyrosine hydroxylase activity in the region
showed some reduction in the present work, but this was not significant.
Moreover, it is known that stimulation of the amygdaloid complex produces
afterdischarge in the hypothalamus. The model also showed that stimulation
of the inhibitory hippocampal-septal-preoptic system inhibited and stabilised
kindling, while moderate elevation of its threshold reduced this inhibition
and facilitated kindling. Thus, it is possible for such reduction in
inhibition by this system to occur with repeated amygdaloid stimulation,
and in effect, this would enhance synaptic transmission within and outside
the stimulated area. This factor, together with the development of
hyperexcitability changes and possibly the self-stimulation properties in
the stimulated amygdala, might explain the enhanced spread of afterdischarge
following repetitive stimulation as well as the development of spontaneous
197.
convulsions on continuing stimulation.
Dopamine agonists and cerebral blood flow
Dopamine and dopamine agonists, like apomorphine, are known to
increase the cerebral blood flow, oxygen uptake and metabolic activity
of cortical neurons, which effects were blocked by pre-treatment with
pimozide. These changes were also seen in areas that are lacking in
dopamine receptors such as the cerebellum (Teasdale § McCulloch, 1977.,
McCulloch 5 Harper, 1977). The absence of any significant effect of
dopamine agonists in kindling, and their profound anti-epileptic effect
on cortical foci in cobalt-implanted rats suggested that the mechanism
of action of these drugs was due to dopamine receptor stimulation without
a definite contribution from increased regional cerebral circulation which
they could induce. Furthermore, a reduction in cerebral blood flow was
detected in some atrophic cortical epileptic foci in man (Lavey, Melamed,
Portnoy & Carman, 1977), while increased vascularity was seen in others.
Discharge and spread - possible mechanisms
It seemed from the present and previous work that the small amount
of dopamine in the amygdala was important in the control of neuronal
excitability of this region . It was possible that a similar mechanism
would apply to other sites that were susceptible to the development of
kindling- convulsion. Disturbances leading to a reduction of its
inhibitory influence at the post-synaptic receptors would facilitate the
initiation or development of hyperexcitability changes and afterdischarge
response to minimal stimuli. These stimuli repeated at optimal
intervals might culminate in the development of generalized convulsions
resulting from the spread of afterdischarge to secondary sites.
The lack of changes in catecholamine production at sites other
than the stimulated amygdala would suggest that non-catecholaminergic
mechanisms were involved in the spread of afterdischarge from the site
of stimulation. Cholinergic transmission might be a candidate for such
a mechanism of spread. However, the results of inhibiting cholinergic
transmission with atropine were diverse (Arnold et al, 1973, Wada, 1975)
in postulating that it would delay the propagation of kindling after-
discharge, but activation of the cholinergic reticular formation is known
to occur prior to the development of generalized seizures in kindling?
Inhibition of multi-synaptic transmission in this reticular system
might well explain the prophylactic value of diazepam in this model.
Moreover, there is evidence that gabbaminergic transmission might
be involved in the mechanism of seizure spread. Valproic acid is known
to increase the concentration of brain gamma aminobutyric acid (GABA) perhaps
by inhibiting the enzyme GABA-transaminase (Godin et al, 1969., Smiler
et al, 1973). Valproic acid was found to retard the development of kindling.
However, it did not prevent the propagation of afterdischarge element to
the frontal cortex. Moreover, valproic acid was found to prevent the
generalization of seizure, and in large doses to inhibit seizures,
altogether in kindled rats (Leviel § Naquet, 1972). Some workers suggested
that GABA counteracted the reduction in the afterdischarge threshold induced
by kindling stimulation (Tanaka § Lange, 1975). Moreover, since the
increase in GABA levels did not prevent focal seizures, and it allowed the
electrographic element of afterdischarge to reach the cortex, it seemed
that GABA acted by preventing the transformation of simple focal discharge
into generalized motor seizure. This, again, shows that the mechanism
underlying the focal afterdischarge and the secondary generalized seizure
are essentially different. The finding of reduced tyrosine hydroxylase
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by kindling stimulation (Tanaka § Lange, 1975) . Moreover, since the
increase in GABA levels did not prevent focal seizures, and it allowed the
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into generalized motor seizure. This, again, shows that the mechanism
underlying the focal afterdischarge and the secondary generalized seizure
are essentially different. The finding of reduced tyrosine hydroxylase
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activity in the stimulated amygdala and absence of significant alteration
in catecholamine production in other brain regions studied support
this assumption further.
Kindling and learning
The fact that kindled behaviour alterations were persistent and might
be permanent (Wada et al, 1974) led to the speculation that kindling and
learning had certain basic mechanisms in common (Gaito, 1974., Goddard
§ Douglas, 1975., Leech § Mclntyre, 1976,, Zaide, 1974). The present
finding of tyrosine hydroxylase activity as well as the previous findings
of local dopamine changes might reveal a plastic property of the cate¬
cholamine projections that could also be invoked to explain aspects of
certain acquired alterations in behaviour. It is well known that
memory and learning involved inhibitory mechanisms (Eccles, 1973), which
could take the form of selectively decreased inhibitory synaptic activity.
The catecholamine system was probably involved in such function due to
its diffuse projections (Fuxe 1965., Jacobwitz § Palkovits, 1974., Lindval
§ Bjorklund, 1974., Sato 5 Nakashima, 1975., Ungerstedt, 1971), and their
plastic properties (Katzman et al, 1971., Moore et al, 1972., Wada § Sato,
1974., Wada et al, 1974). The involvement of catecholamine systems in




HMPG and HVA levels, reflecting noradrenaline and dopamine turnover
respectively, were estimated in the frontal cortex and striatum of cobalt-
implanted epileptic rats. A micromethod was used for this purpose. This
method was precise, specific, and sensitive for the simultaneous measure¬
ment of both metabolites in the small amount of tissue of rat brain.
Previous reports showed dramatic reduction of tyrosine hydroxylase activity
and compensatory reduction in activity of catecholamine catabolising
enzymes in cortical foci and striatum in this model.
No significant change in the concentration of either metabolite was
found in the brain regions studied. It was suggested that impairment
of the saturable transport mechanism and possibly of the enzymatic con¬
jugation of these metabolites due to cellular degeneration and/or cobalt
ion enzyme toxicity prevented the expected reduction in their concentrat¬
ions in those brain regions. It was then concluded that changes in the
concentration of these major catecholamine metabolites did not show and
even could reflect opposite changes of their respective amine turnover
in the presence of tissue degeneration.
Post-mortem studies on brain tissue showed that HVA is much more
stable than HMPG under different conditions after death. This was
possibly due to the greater affinity of the catabolising enzyme for
intermediate catabolites of noradrenaline than those of dopamine, hence
contributing to higher HMPG levels under some of these conditions.
These factors might have contributed to the high HMPG levels previously
reported following cobalt application.
Recent reports in this model in immuno-suppressed animals
showed that cobalt ion is capable of producing
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epileptic changes before the development of substantial cortical or
sub-cortical necrosis or biochemical changes; thus, it seemed that the
biochemical findings in the present and previous works were more due to the
tissue degeneration than to the toxic effect of cobalt on enzyme systems
associated with catecholaminergic neurotransmission.
It also seemed that the earlier onset of cellular degeneration in
cortical foci with possible local denervation supersensitivity facilitated
the development of epileptic changes. The normal concentration of
noradrenaline in epileptic foci, and paralleled by similar findings in
the striatum, could have contributed to the neuronal hyperexcitability in
this model.
To elaborate more on the role of the dopamine system in the cobalt
model of epilepsy, the initial work of Ashcroft et al (1974) was extended
employing different agonists and antagonists.lt was found that apomorphine,
bromocryptine and lisuride all suppressed epileptic activity in a dose-
dependent manner. Lisuride was most potent, followed by apomorphine,
bromocryptine and the least potent was CF 25-397. The chronic admini¬
stration of bromocryptine attenuated the development of epileptic changes,
particularly in the secondary foci. Pimozide, the dopamine receptor
antagonist, potentiated the epileptic activity in cobalt rats, and also
prevented the anti-epileptic effect of dopamine agonists. This is in
contrast to the lack of effect of the anti-cholinergic drug, hyoscine,
previously observed.
Similar anti-epileptic effect for dopamine agonists was also seen
in other forms of sensory epilepsy including the reflex epilepsies and
the later stages of electroshock seizures.
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The intrastriatal administration of dopamine or apomorphine
desynchronized the epileptic cortex while destruction of catecholamine
terminals in striatum potentiated the epileptic changes.
There is evidence that proprioceptive impulses arising from motor
activity play an important role in the evolution of seizure response in
sensory models of epilepsy which include, in addition to the reflex
epilepsies, the focal motor epilepsy such as that induced by cobalt
application to frontal cortex. Thus, it is possible that dopamine agonists
might act directly or indirectly on this recurrent system.
Moreover, since dopamine receptors are not found in the sites of
the primary and secondary foci in frontal cortex, it was suggested that
dopamine agonists induced their anti-epileptic effects,at least in part,
by stimulation of striatal dopamine receptors, in the following ways:
a. increasing the level of arousal by stimulation of ARAS, and
b. modulating the activity of the motor cortex.
These effects were probably mediated by fiber connections of the
striatum with the reticular formation and motor cortex from which the
pyramidal tract originates, as well as through descending extrapyramidal
pathways such as the reticulospinal and tectospinal tracts.
The inhibition of epileptic activity in both cortical epileptic foci
following unilateral intrastriatal injection of dopamine was possibly
mediated by fiber connections between the striatum on both sides via the
thalamus, and then with the motor cortex. This also showed the importance
of the thalamus as a relay station in desynchronizing cortical epileptic
activity, in addition to its reported participation with the corpus
callosum in the propagation of epileptic discharge from the primary focus
as well as its synchronizing effect on cortical epileptic activity.
The role of the dopamine system in subcortical epileptic foci
induced by kindling stimulation was also studied. Previous reports
showed the inhibitory role of catecholamines, in amygdaloid kindling.
In the present work, tyrosine hydroxylase activity was found to be
reduced in the stimulated, but not the contralteral, amygdala or in other
brain regions involved in the spread of afterdischarge in amygdaloid
kindled rats. The reduction of tyrosine hydroxylase activity and dopamine
production could be secondary to repeated alteration of presynaptic events
by the stimulating current, with more contribution from post-synaptic
neurons on becoming progressively hyperexcitable with repeated stimulations.
Since noradrenaline content was reported to be unchanged in the
stimulated amygdala, it is possible that the reduction affected the enzyme
activity associated with dopaminergic neurons. This was reflected as 30%
reduction in the total enzyme activity controlling the biosynthesis of
both catecholamines, as measured in the present method and compared to that
of the contralateral amygdala and controls. It was reported that the
focal sensitization in kindling was associated with the reduction of post¬
synaptic inhibitory influences at the site of stimulation. Dopamine was
reported to be an inhibitory transmitter in the amygdala. The reduced
tyrosine hydroxylase activity, together with the reported lowered dopamine,
but not noradrenaline, content in the stimulated amygdala suggested that a
reduction of dopaminergic neurotransmission was involved during the develop¬
ment of focal hyperexcitability changes in amygdaloid kindling. However,
this focal inhibition might involve other neurotransmitter systems in the
kindling initiated from other sites such as the hippocampus which
virtually lack dopaminergic innervation.
Dopamine agonists produced no significant effect either on the rate
of kindling development or on the afterdischarge threshold and duration in
kindled rats. This finding together with the unaltered tyrosine hydroxy¬
lase activity in the striatum suggested that the striatum neither inhibited
nor did it participate in reducing the focal inhibition at the site of
stimulation in the amygdala. This occurred in spite of the presence
of fiber connections allowing access of the striatum to the limbic system.
Thus it seemed possible that sensitization by low intensity brain stim¬
ulation caused alterations in the number or structural configuration of
the local receptor population in the stimulated amygdala which rendered
them unresponsive to striatal stimulation as induced by dopamine agonists.
The ineffectiveness of dopamine agonists might also be explained by
the presence of dopamine receptor binding mainly in the antagonistic state.
This state might have been perpetuated by the kindling sensitization
procedure, possibly at the expense of agonists binding sites. The fact
that haloperidol was reported to potentiate the spread of afterdischarge
in amygdaloid kindled rats supports this assumption. It is also possible
that sensitization with low intensity current altered the number or
structure of agonist binding sitesof the dopamine receptors which would
render them unresponsive to exogenous or endogenous dopamine or dopamine
agonists.
It is also suggested that the mechanisms involved in the initiation
of afterdischarge (which was implicated with reduced dopaminergic trans¬
mission) are different from those involved in its spread to other brain
regions, which could involve cholinergic and/or gabbaminergic neuro-
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transmission in kindling. It is also possible that reduction in
inhibition by the hippocampal-septal-preoptic system to have contributed
at least in part to the persistence of hyperexcitable changes in the
stimulated amygdala as well as enhancement of synaptic transmission and
spread of afterdischarge in amygdaloid kindling.
It is also possible that repeated electrical stimulation might have
led to the aquisition of self-stimulation properties by the hypersensitive
post-synaptic neurons in the stimulated amygdala. This might explain the
reported development of spontaneous convulsions with continuation of
stimulation in kindled rats.
It is hoped that the above work provided some information on the
role of the dopamine system in cortical as opposed to some subcortical foci
of epilepsy.
It is speculated that some dopamine agonists like bromocryptine
might be useful anti-convulsants in the future. It is also thought that
dopamine receptor binding studies are indicated in kindling. Moreover,
elucidation of the effectiveness of 5-HT transmission in inhibiting
amygdaloid kindling might also be required.
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Reduction in tyrosine hydroxylase activity in the rat amygdala induced by
kindling stimulation
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Kindling, as described by Goddard et al.7 involves electrical stimulation of certain
brain structures, in particular the amygdala in the limbic system, until a previously
ineffective stimulus comes to elicit a full motor seizure. Kindling has become an im¬
portant experimental model for the study of cpilcptogcncsis11-17. However, the me¬
chanisms underlying kindling arc still largely unknown. Some studies have suggested
that catecholamine in the brain are inhibitory to kindling1, and to seizures in general13.
It has been shown that cortical noradrenaline and dopamine levels are reduced in the
brain of kindled cats15. Furthermore, it has been suggested that dopamine is an in¬
hibitory transmitter in the amygdala2-12. More recently, it has been shown that unilate¬
ral lesion of the stria terminalis which contains the catecholaminc-inhibitory afferents
to the amygdala facilitates the early stages of development of kindling induced by ipsi-
lateral amygdaloid stimulation in rats5. Moreover, the dopamine content was found
to be locally reduced at the site of the stimulated amygdala in kindled rats6. However,
other workers have reported a reduction in noradrenaline content in the hypothalamus
but found no change in brain dopamine levels in kindled rats1.
In the present study, the activity of the enzyme tyrosine hydroxylase, the rate-
limiting step of catecholamine biosynthesis11-16, was measured in the amygdala and
other brain regions in rats kindled by amygdaloid stimulation.
Twenty-one male Wistar rats, 180-200 g in weight, were used for this study; 7 of
these rats served as unoperated controls. Under halothane anaesthesia, the left baso-
lateral amygdalae of 14 rats were stereotaxically implanted with bipolar stimulating
electrodes of nichrome wire. The coordinates were: 4.5 mm anterior to the interaural
line, 4.4 mm lateral to the midline, and 7.9 mm deep to the cortical surface10. Rats
were allowed one week for recovery and daily stimulation was begun on the eighth day.
The rats were divided into two groups. Seven were stimulated and 7 were non-stimulated
sham controls. To the stimulated rats, a suprathreshold constant current, ranging
between 100 300 /rA, and consisting of trains of I msec biphasic square wave pulses
at a frequency of 60 Hz, was delivered for one second daily via the stimulating electrode
* I. B. Farjo is on a Ph. D grant from the College of Medicine, University of Baghdad, Iraq.
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using a constant current physiological stimulator (Farncll). Electrical activity was
recorded from the amygdala on a Grass polygraph (model 7) before and after stimulus
delivery and the duration of the ensuing afterdischarge was measured. Daily stimulation
was continued until a generalised convulsion developed14 on 3 consecutive days.
The 7 experimental rats demonstrated afterdischarges on the first day of stimulation,
and developed generalised convulsions between 9 and 13 days. The pattern of de¬
velopment of kindling did not differ from that reported by other workers7'14.
For weeks after the last stimulation, rats were killed by decapitation and their
brains dissected out quickly on a cold stage at 4 "C. The following dissection was done
with the aid of the dissecting microscope. The entire hippocampus was carefully
dissected out on both sides of the brain. Two vertical cuts were then made from the
inferior surface of the brain; the first at the level of the optic chiasma (A 5500 //m)10
and the second at the level of junction of the cerebral peduncles with the base of the
cerebral hemispheres (A 3000 /<m)10, thus dividing the brain into 3 parts. From the
anterior part, tissue portions were taken from the frontal cortex and striatum on both
TABLE I
Tyrosine hydroxylase activity ninole [*H L-DOPA formed/big wet wt.) in different brain regions in
amygdaloid kindled rats
Each value represents the mean activity L S.E. (n).
Right Left
Amygdala
Kindled (7) 1.96 + 0.13 1.31 ± 0.09*'**
Sham-operated (7) 2.11 1 0.17 2.10 i 0.15*
Unoperatcd (7) 1.95 ± 0.10 1.98 ± 0.07
Hippocampus
Kindled (6) 0.36 I 0.02 0.34 t 0.04
Sham-operated (6) 0.38 + 0.03 0.42 ± 0.02
Unopcrated (6) 0.38 I 0.02 0.40 .1 0.03
Hypothalamus
Kindled (6) 4.17 I 0.28 3.58 ± 0.28
Sham-operated (6) 4.31 t- 0.19 4.45 ± 0.25
Unopcrated (6) 5.01 I 0.18 4.89 I 0.27
Thalamus
Kindled (6) 1.13 ± 0.1 1 0.82 ± 0.16
Sham-operated (6) 0.89 | 0.10 0.88 I 0.10
Unopcrated (6) 1.10 I 0.18 0.92 ± 0.16
Striatam
Kindled (6) 23.99 | 1.05 21.79 ± 0.68
Sham-operated (6) 24.02 ± 1.63 24.62 ± 1.24
Unoperatcd (6) 23.99 rh 1.66 25.14 : 1.85
Cortex
Kindled (7) 0.28 L 0.01 0.26 ± 0.02
Sham-operated (7) 0.27 I 0.02 0.27 T 0.02
Unoperated (7) 0.27 ± 0.02 0.28 ± 0.02
* Site of electrode implantation into the left amygdala.
* * /' 0.002 for comparison of right and left sides (Mann Whitney U-tesl)
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sides. From the middle part, both amygdalae were dissected out under the dissecting
microscope. Tissue portions from the hypothalamus and thalamus were then taken.
Kindled, implanted and unopcratcd control rats were treated together in till phases of
sacrifice and biochemical analysis. Tissue samples were stored in liquid nitrogen before
the subsequent biochemical estimation of tyrosine hydroxylase activity.
Tissues were homogenised with 20 mM potassium phosphate buffer, pH 7.4, so
that 10 fi\ buffer was used for each 1 mg tissue. Homogenates of tissue samples were
assayed, in duplicates, for tyrosine hydroxylase activity according to the method of
Hendry and Iversen (1971 )8. Tissue and reagent blanks, in duplicate, were assayed
simultaneously with tissue samples. Recovery was estimated by taking 10 /d of [:1IIJi -
DOPA (specific activity 2.5 Ci/mmolc, Radiochemical Centre, Amcrsham) through
the assay, in duplicate, and compared to 10 //I [:,H]i.-DOPA counted directly tiller the
addition of scintillant. The estimated percentage recovery of the method ranged be¬
tween 49 and 52%. The counting efficiency of tritium was estimated to be 34%.
The results of assaying the enzyme activity are shown in Table I.
Tyrosine hydroxylase activity in brain areas of unopcratcd control rats were not
significantly different from the normal levels previously reported". An analysis of
variance showed no significant difference in the enzyme activity in the amygdala of
both the sham-operated and unopcrated control rats. However, the data showed a
consistent and a significant decrease in tyrosine hydroxylase activity in the left stim¬
ulated, but not the contralateral, amygdala of all kindled rats. This reduction in enzyme
activity was significant at the level of P < 0.002 (Mann- Whitney U-test, U 3)
when compared to that of the contralateral amygdala. However, no correlation was
found between the reduced enzyme activity and the rate of seizure development or the
duration of the evoked afterdischarge.
No significant difference was found in tyrosine hydroxylase activity in the hippo¬
campus, thalamus, hypothalamus, frontal cortex and striatum on the right and left
sides of both implanted and unoperated control rats. Similarly, no significant differ¬
ence in the enzyne activity was found in the hippocampus, thalamus, frontal cortex
on both sides of the brain in kindled rats. However, the enzyme activity tended to be
reduced in the hypothalamus and the striatum in kindled rats, but this reduction was
not statistically significant.
The fact that tyrosine hydroxylase activity is significantly reduced at the site of
stimulation might suggest that a persistent reduction in catecholamine production is
implicated in reducing inhibition with consequent focal hyperexcitability changes in
the stimulated amygdala in kindled rats. It has already been shown -that kindling-
induced hypersensitivity may result, in part, from a persistent decrease in postsynaptic
inhibitory influences3. The absence of any significant change in catecholamine pro¬
duction in other brain regions studied might suggest that the mechanisms underlying
the spread of the afterdischarge are different from those initiating the focal hyper-
excitability in kindling convulsions.
Consequently, it is concluded that kindling produced a definite persistent de¬
crement in tyrosine hydroxylase activity at the site of stimulation in the amygdala.
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